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Abstract 
Despite significant declines, coronary heart disease (CHD) remains a great burden to 
the Portuguese and worldwide health care systems, accounting for substantial 
morbidity and mortality, and with significant costs. Behavioral factors such as 
sedentary life style, high-sodium food intake, and population ageing significantly 
contributed to increased morbidity. The ever-growing understanding of the 
pathophysiology of these diseases and proliferation of health technologies on one 
side and better organization of health services on the other, promoted improvements 
in the survival and quality of life of these patients. However, health care quality 
variations across geographical regions and health care providers continue to be 
reported in the scientific literature. Some variation may be explained by fundamental 
differences in socio-political structures, personal values, organizational structures 
and processes as well as economic constraints. On the other hand, geographical or 
health care provider variation may be the result of underperformance in some health 
care systems due to overuse or underuse of treatments which in turn leads to 
intrinsic concerns regarding waste of resources that could be needed elsewhere. 
This thesis builds on the opportunity that comparative studies afford to contrast 
different healthcare systems, with different practice patterns and needs, to gain 
insights into factors impacting health care quality. Specifically, this thesis aims at 
comparing the health care systems of Portugal and the United States in the context 
of CHD patient management. We selected CHD because it is a highly prevalent and 
fatal disease, for which health technologies have advanced substantially in past 
decades, thus investigating into questions associated with their adoption and 
diffusion is important . We compare access to and use of health technologies, their 
corresponding relationships to clinical outcomes of CHD patients, and contrast these 
relationships between the two countries.   
We first sought to characterize the two health care systems in terms of their 
organization, epidemiological profiles, resource availability, including ability to access 
new health care technologies, and population health status. Briefly, our results 
indicate that relative to the United States, Portugal exhibits lower population risk 
profiles, has fewer CHD-related hospitalizations, and a smaller number of hospitals 
that provide advanced heart procedures. In addition, new health technologies enter 
the market using different regulatory pathways, which frequently result in faster 
diffusion in the United States. Despite the access differences, CHD mortality is 
numerically lower in Portugal but not statistically different than in the US when acute 
myocardial infarction (AMI) mortality is compared. 
We next sought to characterize and compare care of patients hospitalized with an 
AMI in Portugal and the United States during 2000-2010. We selected AMI because 
this represents an acute condition within CHD requiring expensive care treatment. 
Also, restricting the scope of our analysis improved cross-country comparability. 
Concurrent with previous findings, hospitalizations in the United States presented 
more comorbid conditions, yet more hospitalizations in Portugal presented with ST-
segment elevated myocardial infarction. Coronary revascularization procedures – 
coronary artery bypass graft and percutaneous coronary intervention – were less 
frequent in Portugal. Its utilization was associated with survival at discharge in both 
countries, but the probability of survival was  larger in Portugal. Age-sex-adjusted in-
hospital mortality rates in Portugal was twice that for the United States. Furthermore, 
significant declines in risk-adjusted mortality were observed in both countries over 
our eleven-year period.  However, after adjusting for risk factors at presentation, we 
observed larger between-hospital variability in patient survival in Portugal relative to 
the United States – the risk of dying in a high relative to a low mortality hospital was 
2.65 in Portugal compared to 1.03 in the United States. 
Motivated by the variation results, we further investigated whether hospital 
characteristics could explain hospital heterogeneity in health care quality in Portugal.  
 
 
xii 
We studied between-hospital variation in in-hospital mortality and 30-day unplanned 
readmission in AMI patients during 2012-2015.  All else equal, health systems should 
provide high quality of care regardless of the hospital in which patients are treated. 
Our new findings confirmed that hospital represents a contextual effect – some 
hospitals perform consistently better than others, and these variations remain even 
after adjusting for hospital case-mix and hospital characteristics. Moreover, among 
the hospital characteristics examined, higher AMI caseload and larger hospitals were 
associated with lower mortality and readmission rates. Geographical location of the 
hospital was also related to quality of care with an AMI patient hospitalized in 
Alentejo/Algarve and Lisbon regions more than 20% more likely to be readmitted 
within 30-days of discharge compared to a patient treated in the North region.  
This thesis provides significant information for improving the quality of CHD health 
care, and in particular, AMI patient management in Portugal. Limited data are 
available on marketing approval of new health technologies and further investigation 
will be needed to understand their diffusion. In line with the United State, Canada, 
and other countries that boast a strong tradition of monitoring the quality of care 
delivered to its citizens, Portugal could benefit from regular hospital measurement 
and monitoring of expensive, and frequent conditions such as AMI. Furthermore, 
health policies seem more sensible if addressed to specific hospitals depending on 
their risk level, while particular attention should be given to hospital caseload and 
practices across different geographical regions. 
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Resumo 
Não obstante melhorias significativas, as doenças coronárias (DC) continuam a 
representar um peso substancial no sistema de saúde Português e sistemas de 
saúde um pouco por todo o mundo, contribuindo com uma elevada morbilidade e 
mortalidade bem como custos significativos. Fatores comportamentais, tais como um 
estilo de vida sedentário e uma alimentação rica em teor de sódio, bem como o 
envelhecimento da população contribuíram significativamente para o aumento da 
morbilidade. A crescente compreensão da pato-fisiologia dessas doenças e a 
proliferação de tecnologias de saúde, por um lado, e avanços na organização dos 
serviços de saúde, por outro, promoveram melhorias na sobrevida e qualidade de 
vida desses pacientes. No entanto, variações na qualidade dos cuidados de saúde 
entre regiões geográficas e entre prestadores de cuidados de saúde continuam a ser 
relatadas na literatura científica. Parte destas variações podem ser explicadas por 
diferenças fundamentais ao nível das estruturas sociopolíticas, valores pessoais, 
estruturas e processos organizacionais, bem como restrições económicas. Por outro 
lado, variações entre regiões geográficas ou entre prestadores de cuidados de 
saúde podem decorrer de um desempenho insuficiente de alguns sistemas de saúde 
devido à sub- ou sobre-utilização de tratamentos, o que, por sua vez, suscita 
preocupações relativas ao desperdício de recursos que podem ser necessários para 
outro fim. 
Esta tese desenvolve-se sobre a oportunidade de estudos comparativos encerrarem 
a possibilidade de extrair conhecimento sobre a qualidade de cuidados de saúde ao 
contrastar diferentes sistemas de saúde, com diferentes necessidades e padrões de 
tratamentos. Especificamente, esta tese tem como objetivo comparar os sistemas de 
saúde de Portugal e dos Estados Unidos no âmbito do tratamento de pacientes com 
DC. Selecionámos a DC porque ser uma doença muito prevalente e fatal, para a 
qual tecnologias de saúde viram um avanço substancial nas décadas passadas, pelo 
que a investigação de questões relacionadas com a sua adopção e difusão são 
importantes. Comparámos o acesso e utilização de tecnologias de saúde, o seu 
impacto no desfecho desses pacientes, e comparam-se estas relações entre países.  
Em primeiro lugar procurámos caracterizar os dois sistemas de saúde em termos de 
organização, perfis epidemiológicos, recursos disponíveis incluindo a capacidade de 
acesso a novas tecnologias de saúde, e estado de saúde das populações. 
Sumariamente, os nossos resultados indicam que a população de Portugal 
apresenta um perfil de risco menor, com menos internamentos relacionadas a DC, e 
os centros que oferecem procedimentos cardíacos avançados são também em 
menor número quando comparados com os Estados Unidos. Além disso, novas 
tecnologias da saúde estão sujeitas a diferentes regulamentações seguindo 
diferentes vias de aprovação, que favorecem frequentemente uma difusão mais 
rápida nos Estados Unidos. Apesar de diferenças no acesso, a mortalidade por DC é 
menor em Portugal, mas as diferenças entre os países não são estatisticamente 
significativas em relação à mortalidade por enfarte agudo do miocárdio (EAM). 
Procurou-se de seguida caracterizar e comparar a prestação de cuidados 
hospitalares em pacientes com EAM em Portugal e nos Estados Unidos durante o 
período de 2000-2010. Selecionámos o EAM porque esta doença representar uma 
condição agudizada dentro da DC, requerendo tratamentos caros. Além disso, a 
restrição do âmbito da análise melhorou a comparabilidade entre países. 
Apoiado pelos resultados anteriores, hospitalizações nos Estados Unidos 
apresentaram mais doenças concomitantes, mas mais hospitalizações em Portugal 
exibiram um enfarte do miocárdio com o segmento ST elevado. Os procedimentos 
de revascularização coronária – bypass coronário e intervenção coronária 
percutânea – foram menos frequentes em Portugal. A sua utilização estava 
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associado à sobrevivência do paciente à data da alta em ambos os países, contudo 
a probabilidade de sobrevivência era maior em Portugal. A mortalidade intra-
hospitalar ajustada ao sexo e idade em Portugal foi o dobro da observada nos 
Estados Unidos. Além disso, observou-se uma diminuição anual significativa no risco 
de morte para ambos os países durante período de onze anos. Contudo, após 
controlar para factores de risco, observámos uma maior variabilidade intra-hospitalar 
na sobrevivência do paciente em Portugal, em comparação aos Estados Unidos – o 
risco de morte de um paciente num hospital de mortalidade elevada relativamente a 
um hospital de mortalidade baixa foi de 2,65 em Portugal, quando nos Estados 
Unidos era apenas de 1,03. 
Motivado pelos resultados sobre a variabilidade, investigámos se características dos 
hospitais poderiam explicar a heterogeneidade entre hospitais. Nesse sentido, 
estudámos variações na mortalidade intra-hospitalar e readmissão urgentes 
ocorridas até 30 dias após alta de pacientes com EAM durante 2012-2015. Um 
sistema de saúde deve prestar cuidados de saúde de elevada qualidade 
independentemente do hospital em que os pacientes sejam tratados, assumindo que 
tudo o resto é igual. Os nossos resultados confirmaram que o hospital representa um 
efeito contextual – alguns hospitais têm desempenhos consistentemente melhores 
do que em outros hospitais, e essas variações permanecem mesmo depois de 
ajustar para case-mix de pacientes e características dos hospitais. Além disso, entre 
as características ao nível do hospital examinadas, verificou-se que o número de 
casos de EAM tratados e o tamanho do hospital estavam associados com taxas de 
mortalidade e readmissão mais baixas. A localização geográfica do hospital também 
exibiu uma relação com a qualidade dos cuidados prestados, tendo um paciente 
com EAM hospitalizado nas regiões do Alentejo/Algarve ou Lisboa um risco de 
readmissão urgente de mais de 20% quando comparado com um paciente tratado 
na região Norte. 
Esta tese fornece informação vital para melhorar a qualidade dos cuidados de saúde 
na DC, e em particular, no tratamento de pacientes com EAM em Portugal. Os 
dados disponíveis sobre a autorização para comercialização de tecnologias de 
saúde são limitados e mais investigação será necessária para compreender a sua 
difusão. Em linha com os Estados Unidos, Canadá, e outros países que mostram 
uma forte tradição na monitorização da qualidade de cuidados de saúde prestada 
aos seus cidadãos, Portugal poderia beneficiar de atividades regulares de medição e 
monitorização de condições frequentes e dispendiosas como o EAM. Além disso, 
parece ser mais sensato que as políticas de saúde sejam dirigidas a hospitais 
específicos, dependendo do seu nível de risco, devendo ser dada especial atenção 
ao número de casos praticados por hospital e às práticas hospitalares em diferentes 
regiões geográficas. 
 
 
1 
1 Rationale 
1.1 Coronary heart disease – health status and variations across 
and within countries 
Cardiovascular diseases (CVD) are responsible for approximately one third of 
deaths worldwide.(World Health Organisation, 2017) Among these, coronary 
heart diseases (CHD), comprising disorders of the blood vessels (coronary 
arteries) that supply the myocardium (heart muscle), stand out for their 
substantial burden on health care systems and their high morbidity and 
mortality. According to the World Health Organisation (WHO), most of CVD-
related deaths are due to CHD  (41%) or stroke (39%).(World Health 
Organisation, 2017) The latter comprising disorders of the blood vessels that 
supply the brain. CHD accounts for approximately 1.8 million deaths per year, 
representing 20% of all deaths in European countries.(Nichols et al., 2014) In 
addition to being highly fatal, CHD also represents a major economic burden, 
representing an estimated 28% (€59 billion a year) of the overall direct and 
indirect costs attributed to CVD in the European Union (EU). Of costs directly 
supported by health care systems associated with CHD (€19 billion in 2015), 
inpatient hospital care accounted for €10 billion (55%) while drugs accounted 
for €4 billion (20%).(Wilkins E et al., 2017)  
Among the CHD, acute myocardial infarction (AMI) (or heart attack) 
constitutes the highest risk condition to patients. This is a life-threatening 
acute event that occurs when a sudden blockade of the coronaries occurs 
resulting in an insufficient oxygenated blood supply to the myocardium, which 
if not timely reverted may result in the death of the patient.(Thygesen et al., 
2007) The American Heart Association (AHA) estimates an annual incidence 
of 580 000 new attacks (approximately 190 attacks per 100 000 population) 
and 210 000 recurrent attacks (approximately 80 per 100 000 population) in 
the United States alone (US).(Benjamin et al., 2017) Population aging, 
increasingly sedentary life style, obesity rates, and high-sodium food greatly 
contributed for increased morbidity in most countries.(Moran et al., 2014, 
Nichols et al., 2014) Whereas, the understanding of the pathophysiology of 
AMI, new diagnostic and therapeutic technologies, and improved organization 
of health services (e.g pre-hospital care, coronary intensive care units, cardiac 
rehabilitation), vastly contributed to improvements in survival and quality of life 
of these patients.(Braunwald, 1998, Teixeira et al., 2013)  
Although general declines in mortality rates among CHD patients have been 
observed worldwide, variations across health systems in CHD morbidity, 
patient management, and mortality persist.(André et al., 2014, Moran et al., 
2014, Nichols et al., 2014, Puymirat et al., 2013, Wilkins E et al., 2017) 
Variations are also observable within randomized controlled clinical trials 
(RCT), which in principle are less likely to depend on epidemiological profiles 
of populations and treatments are more likely provided in a standardized 
manner.(Chang et al., 2005, Gupta et al., 2003, Simes et al., 2010) These 
studies thus suggest that fundamental differences in socio-political structures, 
personal values, organizational structures and processes and economic 
constraints may overwhelm the pathophysiological similarities of the 
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underlying disease process being treated. Consequently, the accurate 
evaluation of healthcare systems performance and quality of healthcare 
provided requires an understanding of many local factors: disease 
epidemiology, institutional resources, specialized professional training, and 
political planning, surveillance, and evaluation instruments.(Bradley et al., 
2006, Brook and McGlynn, 1996, Chang et al., 2005, Peiró and Maynard, 
2015)  
As new health technologies, particularly those proven to be cost-effective, 
hold the potential for improving the health and well-being of patients, different 
healthcare systems adopt new health technologies at varying speeds and use 
rates. Despite the increasing rates of scientific and technological 
development, clear guidelines and recommendations for prioritizing, 
implementing, and disseminating technologies are currently lacking. These 
inefficiencies likely have a negative impact on the ability of physicians and 
health systems to deliver high quality cost-effective care.(Gonçalves and 
Seabra-Gomes, 2012, Pinto et al., 2015) Importantly, such inefficiencies 
further contribute to heterogeneity in health care quality across healthcare 
systems, centers, and medical providers.  
While variations across health systems raise concerns for sub-optimal care in 
some geographic regions or in particular sub-populations, these differences 
also represent opportunities for a better understanding of determinants of 
health care improvement. This thesis exploits variations within and between 
countries through comparative analyses of CHD patient management. 
Findings from such comparisons would provide concrete measures of 
variations in treatments and outcomes, and identify factors that may improve 
health care quality of these patients. 
 
1.2 Coronary heart disease in Portugal 
Similar to what is generally observed in most high-income countries, CVD 
also represents the leading cause of death in Portugal. Despite significant 
declines in past decades, declines in mortality rates have slowed recently. 
According to age-standardized rates from the Portuguese Health Ministry and 
the Organisation for Economic Co-operation and Development (OECD), CHD 
mortality has in fact increased during 2011-2015.(Wilkins E et al., 2017, 
Direcção Geral da Saúde, 2018) 
When compared to other European countries, Portugal is among those with 
lowest CHD mortality rates for both sexes.(Wilkins E et al., 2017) Yet, less 
favorable figures characterize in-hospital mortality in Portugal relative to other 
countries. André et al. (2014) observed that Portugal was among the 
countries with highest rates of in-hospital mortality in patients admitted with 
ST-segment elevated myocardial infarction (STEMI) and non-ST-segment 
elevated myocardial infarction (NSTEMI) (9.7% and 6.9% respectively). While 
the latter study was based on data collected prospectively during 2008-2010, 
it covered only 6 western European countries and each country contributed 
with data from 8-10 centers. Moreover, OCED reports show that mortality 
within 30 days after admission in AMI patients in EU countries ranged 
between 7.5% of admissions of adults aged 45 years and over in Italy to 
19.1% in Latvia, and ranked Portugal (10.4 %) just above the EU average 
(9.9%) in 2013.(Organisation for Economic Co-operation and Development, 
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2016) Data collected under the auspices of the Portuguese Society of 
Cardiology (SPC) based on voluntary participation of centers provide another 
perspective of health care provided to CHD patients in Portugal. The SPC 
data indicate that health care improved substantially over the past few 
decades, with noticeable improvements in the use of the coronary fast-track 
emergency system, compliance with drug therapies, and adherence to 
coronary revascularization procedures as recommended in the European 
Society of Cardiology (ESC). A significant reduction in in-hospital mortality 
marked the period between 2002 and 2008, from approximately 9% to 6% in 
STEMI patients.(Gonçalves and Seabra-Gomes, 2012, Santos et al., 2009)  
In the United States, several studies report on variations regarding in-hospital 
patient management (Arnold et al., 2015, Jernberg et al., 2011, Mathews et 
al., 2018) and outcomes (Bradley et al., 2010, Bradley et al., 2006, Krumholz 
et al., 2011, Krumholz et al., 2009, Krumholz et al., 2006, Rasmussen et al., 
2008, Stukel et al., 2010, Wakeam et al., 2015, Xian et al., 2014) for patients 
having an AMI. These studies highlight that substantial hospital heterogeneity 
exists, and only partially explained by differences in patient case-mix. While 
the contextual effect of hospitals remains relatively poorly understood, the 
association of hospital characteristics (e.g. AMI volume, teaching status, size, 
cardiac facilities available, geographic location, profile of socio-economic 
status of patients) with outcomes suggest that hospital characteristics may 
play a meaningful role in explaining between-hospital variability. In Portugal, 
no such studies have been undertaken for CHD, and only limited information 
is available on inter-hospital variations in CHD health care quality. For 
example, Portugal’s Health Ministry reported variations in treatment use such 
as volume of advanced hospital procedures (Administração Central do 
Sistema de Saúde, 2003, Direcção Geral da Saúde, 2018) and drug 
prescription practices (Dores et al., 2014, Ferreira et al., 2004). In response, a 
tool developed by the Administração Central do Sistema de Saúde (ACSS) for 
hospital benchmarking within the Portuguese National Health Service (NHS) 
was developed and public reports of several health care quality indicators 
commenced. While this tool provides an important step to fostering 
transparency and public accountability in quality of hospital care, only two 
indicators are specific to CHD hospital care: absolute frequency of coronary 
bypass surgery volume and angioplasty volume per hospital. While these 
metrics are important, they do not permit an assessment of the 
appropriateness of the procedures nor how they may impact on the health 
status of these patients. 
With few metrics to quantify and identify factors that impact treatment use and 
outcomes, it is clear that health services research (HSR) in Portugal is still 
somewhat insipient with regard to certain domains of health care quality, such 
as accessibility and equity, despite a growing interest in the field and priority 
given to health programs in CVD. Important insights may be obtained by 
investing in this field of research, which are invaluable to guide health policies 
and ultimately to improve health care quality in Portugal. 
2 Objectives 
The goal of this thesis is to provide insights regarding quality of care for CHD, 
examining factors associated with access, effectiveness and equity of CHD 
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patient care. Taking advantage of a partnership between academic institutions 
in Portugal and the US, we compare the different health care systems in 
terms of access to and use of health technologies in CHD patient 
management, and their impact on the outcomes of these patients. We identify 
and quantify factors that may explain differences between countries and 
heterogeneity of outcomes across hospitals within countries. With this in mind 
we established three specific aims: 
 
Aim 1: Comparison of healthcare systems (Paper 1) 
To characterize two contrasting health care systems in terms of their 
organization, epidemiological profiles, resources available, and health status 
emphasizing the systems abilities to access new health care technologies 
(medical devices and drugs). 
 
Aim 2: Assessment of AMI health care quality (Paper 2) 
To characterize and compare AMI in-patient management and hospital health 
care quality in Portugal and the United States for hospitalizations during 2000-
2010.  
 
Aim 3: Explaining hospital heterogeneity in health care quality (Paper 3) 
To assess between-hospital variation in treatment use and outcomes, 
accounting for patient-level and hospital-level characteristics. 
3 Background 
3.1 Health services research 
The main concern of HSR is to produce scientific evidence that contributes to 
the development of more effective, more equitable and more efficient health 
care services.(Phillips, 2006) According to the AcademyHealth, the American 
professional organization for HSR, “Put simply, HSR is the science of study 
that determines what works, for whom, at what cost, and under what 
circumstances. It studies how our health system works, how to support 
patients and providers in choosing the right care, and how to improve health 
through care delivery.”(AcademyHealth, 2017) 
Entailing a broad scope beyond assessing efficacy of health care, which is 
usually achieved under very controlled settings (e.g. RCT), HSR focus on 
whether health care works in real world settings, both under conditions similar 
to RCT or under different circumstances if practice differs from trial.(Ebinger, 
2017, Scott and Campbell, 2002, Steinwachs and Hughes, 2008) The breadth 
of this study field is also reflected by the relevance attributed to taking into 
perspective what quality of care represents to patients, health systems, and 
organizations, while acknowledging the challenges of such multidimensional 
and multifactorial systems in which quality of care depends on the efficacy of 
interventions, on the effectiveness of structures and processes, and on 
contextual factors such as practice patterns, personal beliefs and economic 
constraints.(Chen et al., 2010, Da Costa et al., 2015, Enno et al., 2000, 
Nichols et al., 2017, Peiró and Maynard, 2015) Particularly when 
guidelines/consensus documents fail to provide strong evidence to guide 
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practitioners onto which procedures to adopt, personal interpretations are 
more likely to arise, eventually leading to different practice patterns.(Appleby 
et al., 2011, Chiang et al., 2014) Considering the multidimensional context of 
HSR, experimental studies are often difficult or inadequate to implement. For 
example, many decisions involve changes in organizational structures, modes 
of practice, and personnel skills and are often not readily amenable to 
randomization or blinding.(Scott and Campbell, 2002) Furthermore, 
randomization becomes unethical for enquiry of effectiveness after proven or 
judged efficacy of interventions.(Steinwachs and Hughes, 2008) Thus, quasi-
experimental and observational studies take on an important role. 
Accordingly, electronic medical records (EMR), prospective registry data, 
administrative data, and survey data become crucial data sources in the field 
of HSR.(Ebinger, 2017, Pittman, 2010, Scott and Campbell, 2002) These data 
sources consist of systematic and standardized collection of information on 
patients characteristics, treatment, and outcomes. Although different data 
sources have varying levels of clinical detail and quality, they hold important 
advantages in HSR. First, they constitute real-world samples characterized by 
a large number of people, population coverage, and heterogeneity. Second, 
they usually allow for trend analysis, hence are adequate for investigating 
both cross sectional and longitudinal variations in health status and practice 
patterns (e.g. guideline adherence). Finally, the data sources are often 
linkable, e.g. interoperability between data sources (e.g. vital statistics, 
prescription data), and thus reduce lost-to-follow-up information and provide 
longer follow-up period than is possible in RCTs.(Brown et al., 2010) 
3.1.1 Quality of health care 
HSR aims to assess the quality of health care in order to derive insights that 
may improve it.(Blumenthal, 1996a, Blumenthal, 1996b, Brook and McGlynn, 
1996) According to the National Academy of Medicine (NAM)(former Institute 
of Medicine) (Harris-Wehling and Morris, 1991), quality of care is “the degree 
to which health services for individuals and populations increase the likelihood 
of desired health outcomes and are consistent with current professional 
knowledge”. Dating back to the early 90s, this definition calls for the 
importance of evidence-based medical care as a mean to provide high-quality 
health care, which remains the paradigm of ideal health care practice 
today.(Heneghan, 2018) Evidence-based medicine is not just paramount to 
help providers to decide over the most appropriate/effective care, but also it is 
crucial to build more equitable and efficient health systems through 
standardized health care and services that are less permeable to personal 
preferences, and waste.(Appleby et al., 2011, Peiró and Maynard, 2015) 
Furthermore, quality of health care should also be synonymous of timely 
provision of services that are responsive to individual patient needs, 
preferences and values, regardless of their location and social-economic 
status and that protect patients from injuries during the care perceived. A 
systematization of aims around which health care should be built in order to 
achieve high-quality health care see Institute of Medicine (2001) (Table 3.1). 
This list of aims further helps the former definition to provide a structured 
concept and guidance on how to assess quality of health care. Variations of 
this list of aims have been proposed by others (Campbell et al., 2000) both 
more compact and extended versions of it. However, for the purpose of this 
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thesis, this section aims at establishing a broad definition of quality of care so 
that then emphasis is put on two crucial elements of quality of care - 
effectiveness and access (as conveyed through timely and equitable health 
care). 
 
Table 3.1 Health care quality domains.(Institute of Medicine, 2001) 
Safe: avoiding injuries to patients from the care that is intended to help them. 
Effective: providing services based on scientific knowledge to all who could 
benefit and refraining from providing services to those not likely to benefit 
(avoiding underuse and overuse, respectively). 
Patient-centered: providing care that is respectful of and responsive to 
individual patient preferences, needs, and values and ensuring that patient 
values guide all clinical decisions.  
Timely: reducing waits and sometimes harmful delays for both those who 
receive and those who give care. 
Efficient: avoiding waste, including waste of equipment, supplies, ideas, and 
energy.  
Equitable: providing care that does not vary in quality because of personal 
characteristics such as gender, ethnicity, geographic location, and 
socioeconomic status. 
 
Measurement of health care quality is essential. It allows ascertaining 
weaknesses and strengths of health care services and hence identifying 
opportunities for improvement; it provides public accountability and hence 
more transparent health systems; and it makes information available to 
delineate health policies as well to evaluate ongoing reforms.(Papanicolas 
and Jha, 2017) Paraphrasing Porter et al. “what is not measured cannot be 
managed or improved”.(Kaplan and Porter, 2011) However, because health 
care systems are multidimensional and involve a variety of players and 
stakeholder, assessing quality of health care is a hard task to accomplish in a 
meaningful way. 
Seminal work from Avedis Donabedian prompted awareness both for the 
need and difficulties of quality of care appraisal.(Ayanian and Markel, 2016, 
Campbell et al., 2000, Donabedian, 1988, Donabedian, 2005, Normand and 
Shahian, 2007) His conceptual framework for assessment of quality of care 
based on measures of structure, process, and outcome remains a valid and 
important framework nowadays. Structure measures characterize the 
resources available to provide health services, including material and human 
resources and organizational structures. (e.g. number of CT scan machines, 
physician-nurse ratios, availability of cardiac surgery services). Structure 
measures are relatively easy to compute yet the extent of their association 
with health outcomes is difficult to establish. (Donabedian, 1988, Normand 
and Shahian, 2007) 
Interactions between patients and providers are conveyed in process 
measures (e.g. number of appointments, admission through the emergency, 
prescription adherence). Its best use is to evaluate the compliance of health 
services against recommended care given that this is more likely to be 
associated with the final outcome. For instance, the percentage of patients 
admitted with an AMI with documented administration of acetylsalicylic acid at 
admission, or with a timely primary percutaneous coronary intervention 
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(PCI).(Entidade Reguladora da Saúde, 2017) Process measures are often 
straightforward to operationalize, may be the only measures available when 
outcome measures are not available, and may readily elucidate on which 
actions improve quality of health care, yet these measures are limited to a 
segment of the overall care provided for a particular medical condition, which 
may be applicable to only a small percentage of patients with a given 
condition.(Bradley et al., 2006, Donabedian, 1988, Harbaugh, 2006, Krumholz 
et al., 2007, Normand and Shahian, 2007) 
Outcomes are arguably the ultimate validators of quality of health care 
because these represent the final effect of the health care delivered in the 
patient’s health status (e.g. survival, satisfaction).(Donabedian, 2005) 
However, outcome measures are usually more complicated to operationalize 
when compared with process and structure measures because assessment of 
outcomes usually requires large samples, controlling for confounding effects 
and more sophisticated statistical methods to be implemented.(Krumholz et 
al., 2007, Normand and Shahian, 2007) Moreover, relative to other measures, 
outcomes may not render immediate actions to improve those outcomes, 
therefore its use should be done with discrimination.(Donabedian, 2005) 
Quality indicators based on Donabedian’s triad are increasingly used to 
measure, monitor and incentivize performance of health care systems and 
health organizations worldwide.(Bradley et al., 2006) The number of pay-for-
performance programs, which stipulate financial penalties or incentives based 
on performance according to expected/contracted quality indicators, has 
grown over the last decade (e.g. Hospital Compare, Value-Based Purchasing 
programs in the US). In Portugal, pay-for-performance is being applied within 
primary care (PC) services, with 6% of the budget in contract agreements 
between PC units and the Ministry of Health associated with compliance of 
quality indicators goals. At a lesser extent, quality of hospital care is also 
stimulated through pay-for-performance measures, specifically resorting to 
outcome measures regarding adequate and timely access to clinical 
appointments, surgery and biologic medicines.(Administração Central do 
Sistema de Saúde, 2016)  
This thesis aims to provide insights regarding quality of health services in 
Portugal within CHD patient management, emphasizing aspects about 
variability of quality of health care primarily through the analysis of outcomes 
measures. The term variability is used to refer both variability of health care 
quality when compared to other countries (between-country variations) as well 
as between-hospitals variations within two different countries.  
With this in mind the next section motivates the use of comparative studies to 
draw insights of national health care performance. Further details on main 
methodological aspect of the approach adopted are given in section 3.3. 
3.1.2 International studies, benchmarking and hospital profiling 
Despite the publication of international and national updated guidelines, 
variations in CHD patient management, morbidity and mortality across 
countries, regions and institutions persist.(Institute for Health Metrics and 
Evaluation, 2018, Organisation for Economic Co-operation and Development, 
2018) Even among high-income countries staggering differences in rates and 
trends exist.(André et al., 2014, Puymirat et al., 2013, Wilkins E et al., 2017) 
Comparative studies represent an opportunity to contrast different healthcare 
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systems, with different practice patterns and needs, and learn from the 
different realities. These comparisons may be used to evaluate the 
performance of national health systems, shape national health policies and to 
promote public accountability, which ultimately aim at improving health care 
quality, health and the well-being of populations.  
The research conducted by international organization such as the WHO, the 
Organisation for Economic Co-operation and Development (OECD), and the 
Global Burden of Disease (GBD), are examples of international comparisons. 
These type of organizations work as central curators of health data from 
several countries, publishing regular influential reports at the national level, 
(Organisation for Economic Co-operation and Development, 2013, Wilkins E 
et al., 2017) and thus constitute valuable data sources in public health and 
health services research.(Steel, 2017)  
International comparisons are common within the context of coronary heart 
disease health care.(André et al., 2014, European Society of Cardiology, 
2018, McGovern et al., 1997, McNamara et al., 2014, Puymirat et al., 2013, 
Smith et al., 2013, Vargas et al., 2001, Zheng et al., 2017) For example, the 
EURopean HOspital Benchmarking by Outcomes in acute coronary syndrome 
Processes (EURHOBOP) project (http://www.eurhobop.eu) described 
characteristics of patients admitted for acute coronary syndrome (ACS) in 
Western Europe and analyzed international variations of patient management 
and in-hospital mortality.(André et al., 2014) Within the European Society of 
Cardiology, in collaboration with its national congeners, several surveys and 
prospective data registries have been developed to provide a better 
understanding of medical practice and assessment of adherence to guidelines 
and variations across regions or countries.(Gitt et al., 2010, Puymirat et al., 
2013, Zeymer et al., 2017) 
Notwithstanding the opportunities that international comparisons may yield, 
several challenges may undermine these comparisons.(Papanicolas and Jha, 
2017) First, comparability of data sources and what differences represent is of 
crucial importance.(Bottle et al., 2013, Papanicolas and Jha, 2017) For 
example, Bottle et al. (2013) observed that a number of important variables in 
administrative data from several countries contained differing levels of detail 
depending on the country and required reconciliation prior to analysis. These 
authors also observe that different countries used different definitions of 
inpatient hospitalization, which may affect the identification of populations. 
Joseph et al. (2012) suggested that international variations in registration of 
extremely low birth weight and early gestation birth may lead to spurious 
rankings of perinatal and infant mortality rates across countries. Second, the 
association between interventions and observed cross-countries differences is 
difficult to establish and interpretations should be made in light of health 
systems scope, expectations of patients they serve, and national policies, 
values and priorities.(Papanicolas and Jha, 2017) For example, in an OECD’s 
annual report Health a Glance, a 3-fold difference in cesarean section rates 
across countries was observed. Some of this variation may be justified by 
clinical need, but it could also mean that women are either having 
unnecessary operations, or being denied care they should be 
getting.(Organisation for Economic Co-operation and Development, 2013) 
At a national level, comparisons are also common. Benchmarking and 
profiling activities became commonplace for purposes of transparency and 
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public accountability in high-income countries.(Administração Central do 
Sistema de Saúde, 2003, Medicare.gov, 2018) Geographical, social-
economic, inter-hospital, inter-physician variations in health care quality are 
continuously subject of investigation (Maynou et al., 2015, Sinha et al., 2012), 
with several studies indicating that a substantial part of this variation remains 
unexplained even after accounting for the patients underlying risk 
effect.(Bradley et al., 2010, Bradley et al., 2006, Chen et al., 2010, Chung et 
al., 2015, Herrin et al., 2015, Krumholz et al., 2007, Stukel et al., 2010, Xian et 
al., 2014) A concern of access inequalities may provide some rationale for the 
unexplained variation - different care is given to patients with similar 
conditions, undermining the belief that health systems, in general, and health 
professionals, in particular, apply uniformly an unequivocally appropriate 
treatment for each health problem.(Peiró and Maynard, 2015) Moreover, large 
variations may suggest that some providers may produce suboptimal care 
and that potential savings could be allocated in resources needed 
elsewhere.(Appleby et al., 2011) As relevant as studying variations in quality 
of care may be, identifying sources of variations may require for sophisticated 
statistical analysis, especially if targeted at outcome measures.(Ash et al., 
2012, Harbaugh, 2006, Normand and Shahian, 2007, Teixeira ‐Pinto and 
Normand, 2009) These analyses rely on the quality of data and of the choice 
of risk adjustment models, and consequently on the ability to separate 
sampling variability and case-mix effects from provider effects on outcomes. 
Section 3.3 provides additional information on methods used to tackle some 
of the challenges encountered within this context. 
This thesis explores on the ability of international comparisons to extract 
information with potential impact on healthcare, health policy and health 
research. We compared the health systems of Portugal and the US. These 
health systems represent an interesting contrast, with the Portuguese health 
system relying on a National Health Service (NHS) structure, characterized by 
universal coverage and access that is tangentially free at the point of use and 
that is mainly financed through general taxation (Barros et al., 2011); and the 
US health system, having developed largely through the private sector where 
health coverage is mostly delivered through private insurance, mainly through 
an employer. Of note, by 2010, 16% of Americans were still uninsured (Rice 
et al., 2013). Comparable and comprehensive information on the two health 
care systems is available as supplementary data section 7.4.  
3.2 The CUTEheart project 
This thesis was developed under CUTEheart – Comparative use of 
technologies for heart disease project (http://cuteheart.med.up.pt), a grant 
aimed at comparing the use of health technologies between the health 
systems of the US and Portugal focusing on CHD treatment. The project 
encompassed five specific aims: 1) to compare the diffusion rates of new 
technologies for treating CHD, and identify patient, hospital, and 
environmental determinants of use in US and in Portugal; 2) to assess the 
impact of health technology diffusion in high risk patient cohorts; 3) to 
compare clinical effectiveness of the use of procedures to treat CHD; 4) to 
calculate cost-effectiveness of treating CHD in the US and in Portugal; 5) to 
leverage the international collaboration to develop a framework for designing 
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and implementing health services research  between two health care 
systems. This thesis contributed mainly to aims 1, 3 and 5. 
3.3 Materials and Methods 
The main methodological elements of this thesis include information regarding 
data sources, standardization methods of rates between different populations, 
and multilevel models for analysis of clustered data. Further detailed 
information can be found in the papers that compose the results of this thesis 
under the Results section.  
3.3.1 Data sources (considerations about comparability across countries) 
The first objective of this thesis (Paper 1) was accomplished through 
published information or public databases with information at the country level 
(e.g. Eurostat, CDC, OECD, INE). For the reminder of the aims we mainly 
used administrative hospital inpatient data available by request/order. 
Administrative data refers to data collected by health-care providers and 
insurers with the intention of facilitating hospital financing or 
reimbursement.(Iezzoni, 1997) Summary information of all data sources 
considered for the CUTEheart project is available as supplementary material 
(Table 7.2 in Supplementary data 7.2). In this section we focus on aspects 
related with administrative data and its comparability across countries. 
We obtained access to datasets of inpatient hospital administrative billing data 
in the US and Portugal. We opted for these sources of data because they 
represent the only feasible solution for comparison between the US and 
Portugal with nationwide representativeness capturing the natural hospital 
heterogeneity at the population level and with compatible information and 
reconcilable coding schemes variables (Table 7.1 in Supplementary data 7.1). 
Briefly, considering the reporting period spanned between 2000 and 2010, 
information available in these datasets consists of similar diagnosis and 
procedure codes (based on International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM)), including primary and secondary 
diagnoses, type of admission and discharge status, patient demographic 
characteristics, length of stay (LOS), severity metrics and comorbidity 
measures. The majority of these variables have equivalent definitions and 
coding levels between the two countries with some minor differences. The 
number of potential diagnosis or procedure codes is 15 in the US and 20 in 
Portugal, no race/ethnicity information is available for Portugal, ‘urgent’ and 
‘emergency’ are different types of admissions in the US but used 
interchangeably in Portugal, and inpatient hospitalization is defined as an 
over-night or longer stay in the US while in Portugal is defined as a 24-h or 
longer stay. 
We created AMI cohorts using the principal diagnosis variable having an AMI 
diagnosis code (ICD-9-CM 410.xx excluding 410.x2). This approach assumes 
that the two countries have equivalent AMI definitions as well as similar 
practices of coding. Narrowing down the scope of our analysis to AMI within 
CHD was motivated to increase the reliability of cross-country comparability. 
First, given that AMI is an acute condition requiring expensive care treatment, 
it is less likely to be under-coded and more likely to be identified as a principal 
diagnosis variable (i.e. the condition “established after study to be chiefly 
responsible for occasioning the admission of the patient to the hospital for 
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care”).(Centers for Disease Control and Prevention, 2011) Second, even 
though variations in AMI definitions between countries may exist, one would 
expect that these would have been minimized after acknowledgement of the 
role of, less subjective, troponin biomarkers for diagnosis of AMI as conveyed 
in the universal definition of AMI proposed by the European Society of 
Cardiology and the American College of Cardiology collaborative effort that 
began in 2000.(Antman et al., 2000, Thygesen et al., 2012, Thygesen et al., 
2007) Nevertheless, while new universal definitions have likely improved 
objectivity of AMI diagnosis, several authors have reported an apparent 
increase in the incidence of AMI as a result of the new definition. Highly 
sensitive and specific biomarkers facilitate the identification of less-extensive 
necrosis myocardial infarction that would not been classified as AMI according 
to prior definitions. Awareness of this distortion (or correction) factor is 
essential in interpreting results, even though this will likely affect both 
countries proportionally. 
Secondary diagnoses codes were used to identify comorbid conditions and 
risk factors. Again, this implicitly assumes that documentation of comorbid 
conditions is correct or that the degree of under/over recording is 
proportionally equal in every hospital in the two countries.(Bottle et al., 2013) 
While data audits are regularly implemented in both countries, which should 
contribute for more leveled comparisons, it is possible that countries are 
exposed to different levels of coding artifacts motivated by different hospital 
financing systems.  
During 2000-2010 procedural information collected into administrative data 
was operationalized with use of the ICD-9-CM system both in Portugal and 
the US. These codes permitted the identification of relevant interventional or 
surgical cardiac procedures such as percutaneous coronary intervention (PCI) 
and coronary artery bypass graft (CABG) surgery (Table S1 in Supplementary 
data 7.5). However, identification of drugs through the ICD-9-CM is limited 
and investigation on practice patterns regarding drug use could not be 
compared with this type of data. In a preliminary study based on comparisons 
between administrative data for Portugal and data available at the SPC, we 
observed significant coding inaccuracies of procedures regarding the 
implantation of coronary drug-eluting stents (DES) and bare-metal stents 
(BMS) in Portugal. Therefore, overall PCI (including DES, BMS, and balloon 
angioplasty) or stenting (including DES or BMS) use was considered for 
analysis of cross-country comparisons. In the US, because of different 
payments initially for DES and BMS, coding for the two procedures was 
acceptable. 
Patient identification became fully available since 2011 for Portugal, and prior 
to that date, patients were only partially available providing patient traceability 
within a hospital and a year. In the US, our data source was random sample 
each year and thus patients could not be linked if they had multiple 
admissions within and between years. Therefore, our unit of observation is the 
hospitalization. This approach has also been used by Bottle et al. (2013) 
when comparing administrative hospital data between the US, England, 
Europe and Canada. However, this may have an impact in the size of 
denominators defined and revascularization procedures documented for 
Portugal, given that fewer hospitals have capacity to provide revascularization 
procedures hence rendering multiple hospitalizations per patient.  
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Several factors limited our choice of outcome measures for comparisons 
between Portugal and US. Specifically, because vital statistics data was not 
linkable to the administrative data in Portugal, 30-day or any other time frame 
mortality was not possible to ascertain; comprehensive identification of all 
hospitalizations per patient were not possible due to limitations on the patient 
identification variable, hence hospital readmissions were not possible to 
ascertain. Length of stay and the above-mentioned measures are affected by 
discharge policies and the availability and use of intermediate care between 
countries.(Bottle et al., 2013) Therefore, interpretation of results should take 
that into consideration.  
 
3.3.2 Rate standardization for comparisons between groups 
Differences observed in outcome rates between groups or within a group over 
different periods of time may be masked (either exacerbated or attenuated) by 
differences or changes in the distribution of underlying characteristics in those 
groups that are related with the outcome. For example, the difference 
between crude death rates from two different countries may be distorted by 
the composition of the age structure of the two populations. That is, one of the 
countries may have a higher crude death rate simply because its population 
tends to be older and hence a higher proportion of the population is naturally 
at higher risk of dying. Therefore, comparisons across groups, whether these 
are different countries or different hospitals, should use methods for 
controlling for confounding effects so that comparisons are valid.  
One of the simplest ways to adjust for confounders is to standardize outcome 
rates based on a standard population. The standardized rate corresponds to 
the rate that would occur if the observed distribution of the risk of outcome 
across confounder variables (e.g. age-specific rates) were present in a 
population with the distribution equal to that of a standard 
population.(Anderson and Rosenberg, 1998, Bains, 2009) Standardization 
may be implemented according to two methods: direct standardization and 
indirect standardization. The main difference between these methods is that 
the former uses knowledge about the risk observed in the study population to 
estimate the expected outcome events in a standard population whereas the 
latter uses the knowledge about the risk in a standard population to estimate 
the expected outcome events in the study population. (See formulas in 
Supplementary data section 7.3). 
Direct standardization is preferable to indirect standardization because it uses 
information on the actual frequencies of outcome events in the study 
population rather than inferring the risk of the outcome from another 
population (the standard population). However, standardized rates become 
unstable when the outcome is rare or when we want to control for many 
confounder variables, which easily generates small numbers or zero events 
per stratum. In those cases indirect standardization works better because it 
makes use of information based on more stable rates from a larger 
population.(Ash et al., 2012, Bains, 2009, Normand et al., 2016, Normand and 
Shahian, 2007) 
For many disease outcomes, risk factors include demographic characteristics 
(age and sex), disease-specific risk factors (e.g. clinical indicators of risk), and 
indicators of health status (e.g., presence of comorbid 
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conditions).(Steinwachs and Hughes, 2008) While age and sex already 
account for important epidemiologic confounding effects, whenever possible 
the inclusion of other potential confounders in risk-adjustment models is of 
crucial importance so that comparisons between groups are as even as 
possible. For reasons explained above, this is usually implemented through 
indirect standardization using regression models fitted on a standard 
population to compute expected outcome events of groups under study.(Ash 
et al., 2012, Normand et al., 2016, Normand and Shahian, 2007) 
3.3.3 Generalized linear mixed models for clustered data 
Hierarchical data refer to a data structure in which lower-level units are nested 
within higher-level units, such as clustered data or repeated-measures data. 
This type of data arises when observations are made on different subjects 
within the same cluster or multiple observations are made per subject. 
Inherent to the multilevel nature of the data lays the fact that measures within 
a higher-level unit are not independent from one another. For example, 
shared medical practice among patients treated within the same hospital 
tends to yield more homogenous health outcomes within hospitals than 
between hospitals. Failing to address this intrinsic correlation can lead to 
spurious estimates.(Ash et al., 2012, Austin and Merlo, 2017, Daniels and 
Gatsonis, 1999, Gelman and Hill, 2006, Houchens et al., 2007, Normand et 
al., 2016, West et al., 2007) Moreover, substantive information may be gained 
by explicitly acknowledging the data hierarchy when analyzing processes that 
are thought to operate at more than one level. If the research interest is 
focused on describing the variability and heterogeneity in the population, 
rather than on the average values, estimating level-specific effects (e.g. 
hospital effects), and assessing the pathways through which these effects 
operate, that is effects associated with level-specific covariates (e.g. hospital-
level covariates).(European eGovernment Services, 2017, Austin and Merlo, 
2017, Austin et al., 2017, Daniels and Gatsonis, 1999, Houchens et al., 2007, 
Larsen and Merlo, 2005, Merlo et al., 2006, Merlo et al., 2016, Normand et al., 
2016)  
The scope of this thesis falls within the field of health services research, 
addressing aspects regarding variations in the provision and outcome of 
health care. The latter are thought to result from processes dependent both 
on characteristics of hospitals providing health care (also known as contextual 
effects) as well as on characteristics of patients receiving the health care in 
those hospitals (also known as composition effects), hence the data sets have 
a clustered data structure. In this section we introduce generalized linear 
mixed models (GLMM) also known as hierarchical generalized linear models 
(HGLM). These consist of statistical models increasingly used to address 
research questions focusing on variations by explicitly recognizing the nested 
structure of data, which are adequate for binary outcomes and that 
appropriately adjust estimates for within-cluster correlations.(Austin and 
Merlo, 2017) The GLMM represents an analytic strategy that accounts for 
correlations induced by clustering via modeling the outcome conditional on 
random effects (also known as the unobserved cluster effect).(Daniels and 
Gatsonis, 1999, Houchens et al., 2007, West et al., 2007) In its simplest 
formulation (random intercept models), the random effect represents random 
deviations from the relationships described by fixed effects. In contrast to 
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fixed effects, random effects are represented as random variables in a 
GLMM.(Houchens et al., 2007, West et al., 2007) 
The use of random effects permits explicit modeling of sources of variability 
added at each level of the hierarchy. Assuming that the data subject of study 
consist for example of observations regarding patients clustered within 
hospitals, within-hospital variability refers to the variability of outcomes across 
patients within hospitals; and between-hospital variability refers to the 
variability across hospitals. Within-cluster variation is less intuitive for models 
with binary outcomes, where, by definition, the outcome variable takes only 
two possible values. In such cases, it is common practice to reason about 
within-cluster variance with help of a latent variable model. Where the binary 
outcome results from a dichotomization of the latent variable – the 
unobservable propensity of the event.(Austin and Merlo, 2017, Merlo et al., 
2006, Teixeira‐Pinto and Normand, 2009) 
For the purpose of model specification within the context of GLMM consider a 
sample of observations regarding in-hospital mortality of patients clustered 
within the hospital where patients received treatment. Let Yij be 1 if the ith 
patient admitted to the jth hospital died during the hospitalization and 0 if the 
patient survived. The GLMM of a basic random intercept model can be 
specified as follows (Austin and Merlo, 2017, Goldstein, 2003): 
 
𝑌𝑖𝑗|𝑢0𝑗~ 𝑖𝑛𝑑 𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(𝑝𝑖𝑗) 
𝐸(𝑌𝑖𝑗) = 𝑝𝑖𝑗 
η𝑖𝑗 = g(𝑝𝑖𝑗) = log (
1 − 𝑝𝑖𝑗
𝑝𝑖𝑗
) = 𝑙𝑜𝑔𝑖𝑡(𝑝𝑖𝑗) 
𝜂𝑖𝑗 = 𝛽0 + 𝛽1𝑋1𝑖𝑗
𝑝 + 𝛽2𝑋2𝑖𝑗
𝑝 + ⋯ + 𝛽𝑘−1𝑋(𝑘−1)𝑖𝑗
ℎ + 𝛽𝑘𝑋𝑘𝑖𝑗
ℎ + 𝑢0𝑗𝑍𝑖𝑗 
 
 
𝑢0𝑗~𝑖𝑖𝑑 𝑁(0, 𝜎𝑢0
2) 
 
where, 
• E(Yij)=pij is the expected value of the Bernoulli variable which 
corresponds the probability of death of the ith patient admitted to the jth 
hospital; 
• g is the logit transformation of the expected probability, logit(pij), which 
corresponds to the log odds of death (Yij=1). The log odds has a linear 
relationship with the covariates; 
• Xkij is the observation for the ith patient admitted to the jth hospital 
regarding kth covariate, superscript indicates whether the covariate 
represents a patient-level covariate (p) or a hospital-level covariate (h); 
• βk is the fixed effect associated with a one-unit change in the 
corresponding kth covariate on the mean log odds of death (β0 
corresponded to the overall intercept, the mean log odds of death when 
all covariates are zero); 
• exp(βk) is adjusted death odds ratio due to an one-unit change in the  
kth covariate, given that all other covariates and random effects remain 
fixed; 
• Zij is equal to 1 in the random intercept model; 
Fixed effects Random effects 
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• u0j is the hospital random intercept, which is a normally-distributed 
random variable with zero mean and standard deviance σu0. 
Represents the distribution of hospital-specific intercepts. 
 
 
In this specification it is implicitly assumed that, conditional on covariates and 
on the hospital random effect, outcomes among patients treated in the same 
hospital are independent, and the random intercept is independent of the 
model covariates (X).(Gelman and Hill, 2006, Normand et al., 2016) 
Furthermore, several metrics have been proposed (Austin and Merlo, 2017, 
Krumholz et al., 2011, Krumholz et al., 2006, Larsen and Merlo, 2005, Merlo 
et al., 2006, Merlo et al., 2016) to extract from this type of models insights 
regarding the extent to which hospital represents a contextual effect and 
which patient and hospital characteristics influence hospital heterogeneity. 
Table 3.2 lists these metrics along with their definition and 
purpose/interpretation.  
Finally, while not explored in this thesis, the basic intercept random model can 
easily be extended to include a random coefficient (also known as random 
slope). This model allows the magnitude of patient-level associations (e.g. the 
association between a patient’s age and mortality) to vary across 
hospitals.(Gelman and Hill, 2006, Goldstein, 2003) 
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Table 3.2. Common metrics used to assess contextual effects within the context of clustered data.(Austin and Merlo, 2017, 
Krumholz et al., 2011, Krumholz et al., 2006, Larsen and Merlo, 2005, Merlo et al., 2006, Merlo et al., 2016) 
Name of the metric Formula Description Purpose/Interpretation 
Intraclass correlation 
coefficient (ICC) 
𝜎𝑢0
2
𝜎𝑢02 +
𝜋2
3
 
Describes the extent of correlation among 
observations within the hospitals.  
The larger the ICC the more relevant is the 
hospital contextual effect. 
Proportional change in 
variance (PCV) 
𝜎𝑢0
2−𝜎′𝑢0
2
𝜎𝑢0
2 , where 𝜎𝑢0
2 and 𝜎′𝑢0
2
are 
the estimated variances of nested 
models 
PCV is defined by the proportion of the between-
hospital variance that is explained by the 
additional covariates between two nested models. 
The larger the PCV the more influential are 
covariates in the extended model relative to 
the nested model. 
OR between a hospital ±1 
SD relative to the average 
hospital 
𝑒𝑥𝑝 (2 × √𝜎𝑢02) 
OR between a patient in hospital one SD above 
the average hospital relative to a hospital one SD 
below the average hospital. 
The larger the OR the more heterogeneous 
is the risk of patients across hospitals. In 
other words, the more relevant is the choice 
of hospital where the patient is treated. 
Median odds ratio (MOR) exp (0.6745 × √2 × 𝜎𝑢02) 
MOR is defined as the median value of the 
distribution of OR obtained when randomly picking 
two similar patients from two hospitals, and 
comparing the one from higher risk hospital to the 
one from the lower risk hospital. The MOR is 
comparable with patient-level ORs. 
The larger the MOR the more 
heterogeneous is the risk of patients across 
hospitals. In other words, the more relevant 
is the choice of hospital where the patient is 
treated. 
Proportion of opposed  
odds ratios (POOR) 
ϕ (−𝛽/√2 × 𝜎𝑢02), where ϕ 
represents the cumulative distribution 
function for the normal distribution; 
and beta represents the fixed effect 
associated with a hospital-level 
covariate 
Let pairwise OR be computed from comparing two 
subjects whose values of the given cluster-level 
covariate differ by one unit, but who have identical 
values for the other hospital-level and patient-level 
covariates. The POOR is then defined by the 
proportion of pairwise ORs with opposite direction 
to the cluster-level covariate OR. 
POOR may vary between 0% (all ORs have 
the same sign) and 50% (half of the ORs are 
of the opposite sign). A POOR of 50% 
suggests that the association between the 
cluster-level covariate and outcome is very 
heterogeneous. 
Interval odds ratio (IOR) 𝐼𝑂𝑅𝐿 = 𝑒𝑥𝑝 (𝛽 + √2 × 𝜎𝑢02
× 𝜙(0.1)) 
𝐼𝑂𝑅𝐿 = 𝑒𝑥𝑝 (𝛽 + √2 × 𝜎𝑢02
× 𝜙(0.9)) 
The IOR is an interval covering the middle 80% of 
the distribution of odds ratio that result from 
comparing two subjects whose values of the given 
cluster-level covariate differ by one unit, but who 
have identical values for the other hospital-level 
and patient-level covariates. 
The wider the IOR the more heterogeneous 
is the association between the cluster-level 
covariate and outcome. 
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devices were approved  earlier  in  Portugal. Nevertheless,  at least  five  of  these devices were
adopted  firs t  or  diffused  faster  in the US. Mortality due to  CHD and  myocardial  infarction (MI)  was
lower  in  Portugal (CHD:  72.8  vs. 168 and  MI: 48.7  vs. 54.1  in  Portugal and  the  US,  respectively;
age- and  gender-adjusted  deaths  per  100  000 population, 2010); but  only  CHD  deaths  exhibited
a  statistically significa nt  difference between the countries.
Conclusions:  Differences in regulatory  mechanisms  and  price regulations  have  a  significa nt
impact  on  the types  of  health  technologies available in  the two  countries.  However,  other
factors may  influe nce  their  adoption and  diffusion,  and  this  appears to  have a  greater  impact
on  mortality, due to  acute  conditions.
©  2017  Sociedade  Portuguesa  de Cardiologia. Published  by  Elsevier  Espan˜a,  S.L.U.  All  rights
reserved.
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A  divisão  atlântica  na  doenc¸a  coronária:  epidemiologia  e  cuidados  de  saúde
nos  Estados  Unidos  e  Portugal
Resumo
Introduc¸ão  e  objetivos:  O  objetivo  deste  estudo é  comparar  o acesso  a novas  tecnologias  em
saúde no  tratamento  da  doenc¸a coronária  (CHD),  entre  os  sistemas  de  saúde  de Portugal e
dos  Estados  Unidos (US),  caracterizando  as necessidades das  populac¸ões  e  disponibilidade  de
recursos.
Métodos:  Foram comparados dados (2000  e  2010) de  Portugal e  US  para  descrever  perfis  epi-
demiológicos e  recursos disponíveis  na  prestac¸ão cuidados de  saúde na CHD.  Trinta  tecnologias
de  saúde (16 dispositivos médicos e 14 medicamentos),  introduzidas durante 1980-2015,  foram
identific
a
das  por  cardiologistas de  intervenc¸ão  e  calcularam-se  as  diferenc¸as  entre  as datas  de
autorizac¸ão de  introduc¸ão no  mercado/comercializac¸ão  nos  dois países.
Resultados:  Relativamente aos  US,  Portugal apresenta  perfis  de  risco mais  baixos, menos
hospitalizac¸ões  per  capita,  menor  número de  centros per  capita  com valência  para cateterismo
coronário  e cirurgia  cardiotorácica.  Mais  de  70%  dos  medicamentos  foram  comercializados
mais  cedo nos US, enquanto  12  dos 16 dispositivos  médicos obtiveram  autorizac¸ão  para
comercializac¸ão  mais cedo em  Portugal. Contudo, pelo  menos  cinco destes dispositivos  foram
adotados primeiro  ou  sofreram  uma  difusão mais rápida  nos US.  A mortalidade  por  CHD
e  enfarte agudo do  miocárdio  (EAM) foi  inferior  em Portugal (CHD:  72,8  [Portugal] versus
168  [US];  AMI: 48,7  [Portugal]  versus  54,1 [US]; mortes por  100  000  habitantes,  padronizada
por  idade  e  sexo,  2010), tendo-se  apenas  verifica do  uma diferenc¸a significt iva  entre os  países
na mortalidade  por  CHD.
Conclusões:  Diferenc¸as  nos  mecanismos de regulac¸ão  e  controlo de  prec¸os  têm  um  impacto
signific
a
t ivo  no tipo de  tecnologias  disponíveis nos  dois  países.  Contudo,  outros  fatores  influ-
enciam  a sua adoc¸ão  e  difusão,  tendo  um  maior  impacto  na  mortalidade em  condic¸ões  mais
agudas.
©  2017  Sociedade Portuguesa  de  Cardiologia. Publicado  por  Elsevier  Espan˜a,  S.L.U. Todos os
direitos  reservados.
Introduction
The use  of health  technologies  has grown dramatically in
recent decades in developed  countries,  and  now  accounts
for a considerable  share  of national health  expenditure.1--7
Sustainability  of access to  health technologies  has become
a major  priority  in  Portugal and  worldwide, one  that is
grounded on  ethical principles  aiming at  maximizing  health
gains given limited  available  resources.8 A national system
for health  technology  assessment  (SiNATS)  is  currently  being
implemented  in Portugal.  It is  expected  to extend the exist-
ing health technology  assessment  system  to medical devices
and to include new  ways to  support  decision-making  based
on risk-sharing tools and real-world  data  monitoring.9 This
context makes it an opportune  time  to assess  contemporary
access  to  medical  devices  and drugs in  Portugal.
Different healthcare  systems adopt  new  health tech-
nologies at different speeds  and  usage  rates,  leading  to
disparities  in quality  of care between patients in different
countries.10--12 This results  from  a  combination of various
factors related  to different barriers and  needs,  includ-
ing  the  effic
i
ency  of  the  regulatory  process,  limitations
of the reimbursement system,  economic capacity,  avail-
ability  of resources,  and  the  epidemiology  of the  target
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AHA  American  Heart Association
CE Conformité Européenne
CHD  coronary  heart disease
CVD  cardiovascular  disease
DES  drug-eluting  stent
EU European  Union
FDA Food and  Drug  Administration
ICB  intracoronary  brachytherapy
INFARMED  Portuguese National Authority  for
Medicines and  Health Products
ISR  in-stent restenosis
LVS left  ventricular  support
MI  myocardial infarction
NHANES  National  Health  and  Nutrition Examination
Survey
PCI percutaneous  coronary  intervention
PTCA  percutaneous  transluminal coronary
angioplasty
TAVR transcatheter  aortic valve replacement
populations.11--14 Understanding  these  factors  and how  they
relate to  access to  and  initial use  of  health technologies is  of
crucial importance  to  improve  quality of  care,  particularly
when new  health technologies have  been proven  to be cost-
effective compared to previously  available  alternatives.
International  comparisons can provide insight into these
issues by  analyzing alternative settings,  needs,  and  out-
comes,  and providing  useful  information on factors that are
likely  to  affect  access  to  health technologies. This  exchange
of  experiences is  crucial to  generating  enhanced informa-
tion that can support decision-making  for  improved  quality
of  care.
Treatment  of coronary  heart disease (CHD)  has  benefite d
signific
a
nt ly  from technological  innovations,  both  medical
devices and drugs,  which have improved  clinical outcomes
and  quality  of care.2,15--19 However,  CHD remains one
of  the leading  causes  of death  in most  countries, with
signific
a
nt  economic  costs.2,20--23 With this in mind,  our
aim was to  provide  a  contemporary  historical overview  of
the  situation in  Portugal regarding access  to  innovations
in  health  technology  that  are  adjuvant or  alternative  CHD
therapies against  the  backdrop of the  risk profile  of the
population,  available resources  and  mortality rates,  using
information from  the US  as a  benchmark. The  intention  is
to bridge  the  gap  from  previous international comparison
studies assessing  health  technology  access that typically
focus  on  market-related  aspects,  few  of which  character-
ize populations’  needs and  the  resources available that
may  also  impact access to  and diffusion of new  health
technologies.11--13,24,25 We  chose  the  US because  of its  con-
trasting  healthcare system,  which is  driven  by  the  private
sector  and  is characterized  by  strikingly  high  per capita
health expenditures,  and because  its  regulatory  agency,  the
Food  and  Drug Administration (FDA), is  a  world reference  for
drug and  medical device assessment.  Moreover,  as  reported
by  Danzon et al.,13 the  US  launched more  drugs  with shorter
launch delays from  approval compared  to Portugal and
other  major markets during  the  1990s.  On the  other hand,
the  effic
i
ency  of the European Union (EU)’s system for
marketing approval of medical devices is  often  considered
a  key  feature  of the  better  access to  medical  devices in
EU  countries compared  to  the  US.26--28 This  makes the US
an interesting  contrast to Portugal that may  improve our
understanding  of factors  impacting  access  to and  adoption
of health technologies in  the  two  health systems.
Methods
We  conducted  a  comprehensive literature review  using
publications from national governmental  agencies, interna-
tional organizations,  professional  associations,  and  scientific
journals.  Information  was abstracted on prevalence of risk
factors and diseases,  hospitalization  and  mortality  rates,
infrastructure and  human resources associated  with  CHD
observed  between  2000  and  2010,  in Portugal and in the
US.  Approval  dates of selected medical devices and drugs
were abstracted  for chronological characterization of  access
to healthcare technology using databases  available at  the
FDA  and  the Portuguese National Authority  for Medicines
and  Health Products  (INFARMED)  (personal contact  with
INFARMED).29--32
Epidemiologic  profiles  of coronary  heart  disease
Self-reported prevalence  rates of  risk  factors for  CHD in
Portugal,  including  overweight  and  obesity,  hypercholes-
terolemia,  hypertension, diabetes and  current  smoking,
were abstracted  from the  AMALIA  study  on the prevalence
and  distribution of cardiovascular  risk factors  in Portugal.33
The  continuous datasets  of the National  Health and  Nutri-
tion Examination Survey  (NHANES)  were  used to  calculate
comparable  rates  for the  US,  applying  the  same  age inclu-
sion criteria,  time  period  and defini tions  of risk factors  as
in  AMALIA whenever  possible.33,34 Rates  for the  US were
calculated for adults aged 40  years  or  older  surveyed  in
the 2005-2006  and  2007-2008  NHANES cycles.  Calculations
of rates  were  based  on data  of self-perceived  hyperten-
sion,  hypercholesterolemia,  and  diabetes,  define d  as  the
participant’s  awareness of or current medication use  for
that condition,  and  smoking  status  was define d  as one  of
the following:  current smoker,  ex-smoker  or  non-smoker.
However,  overweight/obesity  prevalence  rates  for  the US
were based  on actual  measurements  of weight  and height,
whereas  AMALIA  used  self-reported  measures.  Age-adjusted
prevalence  rates were  computed for comparison between
the countries,  standardized to  the  2010  US  population (Table
A1  in Appendix A.  Supplementary  Material).  US  rates were
computed  using  SAS 9.4 with  code  available  on the  NHANES
tutorial website.35
CHD  prevalence  rates  are  not available  for  Portugal.
Instead estimates of  myocardial  infarction  (MI)  prevalence
were retrieved from the 2005-06  National Health Survey
cycle  and  standardized to the  2010  US population control-
ling  for  gender  and age.36 Both CHD  and  MI  estimates for
the US were  abstracted  from  statistical  reports  available
from  the American Heart Association (AHA) for  2010.2 Crude
per  capita hospitalizations  rates  were produced based  on
the numbers  reported by  the AHA  for the  US,  and by the
Directorate-General  of Health  for  Portugal  divided  by  esti-
mates of  the  total population.37--39
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Table  4  Availability of  specialized  health  facilities  and  per-
sonnel for  treatment  of coronary  heart  disease  in  the US and
Portugal, 2000  and  2010.
Variable  (no.
per  100  000
population)
US Portugal
2000 2010  2000  2010
Hospitals/centers
Cardiac  cath-
eterization
laboratory
- 0.5  0.2  0.3
Cardiotho-
racic  surgery
facilities
- 0.4  0.1  0.1
Medical  specialties
Cardiologists  7.2  7.2  6.8  7.8
Cardiotho-
racic
surgeons
1.7  1.4  0.9  1.1
The  number of centers providing cardiothoracic surgery in  the
US in  2000  was not available at the Area  Health  Resource Files
(AHRF).43 The number of  centers providing cardiac  catheteriza-
tion in 2000 was omitted given that the  AHRF  used  different
measures  over  the years, but numbers for 2010 were  consistent
with  those reported  by the  American  Hospital Association  Annual
Survey  Database for the fisc al  year 2010.
advantage remains  when considering the  firs t  model of  a
new  technological  family.
Earlier  approval  does not always  translate  into  earlier use
of  devices. The  firs t  medical  device approved  for  intracoro-
nary  brachytherapy  (ICB)  received  the CE  mark in  1999  but
only  diffused into Portugal in January  2001.  This  was  moti-
vated  by  the  FDA’s  approval  of the  Novoste  Beta-Cath system
(Novoste  Corp.) in  that  year, establishing ICB  as  an adjuvant
therapy  of PCI for  in-stent restenosis (ISR).46 Nevertheless,
it  ceased to  be used  within six  months of its adoption. In
the  US,  ICB saw  moderate  and decreasing  use due  to  a com-
bination  of factors,  including  the  approval  of drug-eluting
stents (DES)  two years  later,  which signific
a
nt ly  reduced  the
occurrence of ISR,  the logistic complexity  associated  with
ICB, and  the  increasing  evidence  favoring  DES over  ICB  to
treat ISR.19,47--49 Dangas et al. reported  that most  hospitals
no  longer  possess the  necessary  facilities to provide  ICB  in
the  US.50
DES were rapidly  adopted  in both  countries after their
approval.  Routine  implantation  of DES  began  immediately
after approval, in  2002 in Portugal and in  2003 in  the US.51,52
By  2003,  Portugal had the highest rate  of  DES implantation
in  Europe,  in  55%  of  PCI procedures,  and  by  the  third quar-
ter of  2005 the  use  of DES per  PCI peaked  at nearly  90%  in
the  US.51,53 However,  it  should be  noted that  Portugal has
the  lowest primary  PCI rates per  capita in Western Europe
and,  until 2007,  thrombolysis was  more commonly  used
than angioplasty  in the  treatment  of  ST-elevation myocar-
dial infarction.54,55 The  number of PCIs per in-patient case  in
Portugal  is  less  than half of  that in the  US.5 This  is  also  consis-
tent with the  established capacity  to treat patients assessed
by  the number of  specialized  physicians  and existing
infrastructure in each country (Table  4). Considerable  differ-
ences  were  observed between the  two  countries  regarding
the per  capita number  of cardiothoracic  surgeons  and spe-
cialized facilities.  Only  the  number of cardiologists per
capita  was comparable.  Moreover,  the  balance  between
the number  of  cardiac  catheterization  laboratories,  cardiac
surgery  centers,  interventional  cardiologists  and cardiotho-
racic surgeons,  and  the  potential  number  of  patients  to treat
is  an important but complex  topic of discussion  with impact
on access  and quality  of care.51,56,57 Although outside the
scope of this  paper,  this  is an important issue,  given  the
public  vs.  private nature  of the  two healthcare  systems,
their  economic capacity,  and observed  differences  in CHD
incidence  (Tables  2  and A2).
To our  knowledge there  are few  publications reporting
on the  real-world  implantation  of left  ventricular  support
(LVS)  devices,  specifica l ly  the  Impella  2.5  (Abiomed  Inc.)  and
TandemHeart  (CardiacAssist  Inc.). Results from  the Euro-
pella,  EUROSHOCK  and  USpella  registries  indicate  that the
US was  faster  in adopting the  Impella,  perhaps  in response
to early  European experience  with  these  devices.  Three
years after  the  approval  of the Impella  (data  collected
between July  2004  and December  2007), 144  elective high-
risk  PCI  patients with  prophylactic LVS using  the  Impella
were registered in  the Europella  registry  over 10  European
centers,  including one  from  Portugal.58 Hence,  on  average,
fiv
e
 patients  per center per  year were  implanted with this
device.  Maini et al.  reported  the  firs t  results  in the  USpella
registry  of  276  high-risk  PCI patients across  34 US centers.59
The  authors do not clearly  specify  the  reporting period  of
the data  but given the  initial collection  date (March  2010)
and  the submission  date  of the  article  (June  2011),  it can
be  assumed that  these  numbers  represent a  one-year  span.
Thus,  on average,  eight patients per  center  per year  were
implanted  with the  Impella  2.5.  It is  worth noting  that  the
intra-aortic balloon remains the  most frequently  used  device
for LVS.60--62
Transcatheter  aortic  valve replacement (TAVR)  devices
also saw  early  adoption and rapid  increase  in use follow-
ing  market  approval in both countries.63,64 According to  the
TAVR  registry  in Portugal,  TAVR  use  plateaued  in 2010  with
more  than 20  implants  per center (6.1 implants per  million
population).64 In  the  US,  Brennan et al. observed  a  signif-
icant increase in the  volume of TAVR use based  on TAVR
records  collected  between 2008 and  2013.63 In 2012,  one
year  after  the  firs t  TAVR  device  was  approved  by  the  FDA,
approximately  20  TAVR  procedures per  center were  per-
formed (15.8  implants  per million  population).
There  was  a  five - year  gap  between approval of  the
MitraClip device  (Abbott Vascular)  in  Portugal  and  the US.
However,  according  to  numbers  presented  at a  scientific
conference  in  April 2014,  the  firs t  case  treated using the
MitraClip in  Portugal was  in late  2012,  four  years after  its
market  approval.65 Since  then,  a  total  of  nine  cases have
been  treated  with this device.65 In  the  US, adoption appears
to have  been much faster,  given  that more  than five  hundred
cases had been  treated  in the US by  the  end of August  2014,
around  a  year  after  its  approval,  according  to figu r es  from
the TVT  registry  presented by  Sorajja et  al.  at  the  American
College  of Cardiology  2015  Scientific  Sessions.66 Further-
more,  by  August 2014,  there  were  76 centers  in the US
providing MitraClip  therapy  (around 0.25  centers per million
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population)  as opposed  to  two in Portugal  (0.19 centers per
million population).67,68
Drugs
In  contrast  to  devices,  information  on  approval  dates  of
drugs in Portugal is readily  available.  In addition  to approval
dates,  INFARMED  provides  information  on effective  mar-
keting  dates of drugs.  On  average,  marketing  of  drugs in
Portugal was delayed by  81 months  from  approval (median
65  months lag).  Although almost 60%  of the  selected drugs
were  approved  earlier in Portugal,  61%  were  marketed
earlier  in  the  US  (Figure  2  and Table  A5  in  Appendix  A.  Sup-
plementary  Material).  In particular,  outpatient prescription
of clopidogrel in  Portugal  started  in 2003,  the  same year
this  drug became  eligible  for  reimbursement and the  same
year  that effective  marketing  is reported  by  INFARMED.12
By  contrast,  in  the  US,  sales  of  clopidogrel,  marketed as
Plavix,  have  increased since  its approval in  1997.69 Longer
launch  times in Portugal may  be  driven by  both implementa-
tion of maximum  prices  and reimbursement  regulations  that
aim  to  control the governmental  budget,  but  also depend  on
the  launch  strategies  of pharmaceutical companies,  which
ultimately  decide  when to  launch  new  drugs onto  the mar-
ket.  Given the  pricing rules of  each country,  there  will  be
a specific order to  be  followed  by  each  proposed  drug, so
as  to  optimize pricing.  External  (cross-country)  price ref-
erencing  means that low  prices  tend to spill over  across
countries,  often delaying  launches  of new  drugs by  compa-
nies in  countries with  low  expected  prices  and small volume
sales  such  as  Portugal.13
Implications  of results  on  mortality
Our  results  show  that  CHD  deaths were  signific
a
nt ly  lower  in
Portugal compared  to  the US, but no statistical  difference
was  observed for  MI deaths between countries.  These  obser-
vations,  combined  with the  fact that MI is the  most acute
manifestation  of  CHD,  for  which the  use  of  health tech-
nologies by  trained professionals and  adequately  equipped
health  facilities may  prolong  both duration and quality  of
life,  suggest that differences  between  Portugal and the  US
in available resources  and  access to health technologies
(faster  access to  drugs,  earlier adoption and/or  faster  dif-
fusion of devices,  and  more specialized health facilities and
professionals in the  US compared to Portugal)  may  play  an
important role  in quality  of care,  mitigating  differences
in epidemiologic  risk  profile s .  Nevertheless,  only  Portugal
exhibited  a  statistically significa nt  decrease  in MI  mortality
in the decade under  study,  suggesting  that healthcare for
these patients  has  significa nt ly  improved in Portugal.  There-
fore,  it is  possible that  the  trends of approval  lags observed
in Figures 1 and 2,  increasingly  favorable to  Portugal  in more
recent years,  may  have  contributed  to  this  improvement.
Limitations
Our  study  has  some  limitations.  First,  rates  based on
self-perceived  measurements  likely  underestimate  the
prevalence  of risk  factors.  However,  additional evidence
confir
m
s  that most risk  factors  are less  prevalent in Portugal
than the US.  Only  hypertension appears to  be more preva-
lent  in  Portugal  (further details available as  supplementary
material).  Furthermore,  risk  profile s  were  determined
considering  the  overall populations of the two countries.
The  actual  profile s  of the  CHD populations  were not stud-
ied, which could explain the  differences  in usage patterns
and mortality  rates.  Second,  routine in-hospital use  of  clo-
pidogrel,  ticlopidine,  and abciximab in  Portugal began prior
to the  marketing  date  provided by  INFARMED.53,70--72 Particu-
larly in the  case  of  the drugs  indicated for exclusive  hospital
use  (e.g.  glycoprotein  IIb/IIIa  inhibitors),  these reports
substantially contradict INFARMED’s  marketing dates.  There-
fore,  information on  marketing  should  be  regarded  with
caution with regard  to  drugs  that  are  to be  used in-hospital
only.  Third,  the brief discussion on adoption and  diffusion of
healthcare  technology is based  on  key  scientific  papers  for
a few  technologies.  A  deeper  understanding  of the adoption
mechanisms  is thus  required.  Furthermore,  death certifi-
cates  may  inaccurately  state  the  cause  of  death  and fail
to describe  the  effectiveness of  technologies.  There is thus
a need for better  knowledge  of  the  diffusion patterns and
effectiveness of  health technologies,  ideally  through the
development and analysis of equivalent datasets from the
two  healthcare  systems.
Conclusions
Our results  show  that differences in regulatory mechanisms
and price  regulations have a significa nt  impact on market
access  strategies  and  on  the  types of treatment  available for
CHD,  benefit
i
ng  the  US in  the  case  of drug availability  while
favoring  Portugal  in the  case of medical devices.  Differences
in risk  profils  and available  resources  may partially  explain
the  differences in adoption of devices  after approval on the
two  sides of  the  Atlantic,  as  at least five  devices  considered
were adopted  firs t  or  diffused  faster in  the  US despite the
initial  advantage of earlier  approval in Portugal.  Other  fac-
tors may  also  play  an important  role.  On  the  other  hand,
the  ability  of the  US  to adopt and  diffuse health technolo-
gies faster and  over  more centers may  have contributed  to
better  quality  of acute care  compared  to Portugal,  mitigat-
ing  differences between the  two countries in  epidemiologic
risk profil
e
s .
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Understanding hospital heterogeneity in quality of care for acute 
myocardial infarction 
 
ABSTRACT 
Background Between 2000-2010, acute myocardial infarction (AMI) hospitalizations 
increased 33% in Portugal. While in-hospital mortality rates among AMI patients declined by 
32%, marked disparities across geographical regions and hospitals were observed. 
Objective To study the variation of risk of mortality and readmission in AMI patients across 
hospitals using contemporary datasets, assessing the impact of patient and hospital 
characteristics in between-hospital variability. 
Methods Retrospective observational study of AMI cohorts using administrative hospital 
data of adults discharged between 2012 and 2015 from all acute care public hospitals in 
Portugal. All-cause in-hospital mortality in AMI patients and 30-day all-cause unplanned 
readmission in patients surviving the AMI were studied in separate cohorts. Crude rates were 
computed overall, across years and across hospital characteristics. Hierarchical generalized 
linear models were implemented using a step-up strategy that quantifies between-hospital 
variance. 
Results The mortality cohort included 38059 patients while the readmission cohort included 
34256. 10% died and 8% of patients were readmitted. Between-hospital variability was larger 
in the mortality cohort. Patient characteristics accounted for a larger share of the explained 
between-hospital variance regardless of cohort, with hospital characteristics explaining an 
additional 2% and 12% of hospital heterogeneity in the mortality and the readmission cohorts 
respectively. Admissions to hospitals with low AMI caseload or located in Alentejo/Algarve 
and Lisbon had higher risk of mortality. Discharges from larger-sized hospitals were 
associated with increased risk of readmissions. 
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Conclusions Hospital represents a contextual effect as relevant as a patient characteristic. 
However, while hospital characteristics substantially explain this effect in readmissions, 
practically no between-hospital variability was explained by hospital characteristics in the 
mortality cohort. Further investigation addressing geographical disparities, hospital caseload 
and practices is needed. 
 
Keywords: acute myocardial infarction, administrative data, hierarchical regression models, 
hospital healthcare quality, in-hospital mortality, 30-day unplanned readmissions. 
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INTRODUCTION 
Acute myocardial infarction (AMI) remains one of the leading causes of death in most 
developed countries.[1] Moreover, expensive health care management,[2,3] and high risk of 
re-hospitalization make AMI a significant economic burden to health care systems.[4-6] 
Therefore, regular monitoring is essential for an understanding of factors that can alleviate 
this burden and improve health care quality. With increasing numbers of AMI discharges,[1] 
patients hospitalized for AMI in Portugal have  higher in-hospital mortality risk compared to 
other countries with marked differences across geographical regions and hospitals.[1,7-9] 
Prior research indicated that the risk of dying in a high mortality hospital relative to a low 
mortality hospital in Portugal was more than double, after adjusting for patient case-mix.[9] 
Whether similar heterogeneity across hospitals in other quality metrics exists is unknown. For 
example, unplanned readmissions within 30-days of discharge may reflect suboptimal care 
during the index hospitalization or poor transition from inpatient to outpatient care. 
Consequently, 30-day all-cause unplanned readmissions have been endorsed by various 
professional societies and health systems as a meaningful quality metric.  Only a few studies 
have examined readmissions after a AMI in Portugal, with most based on single-center 
experiences that lack national representativeness or focus on 6-month readmission rates 
which is less likely to be associated with the quality of care provided during the index 
hospitalization.[10-16] Moreover, no study has characterized variability across different 
hospitals in readmission rates.   
An increasing body of evidence shows that several key hospital characteristics are associated 
with quality of care for patients hospitalized for AMI.[4,17-19] For example, centers 
providing percutaneous coronary interventions (PCI) and coronary artery bypass graft 
(CABG) surgery have lower mortality when compared to centers without these 
services.[17,19] Hospital size, AMI volume, and teaching status are  also positively 
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associated with hospital’s quality of care.[4,17,18]  Whether hospital characteristics are 
associated with quality of care for AMI patients treated in Portugal and how much of 
between-hospital variation is associated with these characteristics is unknown. 
 
We thus sought to assess heterogeneity in quality of care in AMI management across 
hospitals in Portugal using a contemporary cohort of adults treated for AMI. Specifically, 
after adjusting for patient characteristics, we quantify between-hospital variability in in-
hospital mortality odds and in 30-day unplanned readmission odds for those surviving the 
index admission.  We also determine if hospital characteristics account for some of this 
heterogeneity. 
 
METHODS 
Data Sources 
We identified hospitalizations occurring between January 1st 2011 and January 30th 2016 
from all mainland public hospitals in Portugal kept at the Central Administration of the 
Health System (ACSS).[20]  Public hospitals account for 79% of all inpatient discharges and 
represent 52% of all hospitals in Portugal.[21-23] The data maintained by ACSS includes 
information about patient demographic characteristics, principal and secondary diagnoses, 
discharge status, type of admission, admission and discharge dates, length of stay, unique 
hospital identifiers, and in-hospital procedures. Diagnoses and procedures utilized the 
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) 
system. Information collected reflects both inpatient and outpatient hospital care. Patient 
traceability is available through a unique and anonymous patient identification variable 
provided by ACSS. 
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We obtained hospital characteristics using multiple data sources.  These included hospital 
account reports describing the number of hospital beds available at ACSS and or at hospital 
websites; information regarding geographical classification was retrieved from Eurostat; 
annual reports published by the National Program on Cerebral and Cardiovascular Diseases 
[24] as well as personal communication with hospitals confirmed hospital history of 
provision of coronary revascularization procedures; and official documents of laws enacted in 
Portugal (dre.pt) were used to track hospital merges over time. 
 
Episode of care 
Hospitalizations in which the patient was transferred in or out within the same episode of care 
were identified. These consisted of hospitalizations sharing the same patient identification 
and one of the following was verified: 1) dates of admission and discharge of one 
hospitalization were enclosed in the dates of admission and discharge of another 
hospitalization; 2) discharge date of the initial hospitalization and admission date of the 
subsequent hospitalization differed by ≤1 day and there was indication of the hospital id 
where the patient was transferred from or to; b) the date of admission of the subsequent 
hospitalization occurred on the same day of discharge from the initial hospitalization; c) the 
initial and subsequent hospitalizations had overlapping admission and discharge dates. In the 
case 1), the hospital with longer stay was considered responsible for admitting and 
discharging the patient. The disposition status of an episode of care was defined by the 
disposition status of the final hospitalization; the length of stay was computed as the 
difference between the discharge date of the final hospitalization and the admission date of 
the initial hospitalization. 
 
Study Cohorts/Participants 
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We created two cohorts, the mortality cohort and the readmission cohort (Figure 1). All 
inpatient discharges of adults (≥20 years at admission) with a principal diagnosis of AMI 
(ICD-9-CM code of 410.xx, except if a 2 in the fifth digit) discharged between January 1st 
2012 and December 31st 2015 were identified. In the event of episodes with multiple 
hospitalizations, an AMI episode of care was defined if both principal diagnoses of the initial 
and final hospitalizations of that episode were an AMI. Only the initial hospitalization was 
included in the mortality cohort (referred as index hospitalization in this cohort), while only 
the final hospitalization was included in the readmission cohort (referred as index 
hospitalization in the readmission cohort). Therefore, the responsibility for the episode was 
attributed to the admitting hospital in the mortality cohort and to the discharging hospital in 
the readmission cohort. 
We excluded hospitalizations of patients discharged alive on the same day of admission or 
who left against medical advice or discharged from a specialized hospital (oncological, 
psychiatric, maternity) and without a transfer to another hospital status because these are 
unlikely to represent an AMI. Even after combining hospitalizations into a single episode of 
care, a few discharges remained with a disposition status of transfer to another acute care 
facility (n=981, 2%).  Although we cannot rule out issues related with patient identification, 
this can happen if for example the admitting hospital transfers temporarily the patient to 
another hospital to receive a revascularization procedure returning to the initial hospital and 
both hospitalizations are documented with a transfer out status. These were excluded since it 
is not possible to ascertain the final disposition of the patient. Hospitals with fewer than 25 
index events over the entire time frame were also excluded given the insufficient data for 
evaluating hospital performance.[4,19,25] 
In the mortality cohort we randomly selected an AMI hospitalization per patient with a 
discharge date occurring between January 1st 2012 and December 31st 2015. Patients 
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discharged to hospice were excluded from the mortality cohort because these patient are more 
likely to die in the immediate time after discharge.[26] The readmission cohort included all 
first AMI hospitalization of patients discharged alive between January 1st 2012 and 
December 31st 2015. This approach allows for a clear clustered data structure (one episode 
per patient) in this cohort as well, hence minimizing issues related with correlation among 
outcomes observed for the same patient. 
 
Patient characteristics 
We considered demographic information (age and sex), risk factors and comorbidities to 
characterize patients in the cohorts. For risk-adjustment we identified 29 risk factors and 
comorbid conditions variables derived from the (principal and secondary) diagnoses codes 
and procedure codes of (inpatient and outpatient) hospitalizations of the patient occurring 
during 1 year before the index hospitalization; and secondary diagnoses of the index 
hospitalization.[5,27] These represent pre-existing conditions that are clinically relevant and 
have a relationship with the outcome. In the event of episodes of care with multiple 
hospitalizations in the readmission cohort, complications arising in prior hospitalizations 
within the same episode will also be considered as pre-existing conditions so that the final 
hospital is not accountable for those complications. Inpatient data within 30 days after 
discharge of patients surviving the index hospitalization were used to identify readmissions.  
 
Hospital characteristics 
Hospitals were characterized by their teaching status, capability to provide PCI and CABG 
procedures, volume of AMI cases, number of beds, and geographical location. Teaching 
status was determined according to the Medical National Federation.[28] We defined a 
hospital with capacity to provide PCI and with capacity to provide CABG procedures if, in 
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2010, that hospital had a catheterization lab and cardiothoracic surgery service respectively; 
hospital AMI volume was estimated from the inpatient data during 2011; the number of 
inpatient beds were determined in 2010/2011 (or nearest year); geographical location was 
assigned based on the second level of the Nomenclature of Territorial Units for Statistics 
(NUTS II) that divides mainland Portugal into 5 regions (North, Center, Lisbon, Alentejo and 
Algarve).[29] The region of Algarve was combined with Alentejo because there was only one 
hospital in that region and Algarve only borders with Alentejo in the south of Portugal 
(Figure S1). Hospital identification expresses the merges of hospitals into hospital centers, 
which occurred mostly in the previous decade. Two hospital merges occurred during the 
study period. In these cases we considered the hospital center throughout the entire period, 
hence their characteristics result from the combination of the individual hospital 
characteristics (e.g. size corresponds to the sum of beds of all hospitals included in the 
hospital center). Characterization of each hospital is provided as supplementary data (Table 
S1).  
 
Outcome measures 
We examined two outcome measures.  All-cause in-hospital mortality was accessed through 
the mortality cohort and 30-day all-cause readmission through the readmission cohort. The 
latter was defined by an unplanned re-hospitalization in any public hospital (excluding 
hospitals in insular territory) due to any cause within 30 days after discharge of an index AMI 
hospitalization. Unplanned hospitalizations were identified if urgent status was assigned in 
the variable Admission Type, otherwise the hospitalization was considered elective. 
Readmissions that occur in private hospitals are not captured in this database. 
 
Statistical Analysis 
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Data checks and integrity tests were carried to assure quality of the data.  Hospitalizations 
with an admission date after the discharge date, or hospitalizations belonging to the same 
patient with a disposition status of death in the earlier hospitalization, or hospitalizations of 
patients with unknown gender were excluded. We characterized the cohorts of patients 
overall and across years computing the appropriate metrics for the type of data (count, 
percentage, mean, standard deviation (SD) or median and interquartile range (IQR)). Crude 
readmission and mortality rates were also computed overall and by hospital characteristics 
levels. Funnel plots of hospital-specific risk-standardized rates, defined as the observed-
expected ratio of deaths/readmission in a hospital times the crude death/readmission national 
rate, were produced by hospital characteristics to assess performance of hospitals against a 
measure of its precision.[30]  
We estimated hierarchical models that incorporate the multilevel structure of the data (patient 
discharges within hospitals) and provide measures of source of variability across the different 
data levels.[31] Particularly, we implemented generalized linear mixed models to account for 
data clustering at the hospital level and to explicitly estimate between-hospital variability, 
assuming a normally distributed random intercept for hospital. We estimated a series of 
models that differed in terms of the characteristics included. We first specified an empty 
model (Model 0) that provided unadjusted rates that accounted for clustering.  Next, we 
included patient-level variables (Model 1), and then added hospital-level variables to Model 1 
(Model 2) (model specification is available as supplementary data).  
We estimated the Intraclass Correlation Coefficient (ICC) to describe the extent of 
correlation among observations within the hospitals.[32,33] Caterpillar plots were used to 
summarize hospital random effects across the different models.  To further characterize 
between-hospital variation we estimated the odds of the outcome for a patient treated at a 
moderately high (+1 SD) relative to a moderately low (-1 SD) mortality/readmitting 
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hospital and the median odds ratio (MOR), which is defined as the median value of the 
distribution of odds ratio (OR) obtained when randomly picking two similar patients from 
two different hospitals, and comparing the one from higher risk hospital to the one from the 
lower risk hospital.[5,33] To quantify the association of patient and hospital characteristics 
with hospital heterogeneity, we computed proportional change in variance (PCV) defined by 
the proportion of the between-hospital variance that is explained by the additional covariates 
between two nested models.[34,35] We additionally computed the proportion of opposed 
odds ratios (POOR) for hospital-level covariates to assess the degree of heterogeneity of the 
association of this variables within hospital characteristics.[34,35] The c-statistic was also 
computed to assess quality of classification of the different models. 
RESULTS 
In-Hospital Mortality 
We identified 38 059 AMI index hospitalizations in 37 hospitals. Most hospitalizations 
belonged to male patients and mean age of patients was 69 (±14) years. Coronary 
atherosclerosis (67%), diabetes mellitus (35%), valvular rheumatic heart disease (18%), 
angina pectoris (13%), iron deficiencies (13%), and history of percutaneous transluminal 
coronary angioplasty (PTCA) (11%) were the most common comorbidities.  The median 
length of stay was 5 days (IQR = [4,9]) and 10% of patients died during the hospitalization 
(Table 1). The mean number of index hospitalizations per hospital ranged from 250 
(SD=176) in 2012 to 264 (SD=184) in 2015. Forty-six percent of hospitals exhibited risk-
adjusted in-hospital mortality rates outside the expected range of normal sampling variation, 
half of which were above the upper 95% limit (Figures S2 (A)). 
Table 2 summarizes results obtained from the stepwise multivariable analysis carried. The 
estimated between-hospital variance ignoring the effect of patient and hospital characteristics 
(Model 0) was 0.277 (SE=0.0697) in the mortality cohort, indicating that 8% of the total 
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variation is due to between-hospital variation (ICC=0.078). Inclusion of patient 
characteristics (Model 1) reduced between-hospital variation to 0.135 (SE=0. 03586), a 51% 
decline. The risk of mortality of patients in a hospital 1 SD above average is 2.08 times that 
of patients in a hospital 1 SD below average. The MOR was 1.42, which represents the 
median increased odds of mortality if a patient would be admitted at another hospital with 
higher risk. Only nine of patient-level characteristics exhibited an OR larger than MOR. 
Adding hospital characteristics (Model 2) further reduced between-hospital variability to 
0.129 (SE=03867), representing a 4% relative decrease (Table 2, Figure S3). AMI volume 
(OR=0.86, 95% CI: [0.74,0.98] for a 100-AMI case increase) and geographical location of 
hospital (Alentejo or Algarve: OR=1.58, 95% CI: [1.05,2.36]; Lisbon: OR=1.43, 95% CI: 
[1.01,2.01] relative to the North region) had, on average, significant associations with 
mortality. However, these associations, in particular AMI volume, were heterogeneous 
(POOR= 50%, 19% and 24% respectively). 
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Table 1. Characteristics of patients in the mortality cohort. 
Year 2012 2013 2014 2015 All 
#Discharges 9239 9608 9442 9770 38059 
#Hospitals 37 37 37 37 37 
LOS, median (IQR) days 6 [4,9] 5 [4,8] 5 [4,9] 5 [4,9] 5 [4,9] 
Female, % of discharges 34.7 35.3 35.2 35.0 35.0 
Age, mean (SD) 69 (14) 69 (14) 69 (14) 69 (14) 69 (14) 
≥ 80 years, % of discharges 26.0 26.1 26.5 26.6 26.3 
Cardiovascular comorbidities, %      
MI Location, %       
Anterior (410.0x, 410.1x) 19.6 19.5 18.5 18.8 19.1 
Other location (410.2x - 410.6x) 20.7 21.1 20.4 19.5 20.4 
History of CABG (V45.81, 36.10-36.16) 4.0 4.2 4.4 3.9 4.1 
History of PTCA (V45.82, 00.66, 36.01, 36.02, 36.05, 36.06, 
36.07) 
10.5 10.3 10.0 11.4 10.6 
Angina Pectoris/Old Myocardial Infarction (CC 83) 12.8 12.6 13.3 13.4 13.0 
Congestive Heart Failure (CC 80) 6.2 6.0 6.2 6.0 6.1 
Coronary Atherosclerosis (CC 84) 63.1 66.5 69.8 69.1 67.2 
Acute Coronary Syndrome (CC 81-82) 4.9 4.5 4.1 4.4 4.5 
Specified Arrhythmias (CC 92-93) 4.9 4.9 5.7 5.7 5.3 
Valvular or Rheumatic Heart Disease (CC 86) 17.3 18.3 17.9 16.9 17.6 
Cerebrovascular Disease (CC 97-99, 103) 4.1 4.3 4.6 5.1 4.5 
Stroke (CC 95-96) 1.2 1.0 1.2 1.2 1.1 
Vascular or Circulatory Disease (CC 104-106) 2.9 3.0 3.3 3.4 3.2 
Comorbidities, %      
Hemiplegia, Paraplegia, Paralysis, Functional Disability (CC 
67-69, 100-102, 177-178) 
1.6 1.9 1.8 1.9 1.8 
Diabetes Mellitus (DM) or DM Complications (CC 15-19, 
119-120) 
33.4 34.7 34.9 35.2 34.6 
Renal Failure (CC 131) 4.2 4.2 4.4 4.5 4.3 
End-Stage Renal Disease or Dialysis (CC 130) 0.8 0.9 0.7 0.8 0.8 
Other Urinary Tract Disorders (CC 136) 5.3 5.3 6.4 7.3 6.1 
Chronic obstructive pulmonary disease (COPD) (CC 108) 5.9 6.4 6.4 6.8 6.4 
Pneumonia (CC 111-113) 5.6 5.4 5.7 5.9 5.7 
Asthma (CC 110) 1.2 1.2 1.4 1.7 1.4 
Disorders of Fluid/Electrolyte/Acid-Base (CC 22-23) 2.8 3.7 3.9 4.2 3.7 
History of infection (CC 1, 3-6) 2.6 2.9 2.7 3.1 2.8 
Metastatic Cancer or Acute Leukemia (CC 7) 0.8 0.9 0.7 0.8 0.8 
Cancer (CC 8-12) 3.1 3.4 3.3 3.4 3.3 
Iron Deficiency or Other Unspecified Anemias and Blood 
Disease (CC 47) 
13.1 13.2 13.5 13.8 13.4 
Decubitus Ulcer or Chronic Skin Ulcer (CC 148-149) 0.7 0.7 0.8 0.8 0.7 
Dementia or Other Specified Brain Disorders (CC 49-50) 4.2 4.0 4.8 5.5 4.6 
Protein-Calorie Malnutrition (CC 21) 0.2 0.3 0.2 0.3 0.3 
Outcome measures, %      
In-hospital deaths 11.1 10.1 10.4 9.5 10.3 
LOS – Length of stay; IQR – Inter quartile range; SD – Standard deviation; MI – Myocardial infarction; CABG  - 
Coronary Artery Bypass Graft; PTCA – Percutaneous Transluminal Coronary Angioplasty; CC – Condition category; DM 
– Diabetes Mellitus.  
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Table 2. Risk-adjusted odds ratios for 30-day all-cause in-hospital mortality after AMI. Age centered at 68 years, northern region used 
as reference class in geographical location. Bold font indicates statically significance odds ratios. 
Model 
Model 0  
(Empty model) 
Model 1 Model 2 
Covariate OR 95% CI OR 95% CI OR 95% CI 
Intercept, Estimate (SE) -2.0845 (0.08886) -2.2925 (0.07517) -2.6619 (0.1825) 
Patient characteristics 
         
5-year change increase 
   
1.32 1.28 1.34 1.32 1.29 1.34 
Female vs, Male 
   
0.93 0.86 1.01 0.93 0.86 1.01 
History of CABG    1.27 1.06 1.53 1,27 1,06 1,53 
History of PTCA    0.73 0.62 0.85 0,73 0,62 0,85 
Angina Pectoris/Old Myocardial Infarction     1.08 0.96 1.22 1,08 0,96 1,23 
Congestive Heart Failure    1.12 0.96 1.31 1,12 0,96 1,31 
Coronary Atherosclerosis    0.36 0.33 0.39 0,36 0,33 0,39 
Acute Coronary Syndrome    1.09 0.91 1.32 1,09 0,91 1,31 
Specified Arrhythmias    1.03 0.88 1.20 1,03 0,88 1,20 
Valvular or Rheumatic Heart Disease    0.90 0.81 0.99 0,90 0,82 0,99 
Cerebrovascular Disease    1.14 0.99 1.32 1,14 0,99 1,32 
Stroke    1.04 0.78 1.39 1,04 0,78 1,39 
Vascular or Circulatory Disease    1.10 0.91 1.33 1,10 0,91 1,33 
Hemiplegia, Paraplegia, Paralysis, Functional Disability    1.27 1.00 1.61 1,27 1,00 1,61 
Diabetes Mellitus (DM) or DM Complications    1.13 1.04 1.21 1,13 1,04 1,21 
Renal Failure    1.20 1.00 1.44 1,20 1,00 1,44 
End-Stage Renal Disease or Dialysi    1.72 1.22 2.41 1,71 1,22 2,41 
Other Urinary Tract Disorders    1.56 1.38 1.76 1,57 1,39 1,76 
Chronic obstructive pulmonary disease     1.16 1.02 1.32 1,16 1,02 1,32 
Pneumonia    2.09 1.86 2.34 2,08 1,86 2,34 
Asthma    0.66 0.47 0.92 0,66 0,47 0,92 
Disorders of Fluid/Electrolyte/Acid-Base    1.01 0.85 1.20 1,01 0,84 1,20 
History of infection    1.14 0.94 1.37 1,14 0,94 1,37 
Metastatic Cancer or Acute Leukemia    2.27 1.69 3.07 2,28 1,69 3,07 
Cancer    1.19 1.00 1.41 1,19 1,00 1,41 
Iron Deficiency or Other Unspecified Anemias and Blood Disease    0.95 0.86 1.05 0,95 0,86 1,05 
Decubitus Ulcer or Chronic Skin Ulcer    1.16 0.83 1.63 1,16 0,83 1,63 
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Dementia or Other Specified Brain Disorders    1.10 0.97 1.26 1,10 0,97 1,26 
Protein-Calorie Malnutrition    4.15 2.63 6.55 4,16 2,63 6,57 
Anterior location of MI    2.29 2.09 2.52 2,30 2,09 2,52 
Other location of MI    1.69 1.53 1.86 1,69 1,53 1,87 
Hospital characteristics 
         
100-case increase in AMI volume (centered at the mean) 
      
0.86 0.74 0.98 
POOR       49%   
100-bed increase (centered at the mean) 
      
1.02 0.96 1.08 
POOR       50%   
Teaching vs, non-teaching 
      
1.09 0.73 1.62 
POOR       44%   
Catheterization lab availability (yes vs, no) 
      
1.13 0.78 1.65 
POOR       40%   
Cardio-thoracic surgery capacity (yes vs, no) 
      
1.56 0.97 2.53 
POOR       19%   
Geographic location 
         
North 
 
ref ref ref ref ref ref ref ref 
Alentejo or Algarve 
      
1.58 1.05 2.36 
POOR       19%   
Center 
      
1.24 0.86 1.81 
POOR       33%   
Lisbon 
      
1.43 1.01 2.01 
POOR       24%   
Variability components Estimate Standard error Estimate Standard error Estimate Standard error 
Between-hospital variance 0.277 (0.0697) 0.135 (0.03586) 0.129 (0.03867) 
ICC 0.078   0.039   0.038   
OR between a hospital ±1 SD relative to the average hospital1 2.86   2.08   2.05   
MOR 1.65   1.42   1.41   
PCV    51%   4%   
C-statistic 0.61 (0.0048) 0.80 (0.00359) 0.80 (0.00359) 
SE – Standard error; OR – odds ratio; CI – Confidence interval; POOR – proportion of opposed odds ratios (ϕ(-β/(√2×variance)), where ϕ represents the cumulative 
distribution function for the normal distribution) ; ICC – Intraclass correlation coefficient (variance/(variance+π2/3)); MOR – Median odds ratio 
(exp[0.6745×√(2*varianace)]); PCV – proportional change in variance ((variancemodel(n-1)-variancemodel(n))/variancemodel(n-1)).[33-35] 
1 =exp[(2*sqrt(variance))][5]  
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30-day Unplanned Readmissions 
We identified 34 256 AMI hospitalizations occurring in 37 hospitals in the readmission 
cohort. Most hospitalizations were associated with male patients and mean age of patients 
was 68 (±14) years. The most prevalent comorbid conditions among the readmission cohort 
were coronary atherosclerosis (71%), diabetes mellitus (34%), valvular rheumatic heart 
disease (18%), angina pectoris (12%), iron deficiencies (12%), and history of PTCA (12%).  
8% of patients discharged between 2012 and 2015 were readmitted within 30-days for an 
unplanned hospitalization. The median time between discharge and readmission was 10 days 
(IQR = [5,19])  (Table 3).  Moreover, while crude readmission rates were stable throughout 
this period, the proportion of readmissions for a recurrent AMI decreased from 17% to 14%. 
The mean number of index hospitalizations per hospital was 230 (SD=171) in 2012 and 233 
(SD=168) in 2015. Risk-adjusted readmission rates of 30% of hospitals fell outside the 
expected range of normal sampling variation, but were equally distributed below and above 
the 95% limits (Figures S2 (B)). 
The estimated between-hospital variance in Model 0 was 0.080 (SE=0.026), hence 2% of the 
total variation is due to between-hospital variation (Table 4). Similarly to the mortality 
cohort, in the readmission cohort the inclusion of patient characteristics (Model 1) produced a 
56% decline in the between-hospital variance to 0.035 (SE=0.013). The latter indicating that 
the odds of readmission of patients in a hospital 1 SD above average is 1.46 times that of 
patients in a hospital 1 SD below average. The MOR was 1.20, which represents a stronger 
association than 15 of patient-level variables. Adding hospital characteristics (Model 2) 
further reduced between-hospital variability to 0.027 (SE=0.014), a 23% relative decrease 
(Table 4, Figure S4). Finally, hospital size had a small but statistically significant effect on 
the risk of readmissions (OR=1.03, 95% CI: [1.002,1.06] for a 100-bed increase).  However, 
this association was very heterogeneous (POOR= 49%). 
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Table 3. Characteristics of patients in the readmission cohort. 
  Readmission cohort 
Year 2012 2013 2014 2015 All 
#Discharges 8508 8731 8406 8611 34256 
#Hospitals 37 37 37 37 37 
LOS, median (IQR) 6 [4,9] 6 [4,9] 6 [4,9] 5 [4,9] 6 [4,9] 
Female, % of discharges 33.6 34.0 34.1 33.9 33.9 
Age, mean (SD) 68 (14) 67 (14) 68 (14) 68 (14) 68 (14) 
≥ 80 years, % of discharges 22.9 23.0 22.9 23.6 23.1 
Cardiovascular comorbidities, %      
MI Location, % of STEMI      
Anterior location of MI (410.0x, 410.1x) 18.7 19.2 18.3 18.8 18.7 
Other location of MI (410.2x - 410.6x) 20.9 21.2 21.1 19.8 20.8 
History of CABG (V45.81, 36.10-36.16) 4.2 4.1 4.3 3.7 4.1 
History of PTCA (V45.82, 00.66, 36.01, 36.02, 36.05, 
36.06, 36.07) 
12.3 10.9 11.1 12.2 11.6 
Angina Pectoris/Old Myocardial Infarction (CC 83) 13.1 12.1 12.2 12.0 12.4 
Congestive Heart Failure (CC 80) 5.8 5.1 5.3 5.3 5.4 
Coronary Atherosclerosis (CC 84) 67.8 70.1 73.6 73.3 71.2 
Acute Coronary Syndrome (CC 81-82) 6.8 5.1 5.5 6.5 6.0 
Specified Arrhythmias (CC 92-93) 5.1 4.4 5.3 5.6 5.1 
Valvular or Rheumatic Heart Disease (CC 86) 17.9 18.0 17.4 16.9 17.6 
Cerebrovascular Disease (CC 97-99, 103) 3.7 3.7 4.0 4.5 4.0 
Stroke (CC 95-96) 1.1 0.9 1.1 1.1 1.0 
Vascular or Circulatory Disease (CC 104-106) 3.0 2.6 3.1 3.1 2.9 
Comorbidities, %      
Hemiplegia, Paraplegia, Paralysis, Functional 
Disability (CC 67-69, 100-102, 177-178) 
1.5 1.6 1.7 1.6 1.6 
Diabetes Mellitus (DM) or DM Complications (CC 15-
19, 119-120) 
34.1 34.0 34.7 34.6 34.4 
Renal Failure (CC 131) 3.9 3.6 3.5 3.8 3.7 
End-Stage Renal Disease or Dialysis (CC 130) 0.7 1.0 0.6 0.7 0.7 
Other Urinary Tract Disorders (CC 136) 4.7 4.4 5.4 6.7 5.3 
Chronic obstructive pulmonary disease (COPD) (CC 
108) 
5.7 5.9 6.2 6.5 6.1 
Pneumonia (CC 111-113) 4.7 4.3 4.4 4.7 4.5 
Asthma (CC 110) 1.3 1.2 1.5 1.8 1.4 
Disorders of Fluid/Electrolyte/Acid-Base (CC 22-23) 2.6 3.2 3.5 3.8 3.3 
History of infection (CC 1, 3-6) 2.3 2.5 2.4 2.7 2.5 
Metastatic Cancer or Acute Leukemia (CC 7) 0.6 0.8 0.6 0.6 0.7 
Cancer (CC 8-12) 2.8 3.0 3.0 3.1 3.0 
Iron Deficiency or Other Unspecified Anemias and 
Blood Disease (CC 47) 
12.6 12.3 12.2 12.6 12.4 
Decubitus Ulcer or Chronic Skin Ulcer (CC 148-149) 0.5 0.6 0.7 0.7 0.6 
Dementia or Other Specified Brain Disorders (CC 49-
50) 
3.4 3.3 4.1 4.7 3.9 
Protein-Calorie Malnutrition (CC 21) 0.1 0.2 0.1 0.2 0.1 
Outcome measures, %      
All-cause unplanned 30-day readmissions 7.8 7.9 7.9 7.8 7.8 
Time to readmission, Median [IRQ] 11 [5,19] 10 [5,19] 9 [4,17] 12 [6,19] 10 [5,19] 
AMI unplanned 30-day Readmissions (% of all-cause 
30-day readmissions) 
17.4 14.9 13.6 13.6 14.9 
LOS – Length of stay; IQR – Inter quartile range; SD – Standard deviation; MI – Myocardial infarction; CABG  - 
Coronary Artery Bypass Graft; PTCA – Percutaneous Transluminal Coronary Angioplasty; CC – Condition category; DM 
– Diabetes Mellitus. 
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Table 4. Risk-adjusted odds ratios for 30-day all-cause readmission following hospital discharge with AMI. Age centered at 68 years, 
northern region used as reference class in geographical location. Bold font indicates statically significance odds ratios. 
Model 
Model 0  
(Empty model) 
Model 1 Model 2 
Covariate OR 95% CI OR 95% CI OR 95% CI 
Intercept, Estimate (SE) -2.4474 (0.05281) -2.9388 (0.06284) -3.0865 (0.1159) 
Patient characteristics 
         
5-year change increase 
   
1.20 1.18 1.22 1.20 1.18 1.22 
Female vs, Male 
   
0.95 0.87 1.04 0.95 0.87 1.04 
History of CABG    1.01 0.84 1.23 1.01 0.84 1.23 
History of PTCA    1.07 0.93 1.23 1.08 0.94 1.24 
Angina Pectoris/Old Myocardial Infarction     1.09 0.96 1.23 1.09 0.96 1.24 
Congestive Heart Failure    1.33 1.13 1.57 1.32 1.12 1.56 
Coronary Atherosclerosis    0.83 0.75 0.91 0.83 0.76 0.92 
Acute Coronary Syndrome    1.03 0.87 1.22 1.03 0.87 1.22 
Specified Arrhythmias    1.06 0.90 1.25 1.07 0.91 1.26 
Valvular or Rheumatic Heart Disease    1.24 1.12 1.37 1.26 1.14 1.40 
Cerebrovascular Disease    1.21 1.03 1.43 1.21 1.03 1.43 
Stroke    0.99 0.71 1.37 0.98 0.71 1.36 
Vascular or Circulatory Disease    1.29 1.06 1.57 1.29 1.06 1.56 
Hemiplegia, Paraplegia, Paralysis, Functional Disability    1.35 1.05 1.74 1.36 1.05 1.75 
Diabetes Mellitus (DM) or DM Complications    1.35 1.24 1.46 1.35 1.24 1.47 
Renal Failure    1.26 1.04 1.53 1.26 1.04 1.52 
End-Stage Renal Disease or Dialysi    1.06 0.73 1.54 1.05 0.73 1.53 
Other Urinary Tract Disorders    1.31 1.14 1.52 1.33 1.15 1.53 
Chronic obstructive pulmonary disease     1.35 1.18 1.56 1.36 1.18 1.57 
Pneumonia    1.17 1.00 1.36 1.16 1.00 1.36 
Asthma    0.71 0.49 1.01 0.71 0.49 1.01 
Disorders of Fluid/Electrolyte/Acid-Base    1.18 0.98 1.42 1.18 0.98 1.42 
History of infection    1.16 0.95 1.44 1.16 0.94 1.43 
Metastatic Cancer or Acute Leukemia    1.77 1.20 2.60 1.77 1.20 2.61 
Cancer    1.04 0.85 1.28 1.04 0.85 1.28 
Iron Deficiency or Other Unspecified Anemias and Blood 
Disease 
   
1.45 1.30 1.62 1.45 1.31 1.62 
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Decubitus Ulcer or Chronic Skin Ulcer    1.06 0.73 1.54 1.06 0.73 1.55 
Dementia or Other Specified Brain Disorders    1.32 1.12 1.55 1.32 1.12 1.55 
Protein-Calorie Malnutrition    1.72 0.86 3.44 1.73 0.86 3.46 
Anterior location of MI    1.32 1.18 1.47 1.32 1.18 1.48 
Other location of MI    0.95 0.84 1.07 0.95 0.84 1.07 
Hospital characteristics 
         
100-case increase in AMI volume (centered at the mean) 
      
0.96 0.89 1.03 
POOR       49%   
100-bed increase (centered at the mean) 
      
1.03 1.00 1.06 
POOR       49%   
Teaching vs, non-teaching 
      
1.11 0.89 1.39 
POOR       32%   
Catheterization lab availability (yes vs, no) 
      
0.99 0.80 1.22 
POOR       48%   
Cardio-thoracic surgery capacity (yes vs, no) 
      
1.04 0.80 1.36 
POOR       43%   
Geographic location 
         
North 
 
     1.00   
Alentejo or Algarve 
      
1.24 0.96 1.59 
POOR       18%   
Center 
      
1.11 0.89 1.39 
POOR       32%   
Lisbon 
      
1.21 1.00 1.48 
POOR       20%   
Variability components Estimate Standard error Estimate Standard error Estimate Standard error 
Between-hospital variance 0.080 (0.026) 0.035 (0.013) 0.027 (0.014) 
ICC 0.024   0.011   0.008   
OR between a hospital ±1 SD relative to the average hospital1 1.76   1.46   1.39   
MOR 1.31   1.20   1.17   
PCV    56%   23%   
C-statistic 0.58 (0.01) 0.72 (0.01) 0.72 (0.01) 
SE – Standard error; OR – odds ratio; CI – Confidence interval; POOR – proportion of opposed odds ratios (ϕ(-β/(√2×variance)), where ϕ represents the cumulative 
distribution function for the normal distribution) ; ICC – Intraclass correlation coefficient (variance/(variance+π2/3)); MOR – Median odds ratio 
(exp[0.6745×√(2*varianace)]); PCV – proportional change in variance ((variancemodel(n-1)-variancemodel(n))/variancemodel(n-1)).[33-35] 
1 =exp[(2*sqrt(variance))][5] 
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DISCUSSION 
In this study, we used a large contemporary dataset of administrative hospital data, covering 
all mainland Portuguese public hospitals, to assess the impact of patient and hospital 
characteristics on between-hospital variability associated with the risk of in-hospital mortality 
and 30-day unplanned readmissions in AMI patients. Health systems should provide low 
global adverse event rates with health care provided on equal terms regardless of the hospital 
in which patients are treated.[36]  
One in every ten patients treated for AMI in public Portugal hospitals do not survive.  Which 
indicates no improvements from the previous decade as suggested by the comparison of our 
results with those in previous studies.[7,9] Variance across hospitals regarding the risk of in-
hospital mortality declined over 50% after controlling for patient characteristics - the odds of 
mortality of a patient admitted to a moderately high risk hospital is 2.08 times of that of 
patient admitted to a moderately low risk hospital. These odds remained substantial even 
after adjusting for hospital characteristics. Therefore, supporting that the risk of mortality is 
heterogeneous across hospitals and heterogeneity remains even among hospital with similar 
characteristics. Patients admitted to hospitals with lower AMI case volume or to hospitals 
located in Alentejo or Algarve and Lisbon seem to be more likely to die than patients in 
higher caseload or northern hospitals respectively. Even though hospital AMI volume and 
geographical location may explain only a small share of hospital-level variance (4%) and to 
have heterogeneous associations with mortality (i.e. large POOR), an in-depth understanding 
of regional variations and the impact of caseload practices on in-hospital mortality are needed 
to ensure consistent quality across the country.  
Only 8% of AMI inpatient survivors were re-hospitalized within 30 days after discharge with 
an unplanned admission during 2012-2015. This figure represents about half of readmissions 
rate reported for US,[5,37,38] however between-hospital variance adjusted to patient case-
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mix observed by Krumholz et al. was approximately two thirds of that observed in this study 
(0.023 (SE=0.005) vs. 0.035 (SE=0.013)).[5] This suggests that overall Portugal hospitals 
have lower readmission rates than US hospitals, yet in the US the performance across 
hospitals is more consistent. Furthermore, while variability across hospitals seems to be 
substantially explained by the patient case-mix of hospitals, hospital characteristics also 
explained an additional 12% of the initial variability across hospitals (PCV=23%). Patients 
discharged from larger hospitals are, on average, more likely to be readmitted than those 
discharged from smaller hospital – all else equal, a 100-bed increase in hospital size is 
associated a 3% increase in the odds of an urgent readmission. However, this association is 
extremely heterogeneous (POOR=50%) therefore it is very likely to find a patient discharged 
from a smaller hospital with higher odds of readmission when compared to a similar patient 
discharged form larger hospital. 
Even though the proportions of variability explained by hospital were only 8% and 2% in the 
mortality and readmissions cohorts respectively, the MORs observed were as high as a 
majority of patient-level variables ORs. Therefore, our findings suggest that hospital 
represents a contextual effect in both mortality and readmissions as relevant as a patient 
characteristic. Hospitals are not performing homogeneously and the risk of patients tends to 
be consistently good in some hospitals and consistently poor in other hospitals. However, 
while hospital characteristics substantially explain this effect in readmissions, the same was 
not observed for the mortality cohort – practically no between-hospital variability was 
explained by hospital characteristics. Therefore, a large portion of variability between 
hospitals remains not modeled by our choice of hospital characteristics and further 
investigation is necessary. 
Awareness of such behaviors should be incorporated in health policies aiming at improving 
quality of care of AMI patients.[36] For example, it would not be sensible to direct measures 
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to improve mortality to all hospitals since the risk seems to vary dramatically across 
hospitals, with some hospitals excelling. Measures should rather be addressed to specific 
hospitals depending on their risk level, while particular attention should be given to hospital 
policies as they relate to caseload and practices. 
 
Limitations 
This study has several limitations to consider. First, because linkage between hospital claims 
data and the vital statistics database in Portugal was not available, it is not possible to 
distinguish between patients discharged alive who died within 30 days of discharge from 
those who survived and have not been readmitted within the 30-day time window. Moreover, 
even though the vast majority of inpatient hospitalizations occur in public hospitals any 
unplanned readmissions taking place in private hospital is cannot be identified. While we 
believe this will be unlikely if a patient is readmitted with a recurrent AMI other emergencies 
(e.g. COPD) may be lost. Second, for efficiency purposes of the Portuguese National Health 
Service most hospitals were merged into hospital centers and the individual hospitals became 
untraceable. While we believe that hospitals within the same hospital center still represent a 
contextual effect, it is possible that in some cases there is variability among hospitals within 
the same hospital center. Third, hospital claims data lack detailed information about the 
patient's clinical characteristics, on the other hand, we used a validated model based on 
claims data [5] and correspond to the most comprehensive hospital database in Portugal, 
including the vast majority of inpatient hospitalizations in Portugal.  Finally, we fixed  
hospital-level characteristics to a single year after observing that, in general, the 
characteristics did not change of our study period with the exception of AMI volume.  
However, for simplicity,  characterized hospitals according to their AMI volume in the year 
2011. 
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FUGURE 
 
Figure 1. Diagram flow of samples selection.  
 
AMI – Acute myocardial infarction; dsp – disposition status of patient. 
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5 Discussion and recommendations 
This chapter provides a general discussion of results obtained in the three papers 
that compose this thesis. Furthermore, building on the experience and insights 
gained throughout this work, we propose a series of recommendations and future 
research addressing the impact of our research in health policies in CHD health 
care; and addressing limitations and strengths in the utilization of administrative data 
sources for health services research within the context of CHD.  
5.1 Implication of main findings 
Transatlantic comparisons, conducted in the two first papers of this thesis, revealed 
differences between Portugal and the US in the epidemiologic risk profiles of the 
populations, in the health technologies and services available, and in the quality of 
care provided for coronary heart disease treatment. Variations across hospitals 
within each country were dramatically different between the two countries, with 
Portugal exhibiting an alarming 2-fold risk hospital heterogeneity. 
Our findings indicate that the US general population exhibits a higher risk profile 
when compared to that of Portugal (Lobo et al., 2017b), based on the prevalence of 
hypertension, diabetes, smoking, hypercholesterolemia, and overweight/obesity, 
which is concurrent with the larger AMI morbidity observed for the US (Lobo et al., 
2017a, Lobo et al., 2017b). After narrowing down the scope of our analysis to AMI 
patients (Lobo et al., 2017a), the Portuguese AMI population reveals a higher share 
of STEMI cases when compared to the US, yet comorbidity conditions are more 
frequently documented in the US AMI population. These results are concurrent with 
previous findings reporting a higher prevalence of STEMI in European countries 
relative to the US.(Organisation for Economic Co-operation and Development, 2018, 
Puymirat et al., 2013, Santos et al., 2009, Smith et al., 2013, Yeh et al., 2010) 
With respect to our analysis focusing on access to new health technologies, we 
observed that medical devices in the US receive market approval later than in 
Portugal (assessed based on dates of market approval of the first medical model 
within therapeutic classes). Only four of the sixteen devices reviewed were available 
first in the US and, on average, it took 22 months longer in the US than in Portugal to 
approve the first device model. However, the initial advantage may not be 
materialized into an effective advantage, since adoption of new medical devices into 
routine use is likely to exhibit a different lag pattern, one that seems to dilute this 
initial advantage. For instance, there was no lag between countries regarding the 
adoption of intravascular brachytherapy despite market approval occurred one year 
earlier in Portugal. Faster diffusion of devices such as the DES, Mitraclip and TAVR, 
were more likely in the US than Portugal.(Lobo et al., 2015, Lobo et al., 2017b) 
Diffusion of newly approved medical devices into routine practice requires significant 
investment, both time- and money wise, in health professionals training and adapting 
structural organizations particularly when medical devices represent a truly 
innovative alternative to previous healthcare approaches. Moreover, early 
recommendations of use based on sound scientific evidence and continuous 
monitoring of clinical practice patterns may encourage a more swift and inclusive 
adoption in response to clear indications of use and identification of unmet needs.  
Unlike medical devices, based on the list of selected drugs in Paper 1, 
commercialization of drugs begins earlier in the US than in Portugal. This was 
somewhat expected because the US represents a much larger market share and in 
which drugs reach higher prices than in Portugal and therefore is more attractive to 
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the pharmaceutical industry.(Danzon et al., 2005, Kanavos et al., 2011) The vast 
majority of EU countries use external price referencing to establish prices of new 
drugs. The fear that low price might jeopardize pricing prospects elsewhere may 
further detract distributors from launching new drugs into countries with lower 
prices.(Kanavos et al., 2011) Moreover, mechanisms to determine which 
pharmaceuticals are reimbursed under the NHS may further delay routine outpatient 
use of drugs in Portugal. That has been the case of clopidogrel, which effective 
commercialization was delayed by 6 years from market approval.(Stolk et al., 2008) 
AMI in-hospital patient management assessed through administrative hospital data 
revealed that coronary revascularization procedures are more frequent in the US 
than in Portugal. Surgical procedure use in particularly varied by a staggering 5-fold 
among the two countries in 2010 even after controlling for the effect of age and 
sex.(Lobo et al., 2017a) Results from our first study (Lobo et al., 2017b) regarding 
the number of centers per capita providing advanced cardiovascular medical 
procedures in the two countries support these differences. Other international 
comparisons also report a more frequently use of these procedures in the US when 
compared to what is practiced in several European countries (Herlitz et al., 2003, 
McGovern et al., 1997, McNamara et al., 2014, Vargas et al., 2001), fueling 
concerns over suboptimal care either due to an over or under use of such in-hospital 
procedures in the two sides of the Atlantic respectively.(Cutler, 2014) Importantly 
these concerns may be within the context of effectiveness of health services 
provided, this study only scratches the surface of this discussion by contributing with 
few but important findings. Namely, in-hospital mortality declined in both countries 
during the period between 2000 and 2010, yet, by 2010, the age-sex-adjusted in-
hospital mortality rate in Portugal was twice of that of the US. Revascularization 
procedures use remained high in the US throughout this period while it significantly 
increased in Portugal. Moreover, revascularization use was associated with 
improved survival at discharge in both countries but was larger in Portugal. The latter 
seemed to explain part of the annual decline observed in Portugal but not in the US. 
Therefore supporting that the increasing use of revascularization procedures in 
Portugal may have been decisive for improved outcomes among AMI patients in this 
country during the period between 2000-2010.  
The differences we observed need to be interpreted in light of the characteristics of 
health systems compared. Many factors contribute to health services effectiveness. 
Successful in-hospital care is dependent both on pre- and in-hospital care provided 
as well as the risk of patients. For example, a poor emergency system with deficient 
services for patient referencing may jeopardize the chance the patient receives a 
primary PCI. In fact, age-sex-adjusted death rates based on vital statistics data 
indicate comparable AMI mortality between Portugal and the US (Lobo et al., 
2017b), hence supporting comparable quality of overall health care between these 
countries. Reconciling in-hospital mortality with mortality based on vital statistics is 
not straightforward and different factors could explain the conflicting results. First, 
hospital administrative databases capture patients who were admitted and thereby 
tell us nothing of those who were not.(Bottle et al., 2013) Therefore, while inaccurate 
cause of death in death certificates may result in spurious vital statistics and could 
alone explain inconsistencies, poor pre- and post-hospital care, or unaffordability to 
obtain proper care in the US could explain that some deaths may occur outside the 
hospital where treatment was provided and result in apparent favorable in-hospital 
mortality. Second, according to Papanicolas and Jha (2017), the US health care 
system is optimized for short lengths of stay, tolerating a somewhat higher 
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readmission rate (but fewer total days in the hospital per population) when compared 
to European countries. This is concurrent with our findings indicating that the length 
of hospital stay in Portugal is, on average, approximately 3 days longer than 
hospitalizations in the US. In our opinion, this could further lead to deaths outside the 
hospital or during hospice or long term care, which would not be included in this 
cohort. Also on this note, the follow up time of patients is inherently constrained to 
the hospital length of stay when in-hospital mortality is adopted as the outcome 
measure. The latter may have biased comparisons, given the reliance of the US 
health system efficiency on hospital short stays. Whenever possible, linkage 
between claims data and vital statistics is advised, and outcome measures such as 
30-day or 1-year mortality or survival should be preferred for international 
comparisons purposes. Notwithstanding this caveat, in-hospital mortality captures 
the patient’s expectation of health care while in the hospital. Moreover, we analyzed 
in-hospital survival to minimize potential differences in follow up time. 
Another major insight relates to differences observed in variations in in-hospital 
survival across hospital within the two countries. Between-hospital variation was 
smaller in the US relative to Portugal – the hazard of dying in a high-mortality US 
hospital was essentially no different than that in a modestly low mortality hospital, the 
hazard ratio was equal to 1.03; in Portugal, this hazard ratio was 2.65. One would 
expect that the public-based health system of Portugal, structured based on a NHS, 
out of obligation to provide universal coverage and pressured to control costs and 
disparities, would be able to optimize resources available to achieve a more 
homogeneous quality of health care services across hospitals when compared to the 
US, which can be seen as multiple systems providing health care services to a 
population that is 30 times larger than Portugal. The lack of validated AMI health 
care quality measures in Europe (Schiele et al., 2017), the strong tradition of 
monitoring quality of care indicators in the US with demonstrated association in 
health care quality improvements (Gupta et al., 2016, Jha et al., 2005, Joynt et al., 
2012, Krumholz et al., 2011, Krumholz et al., 2006, Lindenauer et al., 2007) could 
explain these differences. However, other factors, such as hospital characteristics, 
not included in the model, or other relevant clinical information not observable in 
administrative data (e.g. pain/door-to-balloon times) could aid explaining the 
variation across hospitals in Portugal. Additionally, differences in organization of 
health systems mentioned earlier of the US prioritizing for short time hospital stays 
could again explain some of the minimal hospital heterogeneity observed for the US, 
since one would expect this to be more likely if standardized acute care services are 
optimized during the patient’s first hospital encounter.  
Despite potential caveats, our findings are suggestive of disconcerting variations in 
health care quality across hospitals in Portugal motivating an investigation on the 
pathways through which hospital effects operate. With this in mind, the last study of 
this thesis intended to assess whether hospital characteristics could partly explain 
variations across hospitals in Portugal. This opportunity was leveraged by using data 
reporting over a more recent period of time and by analyzing an additional quality of 
care outcome – readmissions. 
Results based on data of hospitalizations occurring between 2012 and 2015 indicate 
that 10% of AMI patients die in hospital while 8% of AMI inpatient survivors are re-
hospitalized within 30 days after discharge with an unplanned admission. Despite 
slight declines of crude in-hospital mortality throughout the period (2012:11% to 
2015:10%), these findings (10% in-hospital mortality) suggest no improvement 
relative to 2010.(Lobo et al., 2017a) However, it is possible that previous estimates 
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were underestimated since patient identification was not available prior 2011 and we 
were not able to identify episodes of care, which might have increased the 
denominator and underestimated rates. 
To our knowledge, all-cause 30-day unplanned readmission occurring after an AMI 
discharge has never been studied in Portugal, hence expanding existing knowledge 
on AMI health care quality in Portugal.  
Eight percent of the variability in the mortality cohort was attributed to a hospital 
contextual effect. Hospital case-mix explained 51% of this variation. Yet, forty-six 
percent of hospitals exhibited risk-standardized in-hospital mortality rates (RSMR) 
outside the expected range of normal sampling variation, half of which were above 
the upper 95% limit. Among these hospitals, those with considerable volume of 
cases, and hence RSMR estimates are assumed more reliable, raise more concerns 
(Figure S2 of supplementary data 7.6). The odds of in-hospital mortality of patients in 
a hospital 1 SD above average is 2.08 times that of patients in a hospital 1 SD below 
average. Hospital characteristics explained a modest additional 2% of hospital 
heterogeneity in the mortality cohort. Importantly, hospitals in some geographical 
location and those with fewer AMI caseloads were significantly associated with 
increased risk of mortality. While these associations may be very heterogeneous 
(large proportion of opposed odds ratios (POOR)), further investigation addressing 
geographical disparities is urgently needed. 
Between-hospital variability was smaller in the readmission cohort, when compared 
to the mortality cohort. Only 2.4% of the variability was attributed to a hospital 
contextual effect. Hospital case-mix explained 56% of this variation.  
Risk-standardized readmission rates (RSRR) of 30% of hospitals fell outside the 
expected range of normal sampling variation, but were equally distributed below and 
above the 95% limits. A patient’s odds of readmission in a hospital 1 SD above 
average relative to a hospital 1 SD below average is 1.46. Hospital characteristics 
explained an additional 12% of hospital heterogeneity in the readmission cohort and 
patients discharged from larger hospitals were significantly associated with 
increased risk of readmission. 
Health systems should provide effective health services that are equally accessible 
regardless of the hospital treating the patients.(Austin et al., 2017, Bradley et al., 
2010, Campbell et al., 2000, Ghaferi et al., 2009, Peiró and Maynard, 2015) This 
does not mean that all hospital should provide the same type of health services, but 
it assumes that patients should be promptly referred to the hospital with services that 
best suit their needs and that both referencing and health services are effective. The 
last study of this thesis provides insights into these questions by characterizing 
heterogeneity in quality of care in AMI patients across hospitals in Portugal. To our 
knowledge, this is the first study ever quantifying hospital heterogeneity in AMI 
quality of care in Portugal using two cohorts for this purposes – a mortality cohort to 
study in-hospital mortality and a readmission cohort to study all-cause 30-day 
unplanned readmissions. 
Our findings suggest that hospital represents a contextual effect as relevant as a 
patient characteristic. This means that the risk of patients tends to be consistently 
larger in some hospitals and consistently smaller in other hospitals. Forthcoming 
health policies aiming at improving quality of care of AMI patients should incorporate 
such information. In our opinion these would seem to be more efficient if addressed 
to specific hospitals depending on their risk level, while particular attention should be 
given to hospital policies as they relate to caseload and practices. 
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While it seemed an “almost impossible mission” (Seabra, 2017), in our opinion this 
tale of two contrasting healthcare systems proved to be a valuable source of insight 
into questions related with quality of health care in AMI patient management, finding 
support among our peers (Chen et al., 2017). We believe that its merits lie mainly in 
the utilization of nationwide representative datasets, endorsed-based risk-adjustment 
model, hierarchical models, and an understanding of the main features of the two 
health systems as well as these could affect interpretations of results. However, 
important limitations regarding data quality issues and information captured by these 
datasets have also been acknowledged and prevented us at times to look into further 
details.  
 
5.2 Recommendations and future investigation 
5.2.1 Considerations about data quality - issues and strengths 
Like in other research fields, quality of data is of paramount importance in HSR. In 
the course of this study we encountered several issues with the data sources 
analyzed. We believe that raising awareness for such issues is crucial to improve 
data quality and produce more reliable information, which ultimately will better serve 
decision-makers to address and improve health care quality. With this purpose, we 
make some recommendations related to data quality based on our experience. 
 
1 Infarmed holds deficient historical data regarding marketing dates on drugs for in-
hospital use and medical devices: 
• Dates of beginning of effective commercialization of drugs for in-hospital use 
only (e.g. GP IIb/IIIa inhibitors) may not translate the beginning of use of these 
drugs in Portugal. Several observational studies report the use of those drugs 
prior the dates provided by Infarmed; Since there was no explicit legal 
framework regarding pricing of medicines used in hospitals up until 2006 in 
Portugal (Ministério da Saúde, 2006), these medicines could have been 
purchased by hospitals directly to manufacturers even if these were not 
marketed in Portugal.  
• Whenever a new generation of a medical device model is approved, dates of 
market approval are updated onto the previous generation model and 
historical information is lost. With regards to coronary DES, this means that 
dates of approval of the first generation Cypher (Cordis Corp.) and Taxus 
(Boston Scientific) were replaced by recent models.  This problem should be 
solved when the European Database on Medical Devices (EUDAMED) 
becomes fully operational collecting “Data related to certificates issued, 
modified, supplemented, suspended, withdrawn or refused according to 
established procedures”.(European eGovernment Services, 2017) 
 
2 Limitations and strengths of administrative hospital data: 
 
Limitations: 
• Regardless of country, administrative hospital data lack on detailed 
information regarding patient’s clinical characteristics. In the context of this 
thesis, this limitation encompass the omission of information regarding 
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coronary anatomy, extent of disease, ejection fraction, surgical risk, pain/door-
to-balloon times, which are relevant predictors of mortality in these patients. 
• Coding consistency and accuracy lacks assessment for Portugal. Problems 
have been identified regarding documentation of type of coronary stents 
implanted. Coding inconsistencies across hospitals could undermine adjusted 
comparisons.  
• The sampling procedure carried to obtain the Nationwide Inpatient Sample 
(NIS) breaks patient traceability and may result in samples in which, due to 
chance, AMI hospitalizations are either over- or under-represented. 
• Patient traceability in Portugal data reporting to the period before 2011 is 
limited to hospitalizations occurring within the same hospital and the same 
year.  
• Outcomes are restricted to events occurring during the hospital stay. The 
utilization of in-hospital mortality as a healthcare quality metric has been 
criticized previously.(Kristoffersen et al., 2012, Reineck et al., 2014) 
Particularly in international comparisons and/or hospital comparisons, 
variation in discharge patterns may result in a biased quality of care 
assessment. 
 
Strengths: 
• Systematically collected in both countries for over two decades mainly for 
hospital budgeting/financing purposes (Administração Central do Sistema de 
Saúde, 2017) and regularly audited.  
• Holds a nationwide representativeness in both countries. In Portugal these 
data includes all inpatient hospitalizations occurring in all mainland public 
hospitals, representing the vast majority of inpatient cases in Portugal. In the 
US, the NIS is the largest publicly available all-payer inpatient healthcare 
database, consisting of a nationwide representative 20% stratified random 
sample of discharges from short-term non-federal American hospitals. 
• By capturing actual clinical practice patterns, hospital administrative data may 
afford insights relevant to broader populations of patients, providers and 
health care systems. 
• When compared with prospective registry and clinical trial data, administrative 
data is considerable less expensive. 
• Discharge- and patient-level analyses with administrative health data are 
currently possible for Portugal. Since 2011, ACSS provides a patient 
identification variable, allowing for patients traceability across hospitals and 
across years. Patient traceability holds several advantages: it allows using 
information from prior hospitalizations to ascertain comorbidities of patients; 
identifying all hospitalizations corresponding to inter-hospital transfers within 
the same episode of care and therefore conduct patient-level analysis and or 
refine definition of denominators; and identifying patient’s readmissions hence 
adding value to the process of health care quality assessment by introducing 
an additional outcome measure. 
 
5.2.2 Recommendations and future investigation 
Based on our results and data quality considerations, we make some practical 
recommendations regarding how to incorporate insights in health policies, future 
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work addressing research questions that have emerged from this study, and 
strategies to overcome data issues and maximize data strengths. 
• In light of our findings supporting that hospital acts as a contextual effect, 
future health policies directed at improving hospital health care quality in AMI 
in Portugal should account for the fact that measures assuming “one size fits 
all” will likely be inappropriate given that it ignores that hospitals are not 
performing homogeneously and the risk of patients tends to be consistently 
greater in some hospitals and consistently lower in other hospitals. 
Accordingly, worst and best practices should be disseminated across all 
hospitals and this should then be used to elucidate on policies that might be 
established to direct certain kinds of patients toward appropriate types of 
hospitals for inpatient care. 
• Metrics of variability regarding healthcare quality in AMI patient management 
across hospitals in Portugal could add valuable information into current 
programs monitoring health care quality in CHD such as the National Program 
for Cerebro- and Cardiovascular Diseases. Their inclusion could help raise 
awareness for issues related with hospital heterogeneity and engage 
healthcare providers and hospital directors in actions to improve disparities.  
• Monitoring activities regarding hospital health care quality in Portugal should 
pay particular attention to geographical disparities, health care practices, and 
hospital size since these factors were found to be associated with increased 
risk of in-hospital mortality and urgent readmissions in AMI patients.  
• Further investigation is urgently needed to better pinpoint and reason about 
patient and hospital factors associated with poorer health outcomes and 
responsible for the hospital heterogeneity observed, which will ultimately 
provide further scientific information for tailoring health policies. A large 
portion of variability between hospitals in Portugal remained not modeled by 
our choice of patient and hospital characteristics. With this in mind, we believe 
that future work should encompass the following aspects:  
o Because the time to receive treatment is crucial in the prognosis of AMI 
patients, assessing the impact of the organization of the patient 
referencing network and of the residence of patients in geographical 
disparities is an important next step.  
o Similarly, the transition of patients from acute care to cardiac 
rehabilitation represents a critical pathway for AMI patients with 
potential implications on urgent readmissions. This should also be 
investigated particularly in the context of large size hospitals. 
o Insights could be gained from looking into measures of process and 
compliance to guidelines since this might be helpful to understand the 
impact and maximize hospital caseload in healthcare quality, as this 
relate with certain high-risk group of patients. 
• From our experience careful selection of inclusion and exclusion criteria 
increase the internal validity of studies based on hospital administrative data. 
Particularly when comparing different health systems, these are important 
tools to achieve meaningful/adequate comparability. Within the context of 
CHD analysis, opting for an analysis restricted on AMI cases holds better 
comparability across countries. Further sensitivity analysis based on type of 
AMI (STEMI and NSTEMI) are particular helpful to address differences in 
definitions of AMI across countries. 
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• In order to minimize bias due different practice patterns, follow up times 
considered for analysis should be independent from the patient’s length of 
hospital stay and take in consideration the fact that patients may be 
transferred to another hospital to receive treatment. With this in mind, future 
research regarding comparative health care quality could benefit from: 
o Exploring distributed research networks. This refers to the 
incorporation of information from several data sources (e.g. hospital 
health care data and vital statistics). The integration of information 
regarding the date of death in the Portuguese hospital administrative 
database would capitalize greatly this database, as it would enable 
longer follow up times of patients (e.g. 30-day mortality, time to death), 
which would provide additional information regarding quality of health 
care, and would be less prone to bias due to variations in practice 
patterns across units of analysis (e.g. hospitals, countries). We strongly 
believe this to be possible to implement in Portugal since proof of 
concept has been established under the CUTEheart project. (Bacelar-
Nicolau 2018)  In the event that fixing a follow up time (independent 
from hospital stay) is unfeasible, analysis of in-hospital survival time 
rather than in-hospital mortality may improve comparability across 
countries or hospitals, if differential follow up times is suspected. 
o Developing a methodological framework to identify episodes of care 
taking advantage of patient traceability across hospitals such as that 
implemented in our third study. This improves identification of 
denominators reducing the risk of underestimating in-hospital mortality 
rates. Alternatively, excluding all discharges with a transfer to another 
acute care hospital status could be used with the same purpose, 
however, this would lead to other limitations: the discharging hospital 
would be always assumed responsible for the hospitalization, which 
could lead to less relevant interpretations if the purpose of the analysis 
is assessing hospital heterogeneity regarding patient mortality; 
procedures carried during initial/intermediary hospitalizations in 
episodes of care with a chain of hospital transfers with two or more 
hospitalizations could be lost. 
• Following the approach used by CMS for Medicare data, patient identification 
should also be used to improve characterization of the patient’s clinical 
information using historical data of hospitalizations available from a 
predefined period of time prior the index hospitalization. This provides better 
control of confounding effects without resorting to other sources of data. 
• Prospective registry data maintained by the SPC (Sociedade Portuguesa de 
Cardiologia, 2018) hold detailed clinical information on the patient. Under the 
agreement celebrated in 2015 between SPMS and SPC (sociedade 
Portuguesa de Cardiologia, 2015), we believe that future work should take 
advantage from such agreement to incorporate data from the SPC’s registries 
and hospital administrative data. This could further help to explain hospital 
heterogeneity by providing more information on patient characteristics (e.g. 
patient risk, door-to-needle times, etc.). Importantly, this should be used to 
validate models derived based on administrative data similarly to work 
conducted in the US (Krumholz et al., 2011, Krumholz et al., 2006), which 
could then be used to monitor AMI health care quality in hospitals.  
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7 Supplementary material 
7.1 Compatibility of variables in administrative data across 
countries 
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Table 7.1. Selection of variables in the inpatient hospital administrative data in Portugal and US.  
 Portugal US  
Variable label 
Variable available  
(variable name) 
Description/Observations Variable available  
(variable name) 
Description/Observations Need for reconciliation 
Patient demographic  
Patient 
identification 
Yes, partially 
(patnum, 
n_ficticio_utente) 
Pseudo patient identification is available. 
Between 2000-2010 patient id was valid 
only within hospital and year. 
Yes, partially 
(UHIN) 
Pseudo patient identification is available, 
but sampling process brakes traceability 
of patients. 
 
Gender Yes (sexo) 1 - male; 2 - female Yes (Gender) 1 - male; 2 - female  
Age at 
admission 
Yes (idade)  Yes (AgeAdmit)   
Race No  Yes (Race)   
Residence 
code 
Yes (reside) Patient residence based on DICOFRE 
classification system that maps 
residence up to the freguesia level (the 
smallest administrative level before 
street) 
Yes (PL_UR_CAT4) Is a four category urban-rural 
designation for the patient's county of 
residence 
 
Hospital information 
Hospital 
identification 
Yes (hosp_id)  Yes (MDPHHospNumber)   
Hospital where 
patient was 
transferred 
form/to 
Yes (hosp_to, 
hosp_from) 
Information is collected but incomplete1 Yes (indexhosp, midlehosp, lasthosp)   
Total charges No  Yes (zerocharge)   
Clinical information 
Admission date Yes (data_entrada)  Yes (AdmitDt)   
Discharge date Yes (data_saida)  Yes (DischDt)   
Length of stay 
(LOS) 
Yes (dias_int)  Yes (LOS) Calculated by subtracting the admission 
date (ADATE) from the discharge date 
(DDATE). Same-day stays are therefore 
coded as 0. Leave days are not 
subtracted. 
LOS was operationalized as 
discharge data minus 
admission date plus one 
Admission 
source 
No  Yes (ASOURCE) 
 
1 - Emergency department;2 - Another 
hospital; 3 - Other health facility including 
long-term care; 4 - Court/Law 
enforcement; 5 - Routine including births 
and other sources; . - missing 
 
Admission type Yes (adm_tip) 1 - Elective; 2 - Urgent; 3 - Programa de 
promoção de acesso; 4 - PECLEC; 5 - 
Private practice; 6 - SIGIC; 7 - PACO.  
 
Categories 3, 4, 6 and 7 refer to 
Yes (ATYPE) 1 - Emergency; 2 - Urgent; 3 - Elective; 4 
- Newborn; 5 – Delivery/Trauma center 6 
– Other; . – missing; A. – invalid; B. - 
Unavailable 
New variables: 
UrgEm : 1  - 
Urgent/Emergency (adm_tip=2, 
AdmissionType=1 or 2) 
2 – Elective (adm_tip=1, 
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governmental programs introduced to 
reduce waiting lists 
AdmissionType=3) 
3 - Not available/missing 
Cause for 
transfer 
Yes (mot_transf)  No   
Patient 
disposition 
status 
Yes (dsp) 1 - Home or self-care; 2 - Another short-
term (general) hospital; 4 - Intermediate 
care facility or custodial/supportive care; 
6 - Discharged/transferred to home 
under care of organized home health 
service organization; 7 - Left against 
medical advice or discontinued care; 13 
– Discharged to rehabilitation hospital; 
20 - Expired; 51 - Hospice- medical 
facility; 63 - Long-term care hospital 
Yes (DISPUB92) 1 - Discharged home or self-care (routine 
discharge); 2 - Discharged to other short-
term general hospital; 3 - Discharged 
Skilled Nursing Facility (SNF) ; 4 – 
Discharged to intermediate care facility 
(ICF) ; 5 – Discharged to other 
institution/referred outpatient services; 6 
- Discharged home under home health 
service organization; 7 - Left against 
medical advice (AMA); 8 - Discharged 
home under home IV drug therapy 
provider; 9 - Not Used; 10 – Discharged 
to chronic hospital; 11 – Discharged to 
mental health hospital; 12 – Discharged 
to other; 13 – Discharged to 
rehabilitation hospital; 14 – Discharged 
to rest home; 15 – Discharged to shelter; 
20 - Expired (or did not recover/Christian 
Science Patient) ; 43 - Discharged to 
federal healthcare facility; 50 - 
Discharged to hospice-Home; 51 – 
Discharged to hospice-Medical Facility; 
62 - Discharged to inpatient rehabilitation 
facility; 63 - Discharged to Medicare 
certified long term care hospital; 65 – 
Discharged to psychiatric hospital or 
distinct unit of a hospital; 66 -Discharged 
critical access hospital (CAH) 
New variables: 
Died: 1 – in-hospital death 
(dsp=20, DISPUB92=20); 0 – 
otherwise; 
AMA: 1 – Left against medical 
advice (dsp=7, DISPUB92=7); 
0 otherwise 
Hospice: 1 – transferred to 
hospice (dsp=51, DISPUB92= 
50 or 51); 0 – otherwise 
Diagnoses Yes (DXX1-DXX20) Up to 20 diagnosis codes (ICD-9-CM) if 
reporting to 2000-2010, up to 70 if 
reporting to 2011 or afterwards. 
The first listed diagnosis (DXX1) is the 
principal diagnosis. 
Yes (DX1-DX15) Up to 15 procedure codes (ICD-9-CM) if 
reporting to 2000-2010. 
The first listed diagnosis (DX1) is the 
principal diagnosis. 
 
New variables: 
DNR: 1 – do not resuscitate 
status (V49.86 in secondary 
diagnoses); 0 – otherwise 
AMIprimary: 1 – principal 
diagnosis of AMI (410.xx excl. 
410.x2); 0 – otherwise  
Diagnosis 
present on 
admission 
(POA) 
Yes, partially Collection of information regarding 
diagnosis present on admission was 
mandated in 2013 (Circular Normativa 
nº.8 de 04/03/2013) 
"Identifica se o diagnóstico estava 
Yes, patially Effective October 1, 2007, the Uniform 
Bill (UB) includes a POA indicator for 
each diagnosis field on Medicare claims. 
January 2011, the UB usage 
requirement for POA reporting was 
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presente aquando da admissão do 
doente, sendo: 
S-Yes; N – No; D – Unknown; I - 
Clinically undetermined; NA - Exempt 
from POA reporting 
expanded to include hospital stays as 
mutually agreed for contracts with 
insurance programs.3  
Y – Yes; N – No; 
U – Unknown; W - Clinically 
undetermined; 1 – Exempt from POA 
reporting4 
Procedure Yes (SRG1-SRG20) Up to 20 procedure codes (ICD-9-CM) if 
reporting to 2000-2010, up to 70 if 
reporting to 2011 or afterwards. 
 
Yes (PR1-PR15) Up to 15 procedure codes (ICD-9-CM) if 
reporting to 2000-2010. The first listed 
procedure (PR1) is usually the principal 
procedure (i.e. the procedures performed 
for definitive treatment). 
 
Sources: 
1 FREITAS, J., SILVA-COSTA, T., MARQUES, B. & COSTA-PEREIRA, A. Implications of data quality problems within hospital administrative databases.  XII 
Mediterranean Conference on Medical and Biological Engineering and Computing 2010, 2010. Springer, 823-826. 
2 https://www.hcup-us.ahrq.gov/db/nation/nis/DataElements_NIS_2004_Core_Volume1_A-M.pdf; https://www.hcup-
us.ahrq.gov/db/nation/nis/DataElements_NIS_2004_Core_Volume2_A-M.pdf; https://www.hcup-us.ahrq.gov/db/nation/nis/nisfilespecs.jsp#2012NIS. 
3 https://hcup-us.ahrq.gov/reports/methods/2011_05.pdf 
4 https://hcup-us.ahrq.gov/datainnovations/clinicaldata/POAAddonfile042208AHRQMod.pdf
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7.2 Summary description of data sources with potential use for comparative health care quality assessment 
Table 7.2. List, description and availability status of datasets in Portugal and the United States. 
Data name US/ 
PT 
Organization Description Available website 
Inpatient hospital 
database (IDD) 
PT ACSS  
Portuguese inpatient discharge database that includes inpatient 
and outpatient data.  Includes variables on demographic, 
diagnostic, procedure, DGR that can be linked to the DRG prices 
(proxy for charges). 
Yes/used for 
Paper 2 
http://www.acss.min-
saude.pt 
http://portalcodgdh.min-
saude.pt/index.php/Págin
a_principal 
SPMS  data 
 
PT SPMS  
Combines data from hospital (as in data from ACSS) with 
primary care settings, prescription and vital statistics data at the 
patient-level. 
 
Includes adult patients admitted to hospital with a primary AMI 
(410.xx) and discharged during the second semester of 2012. 
These patients are then followed through the calendar year of 
2013 in the hospital, primary care and vital statistics databases. 
Depending on the dataset, includes information on 
demographics, hospital readmission, patient disposition, 
comorbidities, consultations, medical test/exams, diagnostics, 
prescribed/filled medication, prices of medication and date of 
death certificates. 
Yes 
http://spms.min-
saude.pt/english-version/ 
National Registry 
for Interventional 
Cardiology (NRIC) 
PT SPC, CNCDC  
Registry for PCI data that uses the CARDS instrument to collect 
information on patients demographics and disposition and 
procedures carried out in Portugal.  
Started in 2002. The number of hospital participations grew from 
19 in 2002 and to all hospitals with a cath lab in 2011. (that’s 
what they say!) 
Includes both public and private hospitals.  
Yes but only in 
the form of 
aggregated data, 
we may request 
specific statistical 
analyses 
http://www.spc.pt/CNCDC
/ 
http://www.spc.pt/Registo
sNacionaisSPC/Public/Lo
gin.aspx?ReturnUrl=%2fR
egistosNacionaisSPC%2f 
National Registry 
for Acute 
Coronary 
Syndromes 
PT SPC, CNCDC 
Includes data on adults admitted with an acute coronary 
syndrome. 
Contains information about demographic, diagnostic elements, 
risk factors and history cardiovascular and non-cardiovascular 
Yes/Same as 
above, access to 
aggregated data. 
http://www.spc.pt/CNCDC 
http://www.spc.pt/DL/Hom
e/listdestaques/Definicoes
_das_Variaveis_RNSCA_
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(NRACS) events, characteristics of the acute event, medication, 
revascularization approach among others. 
Data is collected using the instrument described in links (in 
Portuguese). 
2aFase_Final.pdf 
anamariagomes@me
d.up.pt 
INFOMED –  
Drugs  database 
 
PT INFARMED 
Open access database that contains information regarding the 
identification of brands/generics and time periods for introduction 
(approval, commercialization) of medicines in Portugal. 
This is Portuguese equivalent to Drugs@FDA. 
Yes/used for 
paper 1 
http://www.infarmed.pt/91
nformed/inicio.php 
Registry of 
approved high-risk 
medical devices  PT INFARMED 
Open access database contains information regarding high-risk 
medical devices  (Class III, active implantable, for in vitro 
diagnosis) that are currently approved in the Portuguese market. 
Contains information regarding manufacturer, distributor, brand, 
model, and device designation. 
Open access 
http://www.infarmed.pt/por
tal/page/portal/INFARME
D/DISPOSITIVOS_MEDI
COS/REGISTO_DE_DM_
E_DIV/DISTRIBUIDORES 
Prices of hospital 
episodes and 
medical exams 
 
PT Health Ministry 
DRG prices tables are official tables published by the 
government and link each DRG with a price, relative weight, and 
normal length of stay for each DRG.  
These tables are commonly used as proxies of hospital 
charges/cost. 
Open access 
through the dre.pt 
 
Hospital 
Benchmarking 
indicators PT Health Ministry 
Presents benchmarking indicators (access, quality, performance, 
efficiency) for public hospitals and primary care centers. Years 
reporting: 2013, 2014. Open Access 
http://benchmarking.acss.
min-
saude.pt/monitormensal/e
nquadramento/objetivos.a
spx 
Characteristics of 
PT hospitals – 
annual economic 
reports  
PT ACSS 
Annual accounting reports of Portuguese public hospitals. 
Provide a characterization of hospitals including information on 
the number of beds per ward, productivity, spending, length of 
stay, human resources, among others. Reports vary across ears 
and hospitals in respect to structure/information available.  
Open Access 
http://www.acss.min-
saude.pt/Publicações/Hos
pitaisEPEeSPA/Hospitais
EPEeSPA/RelatórioseCo
ntas/tabid/230/language/p
t-PT/Default.aspx 
Portugal data 
about outpatient 
prescriptions  
PT SPMS, CCF 
The CCF is the organization responsible for clearance of 
reimbursement of community pharmacies; medical care 
providers with agreement with the government for prescription 
and patient care under the SNS. 
 
CFF holds information on data at the patient-level of outpatient 
No 
https://www.ccf.min-
saude.pt/portal/page/porta
l/publico 
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drugs (prescribed under the SNS). 
 
The data from SPMS contains two tables where the source is the 
CFF. One from prescribed drugs and another from filled 
prescriptions. In these tables there’s no information on the date 
of prescription but there is information on the price. 
HCUP 
(Healthcare Cost 
and Utilization 
Project) 
US AHRQ 
National (Nationwide) Inpatient Sample (NIS) 
The National (Nationwide) Inpatient Sample (NIS) is the largest 
publicly available all-payer hospital inpatient care database in the 
United States. Researchers and policymakers use NIS data to 
identify, track, and analyze trends in health care utilization, 
access, charges, quality, and outcomes. 
Yes/used for 
Paper 2 
http://www.hcup-
us.ahrq.gov/nisoverview.j
sp 
MA Hospital 
Inpatient 
Discharge 
Database (HIDD)  
US CHIA 
Comprehensive patient-level information including socio-
demographics, clinical data, and charge data.  
Yes 
http://chiamass.gov/acute-
hospital-case-mix-data-
how-to-apply/ 
MA Outpatient 
Emergency 
Department 
Database (ED) 
US CHIA 
Patient demographics, clinical characteristics, services provided, 
charges, and hospitals and practitioner information, as well as 
mode of transport/data elements that are similar to those 
contained in the inpatient and observation stay databases, with 
some additions relevant to the ED setting. 
Yes 
http://chiamass.gov/acute-
hospital-case-mix-data-
how-to-apply/ 
 
Outpatient 
Hospital 
Observation 
Discharge 
Database (OOA)  
US CHIA 
Comprehensive patient-level information, including socio-
demographics, clinical data, and charge data 
Yes 
http://chiamass.gov/acute-
hospital-case-mix-data-
how-to-apply/ 
Massachusetts 
Data Analysis 
Center clinical 
registry 
(MassDAC); 
US CHIA 
High-quality data that contains detailed information on cardiac 
surgery and PCI on adults performed under inpatient setting only  
Yes 
http://www.massdac.org/ 
Massachusetts 
all-payer Claims 
Database 
(APCD). 
US CHIA 
Database comprised of medical, pharmacy, and dental claims, 
and information about member eligibility, providers, and products 
from public and private payers 
Not available 
http://chiamass.gov/ma-
apcd/ 
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7.3 Standardization and Risk-adjustment formulas 
Rate standardization 
For the purposes of illustration consider that we are interested in estimating 
death rates in a study population controlling for the confounder effect of age. 
In other words we are interested in computing the age-standardized mortality 
rate of a study population using a standard population for reference. 
 
Let  
 
Study population Standard population 
Di – the number of deaths in age interval i,  
Pi – population of age interval i in the study 
population 
The age-specific death rate (Ri) is then given 
by 
Ri = Di / Pi 
 
Psi - the standard population in age interval i. 
Ps=∑ 𝑃𝑠𝑖𝑖  – the total standard population 
The standard weights (wsi) are then given by 
 wsi =Psi /Ps and ∑ 𝑤𝑠𝑖𝑖 = 1 
 
D=∑ 𝐷𝑖𝑖  – the number of deaths in the study 
population 
P=∑ 𝑃𝑖𝑖  – the total study population 
R=D/P – crude death rate in the study 
population 
 
Rsi - the age-specific death rate in age 
interval i in the standard population 
Rs – crude death rate in the standard 
population 
Then 
 
Direct standardized mortality rate (DSMR) 
𝐷𝑆𝑀𝑅 = ∑ 𝑤𝑠𝑖 ×
𝐷𝑖
𝑃𝑖
𝑖
= ∑ 𝑤𝑠𝑖 ×
𝑖
𝑅𝑖 
 
Indirect standardized mortality rate (ISMR) 
𝐼𝑆𝑀𝑅 = ∑
𝐷
𝑅𝑠𝑖 × 𝑃𝑖
𝑖
× 𝑅𝑠 = 𝑆𝑀𝑅 × 𝑅𝑠 
 
where SMR is the standardized mortality ratio. 
 
Under the assumptions of homogeneity of risk across individuals among 
strata and that the number of deaths in a population follows a Poisson 
distribution then, 
𝑉𝑎𝑟(𝐷𝑆𝑀𝑅) = ∑(𝑤𝑠𝑖)
2 ×
𝑖
𝑉𝑎𝑟(𝑅𝑖) = ∑(𝑤𝑠𝑖)
2 ×
𝑖
𝑅𝑖
2
𝐷𝑖
 
which can then be used to compute the 95% confidence interval: 
 
95𝐶𝐼𝐷𝑆𝑀𝑅: 𝐷𝑆𝑀𝑅 ± 1.96 × √𝑉𝑎𝑟(𝐷𝑆𝑀𝑅) 
 
For comparisons between two standardized rates (DSMR1 and DSMR2) the 
logarithm of the ratio between rates is assumed to follow a normal distribution 
with mean zero and variance as 
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𝑉𝑎𝑟 (𝑙𝑜𝑔 (
𝐷𝑆𝑀𝑅1
𝐷𝑆𝑀𝑅2
)) = 𝑉𝑎𝑟(log(𝐷𝑆𝑀𝑅1)) + 𝑉𝑎𝑟(log(𝐷𝑆𝑀𝑅2)) = 
=
1
𝐷𝑆𝑀𝑅1
2𝑉𝑎𝑟(𝐷𝑆𝑀𝑅1)+
1
𝐷𝑆𝑀𝑅2
2𝑉𝑎𝑟(𝐷𝑆𝑀𝑅2) 
 
which can again be used to compute the 95% confidence intervals.( 
http://support.sas.com/documentation/cdl/en/statug/68162/HTML/default/view
er.htm#statug_stdrate_details14.htm.) 
 
Generalization of indirect standardization using regression models 
For illustration purposes consider that we are interested in comparing death 
rates in AMI patients across different hospital. Differences in hospital-specific 
mortality rates may be distorted by differences in the underlying risk of 
patients treated at the hospitals. Therefore, distorting our perception of 
differences in hospital performances. One way to compare hospitals 
correcting for patient case-mix is through risk-adjusted hospital rates. 
 
Let Yj=1 if the jth AMI patient dies and 0 otherwise, j=1,…, N.  Then  
 
𝑌𝑗~𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(𝑝𝑗), where 𝐸(𝑌𝑗) = 𝑝𝑗 
 
𝑙𝑜𝑔𝑖𝑡(𝑝𝑗) = 𝛽0 + 𝛽1𝑋1 + ⋯ + 𝛽𝑝𝑋𝑝 
where  
pj is the probability of death of patient j 
X represents the potential confounder variables  
β is the predicted log odds mean change of a patient’s death associated risk 
with the presence of the corresponding comorbid condition/risk factor X. 
 
Hospital-specific standardized mortality rate corresponds to the number of 
observed deaths divided by the number of expected deaths for a specific 
hospital multiplied by the crude death rate for the whole sample of hospitals. 
Where the number of expected death is obtained by summing predicted 
probabilities based on the coefficients of the logistic regression model fitted 
using the sample of patients from all hospitals as follows: 
 
∑ 𝑌𝑗ℎ𝑗
∑ 𝐸(𝑌𝑗ℎ)𝑗
× ?̅? = 𝑆𝑀𝑅 × ?̅?,    ?̅? =
∑ 𝑌𝑗𝑗
𝑁
 
 
where SMR is the hospital-specific risk-adjusted mortality ratio. This approach 
implicitly uses the whole sample as the standard population representing the 
average hospital performance.  
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7.4 Paper 1 supplementary data 
 
 
The Atlantic divide in Coronary Heart Disease: Epidemiology and Patient 
Care in the US and Portugal 
 
 
Lobo MF, Azzone V, Resnic FS, Melica B, Teixeira-Pinto A, Azevedo LF, 
Freitas A, Nisa C, Nicolau-Bacelar L, Rocha-Gonçalves F, Pereira-Miguel J, 
Costa-Pereira A, Normand SL 
 
 
 
 
Supplementary Data 
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Regulatory mechanisms of health technologies 
 
The Food and Drug Administration (FDA), in the US, and the Autoridade Nacional do 
Medicamento e Produtos de Saúde I.P. (INFARMED), in PT, represent the official local 
regulatory agencies of drugs and medical device marketing and post-market surveillance. 
However, other agencies within the European Union (EU) may articulate with INFARMED for 
marketing authorization of medicines and devices. Approval of medical devices and drugs 
follow different pathways and different levels of control in both countries.  
 
Drugs  
United States – The FDA approves drugs for marketing based on experimental data 
supporting safety and effectiveness of the medical product (drug or device) as well as 
information attesting adequate manufacturing and labelling. Drugs are approved if there is 
clear evidence that benefits outweigh the risks.[1] In order to improve the speed of approval 
reviews, as of 1992, review fees were introduced with the Prescription Drug User Fee Act and 
many special approval programs have been created ever since.[2-4] Production and 
marketing of pharmaceuticals is completely privatized but regulated by the FDA, which does 
not regulate the price of pharmaceuticals.[5] Prices result from market forces such as 
competition, and purchasers and customer negotiation power.[5,6] Unlike Portugal and most 
countries, direct-to-consumer advertising of prescription drugs is allowed in the US provided 
that the advertisements are accurate and not misleading.[5,7] 
Drug coverage and type of cost-sharing vary among different health plans and insurers.[8] 
However, most employer-based health plans cover outpatient drugs in which employees 
typically prefer flat rate co-payment cost-sharing.[5,9,10] In addition, most outpatient drug 
coverage plan formularies follow a three-tier reimbursement scheme with lower co-payment 
for generics and higher co-payments for brand-name drugs with generic equivalent.[8,10] 
Portugal – The European Union regulatory system for drug marketing approval, which 
comprises four possible procedures: centralized, decentralized, mutual recognition or 
national. Briefly, the centralized procedure is offered by the European Medicines Agency 
(EMA) and provides authorization for marketing a drug in all EU countries. The centralized 
procedure is compulsory for some drugs and optional to others. Drugs that fall outside the 
scope of EMA are approved for marketing using one of the other procedures depending on 
the countries for which marketing is sought.[11,12] In 2012, the EMA accounted for 
approximately 13% (66/521) of drug marketing approvals in Portugal.[13] Regardless of the 
type of procedure, drugs receive approval for marketing in Portugal, much like in the US, 
based on experimental data regarding quality, safety and efficacy. INFARMED further 
regulates standards regarding their manufacturing, distribution and labelling.[12] 
Contrary to the FDA, INFARMED is responsible for price control and reimbursement eligibility 
of drugs within the NHS. With this purpose, pharmaco-economic and pharmaco-therapeutic 
reports need to be submitted so that a hospital price or a maximum retail price can be agreed 
with the pharmaceutical company, before asking the government for a reimbursement rate 
and then begin marketing.[14] Maximum prices are currently determined by INFARMED 
based on prices practiced in other European countries of similar GDP per capita to PT.[15] 
Outpatient drugs eligible for reimbursement by the NHS are assigned to one of four 
reimbursement rate categories based on a therapeutic classification.[14,16]   
The use of the national drug formulary is mandatory for doctors prescribing in institutions 
within the NHS and is also an important guiding instrument for hospitals’ pharmacy 
departments and their drug formularies.[17,18] 
 
Medical devices 
United States – Approval of medical devices is centralized at federal government under the 
FDA. Regulations aim to assure the safety and effectiveness of the devices according to a 
risk-tiered classification (Class I, II and III), where regulatory control increases from Class I to 
Class III depending on the risk the device poses to the patient but also on its intended use 
and indications for use.[19] Depending on the class assigned to the device, an additional 
pathway to general controls may be required. This may be either a premarket notification 
(510(k)), or a premarket approval application (PMA), where the PMA is the strictest and more 
formal regulatory control. At its inception, review of medical device applications was free of 
charge but as of 2003, the FDA may charge fees to medical device manufacturers. 
Additionally, a Third Party Program has been implemented which provides the option to seek 
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private parties to review applications. Such amendments have been implemented to improve 
the review process, which has been often criticized as a slow and lengthy process.[4,20] 
Portugal – The medical device approval system falls under the decentralized regulatory 
system implemented at the EU [21,22] The procedure involves a Notified Body, which is 
private for-profit organization accredited by European authorities, that evaluates whether 
manufacturers are conforming to the EU’s Medical Device Directives [21] Similar to the FDA 
system, control requirements depend on the associated-risk group (I, IIa, IIb and III) of the 
device. This review process has been criticized as having lack of transparency and vague 
requirements, which allows for different levels of standards between Notified Bodies.[20] For 
example, there is no publicly available list of all approved devices in EU nor of their review 
application information.[23,24] Furthermore, as emphasised by Fraser et al.[24] regulations 
provide detail on how clinical studies of devices should be performed, but they do not specify 
when they are required.  
The Notified Bodies provide a CE (Conformité Européen) mark certification to the medical 
device if proven that it is safe and functions according to the manufacturer’s intended use, 
enabling it to enter the EU market.[20] High-risk medical devices must be further registered 
with the INFARMED for commercialization.[22] 
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Table S1: Reference population used for direct standardization of rates – 2010 US population. 
Age Male Female 
20-24 11,014,176 10,571,823 
25-29 10,635,591 10,466,258 
30-34 9,996,500 9,965,599 
35-39 10,042,022 10,137,620 
40-44 10,393,977 10,496,987 
45-49 11,209,085 11,499,506 
50-54 10,933,274 11,364,351 
55-59 9,523,648 10,141,157 
60-64 8,077,500 8,740,424 
65-69 5,852,547 6,582,716 
70-74 4,243,972 5,034,194 
75-79 3,182,388 4,135,407 
80-84 2,294,374 3,448,953 
85+ 1,789,679 3,703,754 
Source: Centers for Disease Control and Prevention, National Center for Health Statistics.[25] 
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Table S2. Comparison of health care systems between the US and Portugal, 2000 and 2010.  
 
US  Portugal 
Variable (Unit) 2000 2010  2000 2010 
Population  
Total (million) 281•2 309•3  10•3 10•6 
65 years or older (%) 12•4 13•1  16•3 18•7 
Females (%) 50•9 50•8  51•7 52•2 
White (%) 81•0 78•3  . . 
Health Coverage 
Uninsured (%) 13•1 16•3  0* 0* 
Hospital capacity (per 1,000 population) 
Total hospital beds  3•5 3•1  3•7 3•4 
Beds in public hospitals 0•9 0•8  2•9 2•5 
Health costs 
Total health expenditure (% of GDP) 13•1 17•0  9•3 10•8 
Total health expenditure per capita (US $ PPP) 4,790•5 8,243•5  1,645•9 2,793•1 
Government share (% of total expenditure) 43•0 47•4  66•6 65•9 
Private Insurance (% of total expenditure) 35•3 33•7  4•4 4•3 
Out-of-Pocket (% of total expenditure) 14•9 12•0  23•4 25•8 
Health status 
All-cause deaths (per 100,000 population, ≥20 years, crude rates) 1,169•0 1,074•7  1,309•4 1,255•3 
Males 1,182•4 1,103•8  1,441•5 1,368•8 
Females 1,156•5 1,047•4  1,190•4 1,154•9 
All-cause deaths (per 100,000 population, ≥20 years, age-sex 
adjusted rates) 
1,247•5 1,074•7 
 
1291•4 1,040•7 
Life expectancy at birth (years) 76•7 78•6  76•9 80•0 
Males 74•1 76•2  73•3 76•8 
Females 79•3 81•0  80•4 83•2 
US $ PPP – Purchasing Power Parity in US dollars 
* Implicit from universal coverage  
Sources: OECD, US Census Bureau, CDC Wonder, Portugal Statistics, Eurostat.[26-30] Sex-age-adjusted death rates were computed using the 2010 US 
population as reference.  
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Table S3a: Sample characteristics of studies used for discussion of prevalence of risk factors. 
Sources: Methods of studies describing the CHD risk factors for PT [31-35]. 
  
Study AMALIA [31] PHYSA [32] VALSIM [33] Sardinha et al. [34] Carreira et al. [35] 
Time 
period October 2006 to February 2007 November 2011 to December 2012 April 2006 to November 2007 2008 and 2009 - 
Type of 
study 
Cross-sectional study, using a 
structured questionnaire in a direct 
interview.  
Cross-sectional survey with protocol-
based interviews and examinations.  
Cross-sectional study based on 
questionnaire on sociodemographic, 
clinical and laboratory data. 
Cross-sectional study based on 
measurements of body mass, stature, 
and waist circumference. 
Systematic review of 
nationally 
representative 
samples, published 
and available in 
Pubmed until 211 
Sampling  
Method 
The sample was stratified by 
gender, age-group and region and 
includes individuals of both 
genders, aged 40 years or more 
and resident in Portugal. 
A multistage-stratified (by age and sex) 
cluster random sampling method was 
used to select a nationally (Portugal 
continental) representative sample of 
the general population aged 18-90 
years based in 2001 recent National 
census data.  Community local health 
service centers were the basis for 
recruitment 
Stratified distribution and proportional to 
the population density of each region of 
mainland Portugal and the islands of 
Madeira and the Azores treated at primary 
health care centers.  
Sample selection followed a multi-
stage proportionate stratified cluster 
sampling procedure, considering 
population gender, age and 
geographical distribution. Controlled 
quota sampling was calculated taking 
into account the demographic data 
reported by National Census. 
-  
N 38893 3720 16,856 2539 
 
Age 
range 
 ≥40 years 18-90 years  18-96 years ≥18 yeas - 
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Table S3b: Definitions used of risk factors in studies for discussion of prevalence of risk factors. 
 Sources: Definitions in studies analyzing CHD risk factos for PT [31-35]. 
 
  
Study AMALIA [31] PHYSA [32] VALSIM [33] Sardinha et al. [34] 
Carreira et al. 
[35] 
Overweight 
Declared weight, height as 
indicated on identity card 
25≤BMI<30, BMI =weight/height^2 based on 
actual measurements of height and weight 
25≤BMI<30, BMI =weight/height^2 
based  on actual measurements of 
height and weight 
25≤BMI<30, BMI 
=weight/height^2 based on 
actual measurements of 
height and weight 
- 
Obesity 
Declared weight, height as 
indicated on identity card 
BMI ≥30M; BMI =weight/height^2 based on 
actual measurements of height and weight 
BMI ≥30M; BMI =weight/height^2 based  
on actual measurements of height and 
weight 
BMI ≥30M; BMI 
=weight/height^2 based on 
actual measurements of 
height and weight 
- 
Hypertension 
Self-reported hypertension (“high 
blood pressure”); treatment and 
monitoring of each of the above 
conditions when present 
Hypertension was defined as a systolic blood 
pressure (BP) of at least 140mmHg or diastolic 
BP of at least 90mmHg, or if the participant 
reported a history of hypertension, or if the 
participant reported taking antihypertensive 
medication in any moment of their life. 
Awareness of hypertension was defined as 
participant's self-reported of any previous 
diagnosis of hypertension by a healthcare 
professional (except if only during pregnancy). 
The treatment of hypertension was defined as 
self-reported use of a prescription medication 
for the treatment of hypertension in the past 2 
weeks.  
Blood pressure was estimated as the average 
of three readings or the average of the two last 
readings if there was a difference of at least 
10mmHg of BP from the first reading to the 
second; 
Hypertension (HTA) was defined by a 
previous diagnosis of HTA or the 
presence of systolic BP >140 mmHg or 
diastolic BP >90 mmHg. BP was based 
on actual measurements. 
- - 
Hypercholester
o-lemia 
Self-reported 
hypercholesterolemia ("Blood 
cholesterol") was defined 
treatment and monitoring of each 
of the above conditions when 
present 
Self-perceived hypercholesterolemia was 
defined by "participant's awareness of these 
conditions or current use of antidyslipidemic 
drug" 
HDL cholesterol<40mg/dL - - 
Diabetes 
Self-reported diabetes; treatment 
and monitoring of each of the 
above conditions when present 
Self-perceived diabetes was defined by 
"participant's awareness of these conditions or 
current use of antidiabetic drug" 
Diabetes was defined as a previous 
diagnosis or fasting glucose of >126 
mg/dl, and impaired fasting glucose as 
fasting glucose 110-125 mg/dl. 
- - 
Smoking 
Smoking status was classified as: 
never smoked, ex-smoker (how 
long quit smoking? Smoked for 
how long? Cigarettes per day?), 
current smoker (how long smoker? 
Cigarettes per day?) 
Smoking status was classified as: current, ex-
smoker (not for at least 1 year), and non-
smoker. 
Self perceived; Smoker, Ex-smoker, 
Non-smokers 
-  MISSING 
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Table S3c: Prevalence of main CHD risk factors (%) - additional studies to characterize the risk of the PT population. 
Country US PT 
Study NHANES AMALIA [31]  PHYSA [32]  VALSIM [33]  Sardinha et al. [34]  Carreira et al. [35],  
Risk factor 
Crude 
rate 
Age-
adjusted 
rate 
Crude 
rate 
Age-adjusted 
rate 
Crude 
rate  
Sex-
adjusted 
rate 
Crude 
rate  
Age-sex-
adjusted 
rate 
Crude 
rate 
Age-sex-
adjusted 
rate 
Crude 
rate  
Age-sex-
adjusted 
rate 
Overweight/Obesity 
Both sexes 71•6 
71•6 
51•6 
51•3 
 
51•6 
- 
 
64•99 
62•07 
- 
 Males 77•8 - 53•1 - 
 
67•35 - 
 Females 66•1 - 50•1 - 
 
63•22 - 
 Hypertension 
Both sexes 32•8 
33•7 
23•5 
22•8 
 
40•9* 
65•46 
43•52 
- 
 
- 
 Males 30•3 21•8 44•4 62•48 - 
 
- 
 Females 35•1 24•9 40•2 58•63 - 
 
- 
 Hypercholesterolemia 
Both sexes 48•1 
48•1 
19•7 
19•4 
 
33•2 
27•46 
39•46 
- 
 
- 
 Males 50•0 18•6 29•1 47•74 - 
 
- 
 Females 46•4 20•7 37•0 34•29 - 
 
- 
 Diabetes 
Both sexes 12•3 
12•6 
8•9 
8•5 
 
10•3 
- 
 
- 
 
- 
 
Males 12•1 8•5 11•4 - 
 
- 
 
- 
 
Females 12•4 9•3 9•2 - 
 
- 
 
- 
 
Smoking 
Both sexes 20•3 
19•8 
16•3 
17•1 
 
15•1 
- 
 
- 
 
- 
17•28 Males 22•6 25•3 16•1 - 
 
- 
 
- 
Females 18•3 8•8 14•1 - 
 
- 
 
- 
* age-sex-adjusted rate,  
NHANES – National Health and Nutrition Examination Survey  
Sources: Crude rates retrieved from [31-36]. Age-sex-adjusted rates were computed using the US 2010 population in Table S1 a reference population. 
  
 103 
 
 
Table S4. Health technologies access lag between the US and Portugal per medical device class in selected interventional cardiology procedures. 
Technology 
Country 
First approved device 
(Model, Manufacturer) 
Date (mm/dd/yy) 
Procedure name Device class 
Approval 
 
Difference: US-
PT (months) 
Percutaneous Coronary 
Intervention (PCI) 
PTCA Balloon Catheter 
PT Unknown May 19846  
-47 
US Unknown 19804 
Bare-Metal Stent (BMS) 
PT Palmaz Schatz stent, Johnson & Johnson  6/21/906 
33 
US Gianturco-Roubin coronary flex-stent, Cook, inc. 06/03/931 
Drug-Eluting Stent (DES) 
PT Cypher sirolimus drug eluting stent, Cordis 05/31/024, 6 
11 
US Cypher sirolimus drug eluting stent, Cordis 04/24/031 
Cutting Balloon Catheter (CBC) 
PT Cutting Balloon, Interventional Technologies Inc. 19953 
58 
US Flexatome Cutting Balloon, Boston Scientific 04/18/001 
Drug-Eluting Balloon Catheter 
(DEB) 
PT SeQuent Please, B Braun Melsungen AG 06/30/093 
67 
US N/A Not approved 
Percutaneous Ventricular 
support 
Impella - catheter-based VAD 
PT Impella® 2.5, Abiomed 09/30/043, 6 
44 
US 
Impella Recover LP 2.5 Percutaneous Cardiac Support System, 
AbIomed Inc. 
05/30/082 
 Percutaneous Ventricular Assist 
Device (PVAD) 
PT TandemHeart System, CardiacAssist Inc. 02/26/013 
-12 
 US AB-180 XC System, Cardiac Assist Inc. 02/25/003,1 
Embolic Protection N/A 
PT PercuSurge Guard Wire, PercuSurge Inc. 08/11/983 
29 
US 
PercuSurge GuardWire Temporary Occlusion and Aspiration 
System, PercuSurge Inc. 
06/01/012 
Atherectomy 
Rotational Atherectomy 
PT Rotablator, Boston Scientific Corp. 19993 
-73 
 
Rotablator®, Boston Scientific Corp. 05/28/931 
Directional Coronary Atherectomy 
(DCA) 
PT Unknown 10/23/916 
-13 
US 
Simpson Coronary Atherocath, Devices for Vascular Intervention, 
Inc. 
09/14/901 
Coronary Thromboaspiration 
Manual 
PT Diver CE, Invatec S. p. A. 07/06/013 
17 
US Export Aspiration Catheter, Medtronic Vascular 10/29/022 
Mechanical 
PT 
Angiojet Series 3000 Rheolytic Thrombectomy Syste, Possis 
Meical Inc. 
October 19973 
25 
US 
AngioJet Rheolytic Thrombectomy System, Bayer Medical Care 
Inc. 
03/12/991 
Coronary Brachytherapy 
Intravascular Radiation Delivery 
System/Device 
PT Novoste Beta-Cath System, Novoste Corp. 19994 
17 
US Novoste Beta-Cath System, Novoste Corp. 12/13/001 
Transcatheter Aortic Valve 
Replacement (TAVR) 
Balloon expand 
PT Sapien TransCatheter Aortic Valve Edwards LifeSciences September 20073 
50 
US Sapien TransCatheter Aortic Valve Edwards LifeSciences 11/22/111 
Self-expand 
PT The CoreValve System, Medtronic May 20073, 5 
82 
US The CoreValve System, Medtronic 02/04/141 
Percutaneous Reduction of 
Mitral Regurgitation 
Percutaneous Mitral Repair 
System 
PT MitraClip, Abbott Vascular March 20083 
67 
US MitraClip, Abbott Vascular 10/24/131 
   Mean difference: 22 
   Median difference: 27 
N/A: Not available. 
Sources:  
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1 FDA Premarket Approval (PMA) [37] 
2 FDA Premarket notification 510(k) [38] 
3 Personal communication with MD industry representatives/press release/EUCOMED [39-43] 
4 Scientific journal [44-46] 
5 Personal communication with an interventional cardiology from Centro Hospitalar de Vila Nova de Gaia (Portugal) 
6 First use in Santa Cruz Hospital [47] 
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Table S5. Health technologies access lag per active in selected therapeutic uses between the US and Portugal. 
 
 
Therapeutic use Active substance Country 
Approved drug 
(Brand name) 
Date (mm/dd/yy) 
Approval Marketing1 
Difference between  
marketing dates:  
US-PT (months) 
Platelet inhibitor 
Ticlopidine 
PT Tiklyd 05/15/81 03/21/07 
-185 US Ticlid 10/31/91 
Clopidogrel 
PT Plavix 07/15/98 04/29/03 
-65 US Plavix 11/17/97 
Prasugrel 
PT Efient 02/25/09 04/01/14 
-57 US Effient 07/10/09 
Ticagrelor 
PT Brilique 12/03/10 12/19/11 
-5 US Brilinta 07/20/11 
GP IIb/IIIa inhibitor - Abciximab 
PT Reopro 02/12/96 03/21/07 
-159 US Reopro 12/16/93 
GP IIb/IIIa inhibitor - Eptifibatide 
PT Integrilin 07/01/99 03/21/07 
-106 US Integrilin 05/18/98 
GP IIb/IIIa inhibitor - Tirofiban 
PT Aggrastat 06/30/99 03/21/07 
-106 US Aggrastat 05/14/98 
Anticoagulant 
Bivalirudin 
PT Angiox 09/20/04 06/23/10 
-114 US Angiomax 12/15/00 
Rivaroxaban 
PT Xarelto 09/30/08 01/28/09 
29 US Xarelto 07/01/11 
Apixaban 
PT Eliquis 05/18/11 08/01/14 
-19 US Eliquis 12/28/12 
Dabigatran etexilate 
PT Pradaxa 03/18/08 05/01/10 
6 US Pradaxa 10/19/10 
Antianginal 
Nicorandil 
PT Dancor 08/03/96 03/21/07 
95 US N/A N/A 
Ivabradin 
PT Procoralan 10/25/05 11/01/07 
87 US N/A N/A 
Ranolazine 
PT Ranexa 07/09/08 N/C 
-109 US Ranexa 01/27/06 
Mean difference: -51 
Median difference: -61 
N/A – Not available until February 13, 2015 
N/C – Not commercialized until February 13, 2015 
1 Personal communication with INFARMED  
Sources: US – FDA [48]; PT – INFARMED [49] 
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Expanded Methods and Results 
Table S1. List of ICD-9-CM diagnosis and procedure codes. 
Diagnosis/Procedure ICD-9-CM code 
Acute Myocardial Infarction 410.xx and no 410.x2 
Elevated ST segment AMI (STEMI) 410.0-410.6, 410.8 and no 410.x2 
Non-elevated ST-segment AMI (Non-STEMI) 410.7, 410.9 and no 410.x2 
Cardiac catheterization 37.21 - 37.23 
Percutaneous Coronary Intervention 36.01-36.07, 00.66, 92.27 
Bare metal stent 36.06 
Drug-eluting stent 36.07 
Coronary Artery Bypass Graft (CABG) 36.10-36.17, 37.19 
On-pump CABG 36.10-36.17, 37.19 and 39.61 
Off-pump CABG 36.10-36.17, 37.19 and no 39.61 
Valve procedures 35.00 – 35.99 
Pacemaker/heart assist/defibrillated related 
procedures 
00.50, 37.62, 37.65, 37.66, 37.94 – 37.99, 
00.51 – 00.54 
Coronary brachytherapy 92.27 
 
 
Table S2. 2010 Age-Sex Distribution: United States population.   
Sex Age Group Population Size 
Male 20-29 21,649,767 
 30-39 20,038,522 
 40-49 21,603,062 
 50-59 20,456,922 
 60-69 13,930,047 
 70-79 7,426,360 
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 ≥ 80 4,084,053 
Female 20-29 21,038,081 
 30-39 20,103,219 
 40-49 21,996,493 
 50-59 21,505,508 
 60-69 15,323,140 
 70-79 9,169,601 
 ≥ 80 7,152,707 
Source: Centers for Disease Control and Prevention, National Center for Health Statistics. 
Estimates of the April 1, 2010 U.S. Resident Population by Age and Sex, Prepared under a 
collaborative arrangement with the US Census ( National Vital Statistics Report, Vol 61, No 4, 
May 8, 2013. 
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Table S3.  Comparison of health care systems between the United States and 
Portugal, 2000 and 2010. 
 
United States  Portugal 
Variable (Unit) 2000 2010  2000 2010 
Population  
Total (million) 281.2 309.3  10.3 10.6 
65 years or older (%) 12.4 13.1  16.3 18.7 
Females (%) 50.9 50.8  51.7 52.2 
White (%) 81.0 78.3  . . 
Health Coverage 
Uninsured (%) 13.1 16.3  0 0 
Hospital capacity (per 1,000 population) 
Total hospital beds  3.5 3.1  3.7 3.4 
Beds in public hospitals 0.9 0.8  2.9 2.5 
Health costs 
Total health expenditure (% of GDP) 13.1 17.0  9.3 10.8 
Total health expenditure per capita (US $ 
PPP) 
4,790.5 8,243.5 
 
1,645.9 2,793.1 
Government share (% of total expenditure) 43.0 47.4  66.6 65.9 
Private Insurance (% of total expenditure) 35.3 33.7  4.4 4.3 
Out-of-Pocket (% of total expenditure) 14.9 12.0  23.4 25.8 
Health status 
All-cause deaths (per 100,000 population, 
≥20 years, crude rates) 
1,169.0 1,074.7 
 
1,309.4 1,255.3 
Males 1,182.4 1,103.8  1,441.5 1,368.8 
Females 1,156.5 1,047.4  1,190.4 1,154.9 
All-cause deaths (per 100,000 population, 
≥20 years, age-sex adjusted rates) 
1,247.5 1,074.7 
 
1291.4 1,040.7 
Life expectancy at birth (years) 76.7 78.6  76.9 80.0 
Males 74.1 76.2  73.3 76.8 
Females 79.3 81.0  80.4 83.2 
Sources: Instituto Nacional de Estatística (INE). Resident population (Long series, start 1970 -  No.) by Sex 
and Age; Annual. Available from: 
https://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_base_dados&contexto=bd&selTab
=tab2  [Accessed April 15, 2014]; United States Sensus Bureau. National Intercensal Estimates (2000-
2010). Available from: http://www.census.gov/popest/data/intercensal/national/nat2010.html 
[Accessed July 15, 20114]; Centers for Disease Control and Prevention (CDC). CDC WONDER – Wide-
ranging Online data for Epidemiologic Research, Underlying Cause of Death, 1999-2010. Available from: 
http://wonder.cdc.gov/ucd-icd10.html [Accessed April 15, 2014]; Eurostat. Causes of death - absolute 
number - annual data [hlth_cd_anr]. Available from: 
http://ec.europa.eu/eurostat/web/health/causes-death/data/database [Accessed April 15, 
2014]; Organisation for Economic Co-operation and Development. OECD.stat. Available from: 
http://stats.oecd.org [Accessed January 11, 2014]. 
Abbreviations:  
GDP – Gross Domestic Product 
PPP – Prices and purchasing Power Parity 
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Table S4.  Characteristics of Hospitalized Patients with AMI, by Country and Year of Discharge (unweighted US estimates). 
                                                        
1 For over 20 years old patients, after eliminating discharges indicating left against medical advice, patient discharged to hospice, or invalid charges. 
Variable 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 All years 
# of AMI discharges1  
Portugal 8,749 9,775 10,809 11,829 11,799 11,396 11,528 11,816 12,273 11,762 11,706 123,442 
U.S. 141,58
3 
147,22
2 
148,32
8 
145,82
5 
132,77
5 
126,07
7 
130,35
1 
116,87
5 
122,34
6 
118,43
8 
113,33
9 
1,443,159 
STEMI, %  
Portugal 77 74 68 66 61 62 59 55 54 52 50 61 
U.S. 43 40 39 38 35 34 34 32 30 29 28 35 
Anterior MI, % 
Portugal 31 30 28 26 25 24 23 23 22 21 21 25 
U.S. 17 16 15 14 13 13 13 12 12 11 11 14 
Infero MI, % 
Portugal 32 30 27 25 23 22 21 20 20 20 20 23 
U.S. 22 21 20 19 18 17 17 16 16 15 15 18 
Other MI locations, % 
Portugal 37 40 45 49 52 54 56 57 58 59 59 52 
U.S. 61 64 64 67 69 70 70 71 72 74 74 68 
Age 80+, %  
Portugal 16 17 20 20 22 22 22 24 24 24 25 22 
U.S. 22 23 22 23 23 24 22 23 23 22 22 23 
Mean Age [std] 
Portugal 67 [13] 67 [13] 67 [13] 68 [13] 68 [13] 68 [13] 69 [13] 69 [13] 69 [14] 69 [14] 69 [14] 68 [13] 
U.S. 68 [14] 69 [14] 68 [14] 68 [14] 68 [14] 68 [15] 67 [15] 68 [15] 68 [15] 67 [14] 67 [14] 68 [14] 
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2 Reported in U.S. only. 
Female, %  
Portugal 32 33 34 36 36 35 35 36 35 35 35 35 
U.S. 41 41 41 41 41 41 40 40 40 39 39 41 
Race , %2  
White 63 61 55 57 57 58 58 56 62 64 66 60 
Black 5.2 5.6 5.8 6.4 6.5 5.3 6.2 7.3 7.2 7.6 9.6 6.5 
Hispanic 3.8 4.6 4.6 5.8 4.8 5.3 5.6 5.4 5.1 6.0 6.1 5.1 
Asian/Pacifi
c Islander 
1.1 1.1 1.2 1.3 1.3 1.1 1.4 1.6 1.7 1.7 2.0 1.4 
Native 
American 
0.2 0.3 0.1 0.1 0.2 0.2 0.4 0.5 0.8 0.5 0.7 0.4 
Other 1.6 1.8 2.1 1.9 2.0 2.2 2.1 2.3 2.8 3.4 2.3 2.2 
Missing 25 25 31 28 28 28 27 27 20 17 13 25 
Emergent/Urgent Admission, %  
Portugal 97 97 96 97 97 98 97 97 96 94 93 96 
U.S.  82 82 83 83 85 84 84 83 86 86 85 84 
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Variable 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 All years 
Cardiovascular Morbidity, %  
History of PTCA/V45.82 
Portugal 0.5 1.1 1.2 1.6 2.1 2.5 2.9 3.8 4.1 4.9 6.2 2.9 
U.S. 5.9 6.3 6.2 6.3 6.3 7.2 8.5 9.2 10.1 10.5 10.8 7.8 
History of CABG/V45.81 
Portugal 1.0 1.3 1.4 1.9 2.0 2.3 2.3 2.8 2.5 2.3 3.0 2.1 
U.S. 8.0 7.5 6.9 6.8 6.7 6.5 6.6 6.5 6.8 6.6 6.7 6.9 
History of Congestive Heart Failure/MCC80, 429 
Portugal 14.3 15.2 15.8 18.0 18.2 18.0 18.2 19.8 20.4 20.2 20.9 18.3 
U.S. 35.1 34.4 34.2 35.1 36.0 35.4 34.1 34.9 34.7 35.4 35.4 34.9 
History of AMI/412, 410.x1 
Portugal 4.8 4.7 4.5 6.0 5.8 5.7 5.4 9.9 5.0 6.3 7.6 6.0 
U.S. 8.2 8.1 8.3 8.0 8.3 8.4 9.1 9.6 10.0 11.2 11.4 8.9 
Unstable Angina/ 411, 410.x2 
Portugal 3.5 3.0 2.1 1.7 1.3 1.1 2.0 1.2 0.7 0.7 0.8 1.6 
U.S. 3.6 2.8 2.3 2.1 1.9 1.6 1.5 1.3 1.2 1.2 1.1 1.9 
Chronic atherosclerosis/413, 414,  746.85 
Portugal 29.6 31.4 32.0 32.9 35.6 36.8 40.7 43.6 43.1 45.7 51.5 38.8 
U.S. 66.9 68.1 70.0 70.9 71.4 72.8 75.1 75.4 77.6 80.2 80.0 73.1 
Cardiorespiratory Failure and Shock/MCC79 
Portugal 8.1 8.4 7.7 8.5 8.6 9.0 8.4 8.0 8.0 8.5 9.2 8.4 
U.S. 12.4 12.4 12.9 12.8 12.9 12.7 13.8 14.8 15.8 16.0 16.0 13.8 
Valvular or Rheumatic Disease/MCC86 
Portugal 6.5 8.2 9.1 10.3 9.5 9.6 10.1 10.2 10.5 11.1 12.4 9.9 
U.S. 11.5 11.4 12.3 12.1 12.1 13.0 13.6 12.9 11.4 12.0 12.0 12.2 
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Variable 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 All years 
Comorbidities, %  
Hypertension/MCC89 
Portugal 32.4 39.1 42.0 44.5 45.6 47.3 47.7 48.8 49.1 52.2 53.9 46.2 
U.S. 44.6 46.0 48.2 49.5 51.0 51.9 52.6 59.3 61.9 64.8 65.7 53.5 
Stroke/MCC95 
Portugal 1.4 1.4 1.3 1.3 1.1 1.3 1.2 1.3 1.1 1.1 1.1 1.2 
U.S. 1.8 1.8 1.7 1.7 1.7 1.7 1.7 1.6 1.7 1.5 1.4 1.7 
Cerebrovascular Disease/MCC97 
Portugal 2.3 2.7 3.3 3.5 3.6 3.2 3.8 3.7 3.3 3.8 4.5 3.5 
U.S. 2.9 2.8 2.9 2.8 2.9 2.9 2.9 3.0 3.3 3.7 3.6 3.1 
Renal Failure/MCC131 
Portugal 2.3 3.1 2.9 2.9 3.3 3.9 4.3 5.4 7.2 8.9 10.9 5.1 
U.S. 8.0 9.0 9.8 10.8 11.9 14.2 18.4 21.3 22.5 24.5 25.5 15.4 
Chronic Obstructive Pulmonary Disease/MCC108 
Portugal 3.9 4.5 4.4 4.5 4.3 4.2 4.2 3.9 4.1 4.4 4.7 4.3 
U.S. 16.6 16.3 17.5 17.3 17.5 18.4 17.9 18.0 16.6 17.1 16.9 17.3 
Pneumonia/MCC111 
Portugal 3.3 3.1 3.4 3.6 3.7 3.9 3.8 4.2 4.2 4.3 4.8 3.9 
U.S. 7.2 7.3 7.8 8.5 8.7 9.2 8.4 9.0 9.8 9.3 9.1 8.5 
DM and DM complications//MCC15 
Portugal 22.1 23.1 24.1 25.7 26.4 27.3 27.4 29.1 28.6 29.1 30.4 26.8 
U.S. 28.2 28.4 29.0 29.5 29.8 30.0 30.6 31.9 32.4 34.1 34.8 30.6 
Pure Hypercholesterolemia/272.0 
Portugal 3.6 3.9 4.0 5.5 4.7 4.2 4.9 5.3 4.7 4.6 3.9 4.5 
U.S. 13.2 13.4 13.7 12.7 13.4 12.0 11.3 11.5 10.3 9.8 9.5 12.0 
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Protein-Calorie malnutrition/MCC21 
Portugal 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
U.S. 1.0 1.0 1.0 1.1 1.3 1.3 1.4 1.6 2.1 2.3 2.3 1.4 
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U.S. – United States 
STEMI – ST-elevated segment myocardial infarction 
MI – Myocardial Infarction 
Variable 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 All years 
Comorbidity, % 
Dementia and Senility/MCC49 
Portugal 0.8 1.0 1.2 1.4 1.6 1.7 2.0 2.1 2.2 2.4 2.8 1.8 
U.S. 4.1 4.5 4.8 4.9 5.1 5.4 5.3 5.7 6.1 6.2 6.3 5.2 
Hemiplegia, Paralysis and Functional Disability/MCC67 
Portugal 2.3 2.4 2.7 2.7 2.8 3.0 2.6 2.9 3.0 3.1 3.0 2.8 
U.S. 2.7 2.6 2.6 2.6 2.6 2.4 2.5 2.7 3.2 3.3 3.4 2.8 
Peripheral Vascular Disease/MCC104 
Portugal 2.2 2.4 3.2 3.3 3.2 3.5 3.6 4.2 3.9 4.5 4.5 3.6 
U.S. 7.8 8.2 8.7 8.9 9.4 9.6 10.2 11.0 11.4 12.7 12.0 9.9 
Metastatic Cancer and Acute Leukemia/MCC7 
Portugal 0.4 0.4 0.6 0.5 0.5 0.4 0.4 0.5 0.6 0.6 0.7 0.5 
U.S. 1.1 1.1 1.1 1.1 1.2 1.2 1.1 1.3 1.3 1.4 1.3 1.2 
Trauma/MCC154 
Portugal 0.6 0.6 0.6 0.7 0.7 0.8 0.7 0.8 0.8 0.6 0.7 0.7 
U.S. 2.0 2.3 2.7 1.6 1.7 1.7 1.7 1.9 2.1 2.2 2.1 2.0 
Major Psychiatric Disorders/MCC54 
Portugal 0.3 0.4 0.3 0.4 0.3 0.3 0.3 0.3 0.5 0.5 0.4 0.4 
U.S. 1.1 1.1 1.2 1.3 1.4 1.3 1.4 1.5 1.9 2.0 2.2 1.5 
Liver and Biliary Disease/MCC25 
             
Portugal 
0.4 0.4 0.4 0.3 0.4 0.4 0.3 0.4 0.3 0.6 0.6 0.4 
             U.S. 0.4 0.5 0.6 0.6 0.7 0.7 0.7 0.8 0.7 0.8 0.9 0.7 
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PTCA – Percutaneous transluminal coronary angioplasty 
CABG – Coronary artery bypass graft 
AMI – Acute myocardial infarction 
DM – Diabetes Mellitus 
MCC – Modified hierarchical condition categories 
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Table S5: Hazard ratios for comorbidities in survival models [Model 1]. 
Country Portugal United States 
Comorbidities Pr > ChiSq 
Hazard 
Ratio 
CI Pr > ChiSq 
Hazard 
Ratio 
CI 
STEMI <.0001 1.371 [1.302,1.444] <.0001 1.209 [1.171,1.248] 
Anterior MI 0.4581 0.981 [0.934,1.031] 0.8364 1.105 [1.067,1.143] 
Inferior MI <.0001 0.751 [0.710,0.793] 0.074 1.049 [1.014,1.086] 
History of CABG/V45.81 0.5203 1.043 [0.918,1.185] <.0001 1.014 [0.986,1.043] 
History of PTCA/V45.82 0.0079 0.824 [0.715,0.951] 0.2058 0.962 [0.933,0.992] 
History of Congestive Heart Failure/MCC80, 
429 
0.1354 
1.029 
[0.991,1.068] <.0001 
1.02 
[1.006,1.033] 
History of AMI/412, 410.x1 0.0811 0.935 [0.866,1.008] 0.0383 1 [1.006,1.033] 
Unstable Angina/ 411, 410.x2 <.0001 0.704 [0.602,0.825] 0.0095 0.985 [0.942,1.031] 
Chronic atherosclerosis/413, 414,  746.85 <.0001 0.524 [0.502,0547] <.0001 0.717 [0.707,0.726] 
Hypertension/MCC89 <.0001 0.610 [0.588,0.632] <.0001 0.832 [0.821,0.843] 
Cerebrovascular Disease/MCC97 0.058 1.073 [0.998,1.154] 0.7963 0.977 [0.707,0.726] 
Chronic Obstructive Pulmonary 
Disease/MCC108 
<.0001 
0.819 
[0.761,0.881] <.0001 
0.978 
[0.964,0.993] 
Dementia and Senility/MCC49 0.0078 1.122 [1.031,1.221] <.0001 1.064 [1.04,1.088] 
DM/DM with complications/MCC15 <.0001 1.092 [1.053,1.133] 0.0017 0.988 [0.974,1.002] 
Pure hypercholesterolemia/272.0 <.0001 0.520 [0.456,0.592] <.0001 0.907 [0.885,0.929] 
Hemiplegia, paralysis and functional 
disability/MCC67 
<.0001 1.242 [1.153,1.338] <.0001 1.033 [0.999,1.069] 
Liver and biliary disease/MCC25 0.0016 1.350 [1.120,1.626] 0.2802 1.019 [0.95,1.092] 
Metastatic Cancer and acute leukemia/MCC7 <.0001 1.724 [1.495,1.988] <.0001 1.049 [1.001,1.1] 
Protein-Calories Malnutrition/MCC21 0.0127 1.403 [1.075,1.830] 0.0081 0.994 [0.965,1.024] 
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Pneumonia/MCC111 <.0001 0.809 [0.765,0.855] <.0001 1.05 [1.033,1.066] 
Major Psychiatric Disorders/MCC54 0.4704 0.913 [0.713,1.169] 0.7671 0.992 [0.943,1.043] 
Peripheral Vascular Disease/MCC104 0.1439 1.056 [0.982,1.136] <.0001 1.008 [0.99,1.028] 
Renal Failure/MCC131 0.0003 1.098 [1.043,1.155] <.0001 1.277 [1.258,1.295] 
Cardiorespiratory failure and shock/MCC79 <.0001 5.695 [5.492,5.905] <.0001 2.372 [2.339,2.406] 
Stroke/MCC95 <.0001 1.437 [1.317,1.567] <.0001 1.074 [1.041,1.108] 
Trauma/MCC154 0.0003 0.739 [0.627,0.870] 0.0561 0.991 [0.957,1.026] 
Valvular or rheumatic heart disease/MCC86 <.0001 0.601 [0.566,0.639] <.0001 0.928 [0.913,0.944] 
STEMI – ST-elevated segment myocardial infarction 
CABG – Coronary artery bypass graft 
PTCA – Percutaneous transluminal coronary angioplasty 
MI – Myocardial infarction 
AMI – Acute myocardial infarction 
DM – Diabetes Mellitus  
MCC – Modified hierarchical condition categories 
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Extended Methods 
 
Table S1. Characteristics of hospitals in the study. 
Hospital 
# 
Geographic 
region 
Teaching 
status 
Catheterizat
ion 
laboratory 
on-site 
Cardia
c 
surger
y on-
site 
AMI 
volume 
(2011) 
# of index 
events 
(Readmis
sion 
cohort) 
Crude 
readmissi
on rate 
(%) 
# of 
index 
events 
(Morta
lity 
cohort) 
Crude 
death 
rate 
(%) 
Adult 
populatio
n (Census 
2011) 
1 Alentejo/Algarve 0 0 0 56 110 16.4 196 38.3 
980 442 
2 Alentejo/Algarve 0 0 0 66 191 15.2 282 26.2 
3 Alentejo/Algarve 0 0 0 118 271 11.1 320 15.0 
4 Alentejo/Algarve 0 0 0 224 579 4.7 621 7.2 
5 Alentejo/Algarve 0 1 0 279 995 6.6 1097 8.9 
6 Alentejo/Algarve 0 1 0 645 2126 6.6 2330 8.8 
7 Center 0 0 0 94 240 7.1 347 22.2 
1 890 381 
8 Center 1 0 0 116 326 10.4 384 13.3 
9 Center 0 0 0 128 282 6.0 340 16.8 
10 Center 0 0 0 211 876 9.0 1026 12.7 
11 Center 0 0 0 214 630 7.3 676 5.5 
12 Center 0 0 0 215 604 6.8 652 10.1 
13 Center 0 1 0 256 874 9.7 1005 12.8 
14 Center 1 1 1 789 2372 11.0 2591 9.4 
15 Lisbon 0 0 0 125 399 10.0 460 11.5 
2 240 649 
16 Lisbon 0 0 0 131 275 12.0 566 10.1 
17 Lisbon 0 0 0 145 558 7.9 525 22.5 
18 Lisbon 0 0 0 170 848 8.1 917 7.7 
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19 Lisbon 0 1 0 236 954 8.5 1073 9.2 
20 Lisbon 0 1 0 322 1002 6.0 1327 11.4 
21 Lisbon 0 1 0 432 1717 6.8 2023 13.8 
22 Lisbon 0 1 0 451 1331 8.3 1476 10.3 
23 Lisbon 0 1 1 535 1599 8.0 1676 9.1 
24 Lisbon 1 1 1 663 1900 10.8 2151 13.7 
25 Lisbon 0 1 1 895 2273 6.9 2179 10.0 
26 Norte 0 0 0 69 180 11.1 223 22.4 
3 920 372 
27 Norte 0 0 0 79 177 6.8 198 11.1 
28 Norte 0 0 0 127 284 12.3 382 17.8 
29 Norte 0 0 0 180 741 4.9 746 6.6 
30 Norte 0 0 0 194 732 11.1 771 8.2 
31 Norte 0 0 0 195 649 7.4 676 5.6 
32 Norte 0 1 1 221 898 4.6 1014 7.6 
33 Norte 0 1 0 261 1114 7.4 1226 8.9 
34 Norte 0 1 0 266 1146 6.4 1180 5.3 
35 Norte 1 1 0 309 965 4.7 1073 9.7 
36 Norte 1 1 0 412 1996 5.9 2078 4.6 
37 Norte 1 1 1 566 2042 7.8 2252 8.3 
Hospital size has been omitted to protect hospital identification. 
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Figure S1. Geographical distribution of hospitals and adult population 
(Census 2011). 
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Implemented Models 
Let Yij be 1 if the i
th patient at the jth hospital was readmitted/died in hospital and zero 
otherwise then, the log odds of the ith patient admitted in the jth hospital being 
readmitted/dying during the hospitalization were modeled on a stepwise fashion 
through models 0 to 3 as follows: 
 
Yij ~Bernoulli(P(Yij=1)) 
 
Model 0 (empty model): logit[P(Yij=1| β0)] = β0 + u(hospital)j 
 
Where, 
β0 – is the intercept, represents the log odds of a patient admitted being 
readmitted/dying in an average hospital; 
u(hospital)j – is the random intercept for hospital, describes the variation of the jth 
hospital intercept relative to the average hospital, u(hospital)j ~ N(0,σu(hospital)); 
 
 
Model 1: logit[P(Yij=1| β0, βp, h=j)] = β0 + βp*Patient_characteristicsij + u(hospital)j 
 
Where β0 and u(hospital)j have the same interpretation as before and, 
βp – are the fixed effects of patient characteristics, represent log odds of being 
readmitted/dying when presenting that characteristic relative to not presenting it 
(patient-level predictor). 
 
 
Model 2: logit[P(Yij=1| β0, βp, βh, h=j)] = β0 + βp*Patient_characteristicsij + 
βh*Hospital_characteristicsij + u(hospital)j 
 
Where β0, βp and u(hospital)j have the same interpretation as before and, 
βh – are the fixed effects of hospital characteristics, represent log odds of being 
readmitted/dying when the hospital presents that characteristic relative to not 
presenting it. Patients admitted to the same hospital share the same hospital 
characteristics (hospital-level predictor). 
127 
 
Extended Results 
 
Table S2. Distribution of hospital characteristics, by cohort 
Characteristic # Hospitals 
Mortality cohort Readmissions cohort 
#Discharges 
Median [IQR] 
% In-hospital crude mortality  
Median [IQR] 
# Discharges per 
hospital 
Median [IQR] 
% Crude 30-day 
unplanned readmission  
Median [IQR] 
All hospitals 37 917 [460,1327] 10.07 [8.26, 13.67] 848 [326, 1146] 7.84 [6.63, 10.43] 
Teaching status 
Teaching hospital 6 2115 [1073,2252] 9.54 [8.26, 13.28] 1948 [965,2042] 9.13 [5.86,10.79] 
Non-teaching hospital 31 746 [382,1180] 10.12 [8.17, 15.00] 732 [282,1002] 7.40 [6.63,10.03] 
Size (number of beds) 
Above the median (>425 beds) 18 1203 [1014,2078] 9.54 [8.80, 12.67] 1130 [876,1900] 7.38 [6.63, 9.02] 
Below the median (≤425 beds) 19 525 [340,771] 11.38 [8.17, 17.80] 399 [271,741] 7.89 [6.63, 11.07] 
AMI volume 
Above the median (>215) 18 1402 [1073,2151] 9.15 [8.26, 10.30] 1239 [965,1996] 6.83 [5.99, 8.34] 
Below the median (≤215) 19 460 [320,676] 12.67 [8.17, 22.19] 326 [240,649] 9.02 [7.08, 11.11] 
Services provided, % 
Both catheterization lab and 
cardio-thoracic surgery 
6 2165 [1676,2252] 9.22 [8.26, 10.00] 1971 [1599,2273] 7.92 [6.91, 10.79] 
Only catheterization lab 11 1226[1073,2023] 9.23 [8.80, 11.38] 1114 [965,1717] 6.63 [5.99, 8.34] 
No revascularization service 20 493 [330,676] 12.10 [7.96, 20.00] 363 [256,640] 8.58 [6.94, 11.09] 
Geographic region 
North 12 893 [529,1203] 8.22 [6.09, 10.40] 820 [467,1130] 7.07 [5.36, 9.45] 
Center 8 664 [366,1016] 12.75 [9.75, 15.02] 617 [304,875] 8.16 [6.94, 10.08] 
Lisbon 11 1327 [566,2023] 10.30 [9.23, 13.67] 1002 [558,1717] 8.14 [6.91, 10.03] 
Alentejo or Algarve 6 471 [282,1097] 11.97 [8.80, 26.24] 425 [191,995] 8.85 [6.63, 15.18] 
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Figure S2. Funnel plot of risk-adjusted (A) in-hospital mortality and (B) 30-day 
all-cause readmissions by hospital location. 
 
(A) In-Hospital mortality 
 
(B) 30-day all-cause readmissions 
 
 
 
  
129 
 
Figure S3. Caterpillar plots of hospital-specific mean predicted log odds of in-
hospital mortality, by model. Predictions are for the reference patient. Colors 
characterize hospital regarding their geographical location: Blue – north; green – 
center; yellow – Lisbon; red – Alentejo or Algarve. 
 
 
 
Figure S4. Caterpillar plots of hospital-specific mean predicted log odds of 30-
day all-cause readmission, by model. Predictions are for the reference patient. 
Colors characterize hospital regarding their geographical location: Blue – north; green 
– center; yellow – Lisbon; red – Alentejo or Algarve. 
 
